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Introduction 
 
1. Synthetic biology 
 
The ability to ‘read’ and rationally ‘write’ genetic information is transforming basic and applied 
research. This ability defined a new field roughly 44 years ago when Wacław Szybalski, a 
Polish geneticist coined the term “synthetic biology” [1]. As Szybalski noted, “Up to now we 
are working on the descriptive phase of molecular biology. […] But the real challenge will start 
when we enter the synthetic biology phase of research in our field. We will then devise new 
control elements and add these new modules to the existing genomes or build up wholly new 
genomes. This would be a field with unlimited expansion potential.” Szybalski was right. His 
pioneering vision has become reality through the singular development of molecular biology, 
chemistry, and informatics [2]. This has evolved into the modern field of synthetic biology, 
which is broadly defined as a discipline for "designing and constructing biological modules, 
biological systems, and biological machines, or the re-design of existing biological systems for 
useful purposes” [3]. 
Although a detailed review of synthetic biology is largely beyond the scope of this thesis, since 
Szybalski’s first notes on synthetic biology, the ability to rationally engineer biological systems 
has led to a plethora of novelties which have transformed both biotechnology and basic 
research. Briefly, biological engineering has paved the way for unprecedented advancements, 
including the production of antimalarial artemisinin in baker’s yeast [4], the de novo design of 
enzymes with novel catalytic activities [5,6], as well as the manufacturing of artificial protein 
and DNA shells to specifically deliver payloads [7,8], and the construction of programmable 
genetic circuits and memories within living bacteria, yeasts, and mammalian cells [9,10].  
Synthetic biology is inherently multidisciplinary and has relied on advances in distinct 
fields, including DNA sequencing, chemistry, informatics, and analytics. However, most 
directly, the development of this field is a result of breakthroughs in the synthesis and editing 
of genetic material [11]. The advent of technologies suitable to edit and write DNA sequences 
has created the subfield of genome engineering within synthetic biology [11–14]. Genome 
engineering aims the construction and rational modification of organismal genomes to 
construct genotypes that give rise to a desired function, i.e. a specific phenotype [11,15].  
Given the sheer size of bacterial chromosomes and the rapidly decreasing cost of de 
novo DNA manufacturing, the construction of entire organismal genomes is now possible [14]. 
This “bottom up” approach of genome engineering gave the first evidence of the feasibility of 
generating infectious viruses (first the polio [16], later the “Spanish flu” H1N1 influenza [17], 
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and horsepox viruses [18]), entirely from computationally designed and stored DNA 
sequences. Then, by building on advancements in massively parallel DNA synthesis and 
assembly, in 2010 scientists from the J. Craig Venter Institute (JCVI, Rockville, USA) reported 
the preparation of the first self-replicating bacterial cells with an entirely synthetic genome [19]. 
By transplanting a computationally designed and in vitro synthesized Mycoplasma mycoides 
genome into Mycoplasma capricolum cells, Daniel Gibson and his coworkers at JCVI booted 
up the first bacterium whose genome was designed on a computer hardware [19,20]. However, 
while this de novo, “bottom up” construction of functional genomes holds far-reaching promise 
and will likely enable powerful applications in the future, it also comes with several drawbacks. 
First and most importantly, synthesizing entire genomes remains a substantial technical 
challenge. The 1.08×106 base pairs of the Mycoplasma mycoides genome represented 
hundreds of man-years of intense laboratory work, costing millions of US dollars. Also, scaling 
up de novo construction of entire genomes to the genome size of most biotechnologically 
applied bacterial species or yeasts turned out to be cumbersome and extremely time 
consuming [11,21]. Two ongoing endeavors, namely (I) the Synthetic Yeast 2.0 project which 
aims at the de novo construction of the entire chromosomal assembly of baker’s yeast 
(Saccharomyces cerevisiae) with a genome size of approximately 12.1 megabase pairs [21], 
and (II) rEcoli-57, an Escherichia coli strain with a genome size of 3.97 megabase pairs in 
which the codon use is being reprogrammed to use only 57 distinct codons [22], have 
demonstrated that totally de novo synthesis and assembly of multi megabase pairs of DNA is 
frequently hampered by synthesis errors and the unpredictability of biological designs. As a 
notable example, a single base pair deletion in the essential gene dnaA resulted in the 
temporal inability to generate a viable Mycoplasma genome [14,19]. Thus, designing, 
constructing, and booting up genomes with perfect fidelity has remained a tremendous 
technical challenge so far.  
Instead of synthesizing genetic material de novo, “top down” synthetic biology 
approaches are focusing on re-designing existing biological systems [11]. This approach has 
several advantages over “bottom up” construction. First, it does not necessitate the labor-
intensive synthesis of long and costly genetic elements. Second, as it allows the construction 
of desired edits in living cells, it inherently couples modifications to survival and organismal 
fitness. Therefore, it provides a straightforward way to identify and counter-select deleterious 
changes and designs. This way, variants with a non-viable genotype will fail to survive during 
the construction process, and thus can be avoided. Additionally, deleterious changes will result 
in an immediately detectable growth defect which can be mitigated later. Finally, and most 
importantly, engineering living biological systems in vivo enables the simultaneous prototyping 
of billions of variants. This ability, in turn, greatly increases our chances to identify variants 
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with the desired trait. In living cells genotype is inherently linked to a phenotype, thus the 
desired traits of engineered cell populations can be isolated and continuously enriched by 
screening and selection. This approach enables the continuous directed evolution of desired 
traits – a method acknowledged by the Nobel prize in Chemistry in 2018, awarded to Frances 
Arnold for random mutagenesis and the directed evolution of enzymes and to George Smith 
and Sir Gregory Winter for the phage display of peptides and antibodies [23].  
Thus, in vivo, “top down” construction of novel biological functions is a powerful and 
less failure-prone alternative to de novo synthesis. 
 
2. Methods of microbial genome engineering 
 
The availability of the first microbial genomic sequences at the end of the 20th century created 
the opportunity for functional genomics, to understand the genotypic background of 
phenotypes. By systematically interrogating gene functions at the genome scale, the first 
genome engineering endeavors focused on the systematic analysis of genotypic information. 
Based on the systematic assessment of these phenotype-to-genotype relationships, synthetic 
biology then exploited this knowledge to engineer novel biological functions.  
Ideally, a method for genome engineering would allow the precise construction of 
multiple genotypic changes with high efficiency. Thereby, it minimizes the time and effort 
required to identify a specific genotype, and allows of generating multiple edits to efficiently 
explore the sequence space. These features directed method-developments for genome 
engineering towards achieving higher precision, higher number of simultaneous edits, and 
multiplexability within the same cell [24]. Techniques incorporating zinc-finger nucleases, 
transcription activator-like effector nucleases (TALENs), single- or double-stranded DNA-
recombineering, RNA-directed nucleases (e.g. CRISPR-Cas9) and base-editors have been 
essential tools for the efficient modification of DNA in numerous species, including viral, 
bacterial, yeast and mammalian cells [24].  
Although RNA-directed nucleases have greatly extended the range of organisms 
which can be subjected to genomic changes, there seems to be an upper practical limit when 
it comes to utilizing these techniques for simultaneous modifications of multiple loci [25,26]. In 
contrast, multiplex genome editing is required for explicit genotype-phenotype mapping, as 
well as for the modification of protein complexes and biosynthetic pathways. Given the 
plethora of currently available genome engineering techniques, rather than presenting a 
detailed introduction of one-by-one which has already been done by others [26–28] and our 
research group as well [24,29], I would focus on recent developments in recombination-
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mediated genetic engineering (recombineering) reckoned as the most high-throughput and 
multiplexable genetic engineering technique to date [30,31]. 
Recombineering utilizes homologous recombination to integrate linear DNA strands 
into chromosomal or episomal DNA [32–34]. Linear DNA strands can be either double-
stranded (ds) or single-stranded (ss). Among those, dsDNA-recombineering has been widely 
utilized to create gene deletions or the insertion of novel genetic material, i.e. new biosynthetic 
pathways or sensory circuits [34–36]. However, the advent of recombineering in genome 
engineering originates from the development of ssDNA-recombineering [37]. Compared to the 
dsDNA-based recombineering, ssDNA-recombineering uses short, computationally 
designable and mass-manufacturable ssDNA oligonucleotides (oligos) to introduce user-
defined DNA alterations to the target locus of interest [30]. The most notable advantage of 
ssDNA-recombineering is that it can use short ssDNA oligonucleotides resulting in editing 
efficiencies up-to 35% without the necessary selection of the desired genotype, 
simultaneously at multiple positions on microbial chromosomes [38]. Moreover, recent 
advances have allowed to improve the synthesis of such oligos, reaching a throughput of 
hundreds of thousands of user-definable sequences in a single synthesis reaction [31]. These 
features, in conjunction with the straightforward and automatable execution of recombineering 
experiments (Figure 1), have allowed continuous recombineering and thus engineering billions 
of microbial variants within laboratory timescale [38]. 
Thus, single-stranded DNA oligonucleotide-mediated recombineering is an especially 
powerful tool to perform large-scale genome editing in bacteria. In Enterobacteriaceae, a 
diverse and both biotechnologically and medically relevant family of Gram-negative 
Proteobacteria, oligo-mediated recombineering utilizes elements derived from the λ 
bacteriophage in order to carry out genetic modifications [39–41]. Specifically, it is based on 
Beta, the ssDNA annealing protein of the λ Red recombination machinery. This so-called λ 
Red recombination system is RecA-independent and consists of 3 phage-derived proteins: 
Gam, Beta, and Exo. The first protein, Gam, prevents the degradation of linear dsDNA by 
blocking the cellular action of endogenous RecBCD nuclease. Exo then degrades the ends of 
recombinogenic linear dsDNA with its 5′ - 3′ exonuclease activity, and thereby generates 
ssDNA regions. Finally, Beta catalyzes the annealing of ssDNA fragments to the lagging 
strand at the open replication forks of bacterial chromosomes [34,42]. While dsDNA 
recombineering requires both Exo, Beta, and Gam, ssDNA recombineering requires only Beta 
to be present in the cell [37,40]. Beta in itself mediates the annealing of ssDNA 
oligonucleotides to the lagging strand of the replication fork. Following annealing, these 
oligonucleotides become incorporated into the replicating chromosome as Okazaki fragments. 
By exploiting the remarkable efficiency of Beta-mediated ssDNA annealing, small 
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modifications including single-nucleotide changes, insertions and deletions up to a length of 
30 nucleotides can be encoded within a single oligo, which can be repeatedly and 
simultaneously introduced to target DNA to achieve targeted reprogramming at multiple loci 
of the host genome [43]. 
 
3. Multiplex Automated Genome Engineering 
 
Recombineering can be multiplexed, i.e. multiple oligos are capable of modifying their genomic 
targets simultaneously and independently. These modifications may range from single 
individual mutations to large-scale genome refactoring, involving thousands of simultaneously 
edited targets in a cell population [31,38]. The straightforward computational design and cost-
effective synthesis of the mutagenizing ssDNA strands (i.e. 90-nucleotide-long 
oligonucleotides) have made ssDNA recombineering a fundamental tool for synthetic biology 
[11,30]. This technique – called multiplex automated genome engineering (MAGE) [38] – is 
currently the most versatile and high-throughput approach available for real genome-scale 
editing, which allows the continuous generation of billions of genetic variants within a 
population (Figure 1). MAGE utilizes λ Red ssDNA-recombineering to simultaneously 
incorporate multiple ssDNA oligonucleotides in a rapid, automated, and high-throughput 
manner, and thereby rapidly creates the desired alleles and combinatorial mutational libraries. 
 
 
Figure 1. Overview of Multiplex Automated Genome Engineering. Chemical DNA oligo 
synthesis precisely determines the sequence of the editing template (ssDNA oligos). These 
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oligos are complementary to the genomic lagging-strand and introduce mutations into their 
target after annealing and subsequent integration as Okazaki-fragments.  Iterative repetition 
of this process, consisting of cell growth (1), oligo delivery (2) and incorporation (3) increases 
editing efficiency and genetic diversity within the mutagenized cell population (4).  
 
MAGE has the advantage of allowing genome engineering endeavors of unparalleled 
complexity, and it produces up to 1010 unique variants within a single screen, uniquely within 
days [38]. Through the accelerated optimization of biosynthetic pathways (e.g. lycopene and 
violacein [38,44,45]) and proteins [46–49], as well as by genome-wide codon replacement to 
create a so-called “genomically recoded organism” (GRO) engineered to depend on synthetic 
amino acids [50–52], MAGE has paved the way for previously unimaginable evolutionary 
innovations. 
The functionality of ssDNA-mediated recombineering, and thus the opportunity to perform 
MAGE has been described in various species besides enterobacteria, including 
Staphylococcus aureus [53], Lactococcus lactis [54], Lactobacillus species [55], 
Corynebacterium glutamicum [56], Salmonella enterica [57], Bacillus subtilis [58], and 
Pseudomonas syringae and putida [59,60]. However, the straightforward implementation of 
MAGE beyond these early systems has remained considerably limited, and so far, most of 
these efforts have demonstrated only minor efficiency in species besides E. coli. Moreover, 
they all require time-consuming prior optimization for each individual species. 
 
4. The role of methyl-directed mismatch repair 
 
Even in E. coli, the efficient and unbiased incorporation of mutations by MAGE, as well as 
extensive modifications, including the expression of the λ Red recombinase enzymes and the 
inactivation of the native methyl-directed mismatch repair (MMR) system need to be executed 
for a successful genome editing process in the host strain [40,61]. It is explained by the fact 
that the incorporation of mutagenizing MAGE oligonucleotides unavoidably create a 
mismatch, and these mismatches are inevitably recognized by the cells’ endogenous MMR 
system. Short stretches of mismatching nucleobases, deletions or insertions of up to six 
consecutive nucleotides are efficiently recognized by MMR, resulting in the complete removal 
of the integrated modifications [62]. 
In E. coli and evolutionarily-related Proteobacteria these DNA lesions are recognized by MutS, 
and the removal of a mismatching base is initiated jointly with MutL and MutH [63,64]. Of these 
three proteins, the role of MutS is to locate and recognize mismatches on the newly replicated 
and thereby hemimethylated DNA strand. After the mismatch is recognized, MutS forms a 
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complex with multiple monomers of MutL. MutL acts as a linker to recruit MutH. MutH then 
binds to the hemimethylated strand and incises the newly synthesized, nonmethylated DNA 
strand. After the strand is cut, UvrD (formerly MutD) with a helicase action separates the two 
DNA strands, and the mismatch-containing strand is digested by exonucleases. Finally, the 
daughter strand is repaired by DNA polymerase and ligase. The name of Mut proteins reflects 
that their absence results in an elevated mutation rate [63,64]. 
Therefore, efficient ssDNA-mediated recombineering requires the inactivation of the mismatch 
repair system [61]. However, in this case background mutation rate consequently increases 
by nearly two orders of magnitude compared to the wild-type mutation rate. In turn, this 
elevated mutagenesis leads to the accumulation of undesired, off-target mutations during the 
course of long-term MAGE experiments (i.e. in multiple MAGE cycles). To demonstrate the 
magnitude of this problem it should be noted that in a recent work where MAGE was used to 
construct the aforementioned, so-called “genomically recoded organism”, the authors 
recognized that off-target mutations caused reduced fitness in engineered strains [51,65,66]. 
Strikingly, besides the 321 mutations which were intentionally generated by MAGE, a total of 
355 unwanted off-target mutations were also detected. These off-target mutations may in turn 
interfere with the phenotypic effects of the engineered modifications, and in extreme cases, 
they may mask the desired mutational effects.  
Recently, we have attempted to address this issue by replacing wild-type mutL and 
mutS with heat-sensitive mutants of those genes, accompanied by limiting the inactivation of 
mismatch repair to the short period of the MAGE cycle only, executed by altering the 
temperature between permissive and non-permissive values during MAGE cycles [67]. 
Although we have managed to reduce the number of off-target mutations by 85%, the time-
consuming genetic manipulation of the parental strain was still a prerequisite. This issue has 
been recently addressed by the so-called transient-mutator MAGE (TM-MAGE) technique, 
which allows the plasmid-based engineering of E. coli chromosomes by temporally 
downregulating MMR activity via the transient hypermethylation of bacterial chromosomes 
[68]. However, the functionality of TM-MAGE was only demonstrated in certain E. coli strains, 
therefore portability of MAGE across species remained an unsolved challenge. 
 
5. Using genome engineering to understand microbial evolution 
 
Methods of genome engineering enable the modification of organismal genomes in a directed 
and combinatorial manner. Thereby, these methods offer an unprecedented opportunity to 
study evolutionary processes which otherwise would not be possible with standard laboratory 
methods [29].  
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 Traditional adaptive laboratory evolution (ALE) experiments have already been 
acknowledged as a powerful tool to observe and analyze evolutionary processes real-time, 
within laboratory timescales [69–72]. Bacterial populations offer an exceptionally great 
opportunity to perform ALE for several reasons. (I) Due to their small cell size, bacterial 
populations containing up to 108–1010 bacteria can be handled and iteratively cultured easily; 
(II) due to the modest generation time (ranging from tens of minutes to hours) of most bacterial 
models, ALE experiments can run for hundreds to thousands of cell generations, and also (III) 
due to their small genome size and the wealth of available analytical techniques, whole-
genome sequence, transcriptomic, and phenotypic information can be obtained on the entire 
course of an evolutionary experiment. Moreover, as a practical advantage, (IV) samples taken 
at various time points during the experiment can be stored frozen and conveniently analyzed 
later [29,69,71,72].  
On the other hand, even bacterial adaptive laboratory evolution experiments suffer for 
limitations that prevent the truly comprehensive analyses of sequence landscapes and 
evolutionary innovations. These limitations are primarily explained by the lack of natural 
variation within microbial populations, as evidenced by modest natural mutation rates and 
biases in natural mutagenic processes in most bacteria. These limitations, in conjunction with 
microbial population sizes and experimental time-frames feasible under laboratory conditions, 
hinder the in-depth exploration of evolutionary forces which drive complex and slowly evolving 
traits [15,29,73].  
Genome engineering, however, offers the opportunity to overcome these limitations. 
Methods for multiplex, high-throughput genome engineering, including MAGE, RNA-guided 
endonucleases, and base-editors, enable the rapid and targeted construction of chromosomal 
alterations, i.e. the evolutionary steps which otherwise would not occur under laboratory 
conditions [26,38,74–77]. Also, genome engineering is suitable to generate diverse and 
unbiased mutational libraries at many different loci, thereby it facilitates the development of 
genetic changes that otherwise would not occur spontaneously in living cells [11,24,29].  
Exploiting these capabilities has already led to a plethora of advancements in and 
novel insights into both biotechnology and basic science [2,78–83]. De novo genome 
constructions have shed light on genome architecture in bacteria and yeast [14,21], and top-
down genome reduction has increased our understanding of the role of mobile genetic 
elements and prophages [84,85], as well as the feasibility of creating synthetic, minimal 
genomes [14,21,86]. Last but not least, genome editing and large-scale mutagenesis coupled 
to phenotypic screens have allowed the systematic exploration of evolutionary landscapes, 
the directed evolution of novel phenotypes, and the understanding of evolutionary effects 
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which play a role in the development of drug resistance, the evolution of metabolic pathways, 
and other complex cellular traits [6,27,87–90].  
 
6. Evolution and consequences of antibiotic resistance 
 
Microbial evolution, however, is not restricted to the laboratory only. Bacteria constantly face 
selection pressure, including the artificial defense lines of host organisms, including 
antimicrobials and small-molecule antibiotic drugs applied in therapy and agriculture. This 
selection pressure, coupled with the exceedingly large population size of natural bacterial 
populations and the ability to mutate and exchange genetic material (i.e. horizontal gene 
transfer), has led to the salient rise of bacterial antibiotic resistance [91–93]. 
Worldwide, the emergence of bacterial resistance against existing antibiotics is 
currently responsible for an estimated 700,000 deaths annually. According to pessimistic 
estimates, antimicrobial drug resistance of pathogenic bacteria will be the leading cause of 
death by 2050, unless novel antimicrobial strategies are developed [94]. Strikingly, 90% of 
major pharmaceutical companies had discontinued their antibiotic research programs by 
2018, primarily because of the rapid appearance of resistant bacteria, which makes the 
commercial success of new antibiotics unpredictable [95–97].  
Antibiotics selectively target essential constituents of microbial life, i.e. mechanisms 
and molecules which solely exist in bacteria and are absent in the human host [98]. This 
selectivity relies on targeting bacterial enzymes, ribosomal proteins, or the bacterial cell wall. 
However, bacteria typically utilize one or more of a few possible opportunities to evade the 
antibiotics’ mode of action [93,99,100] (Figure 2).  
 
Figure 2. Schematic mechanisms of antibiotic resistance. For a detailed description of 
each mechanisms, see the section “Evolution and consequences of antibiotic resistance” on 
page 14. 
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Briefly, one of these resistance mechanisms relies on the inactivation of drug 
molecules by chemical modification or degradation (such inactivators include the widely used 
selection markers chloramphenicol-acetyltransferase and beta-lactamase enzymes). Second, 
bacteria are capable of altering or overexpressing the drug target, leading to decreased 
susceptibility. Such modifications explain resistance to e.g. fluoroquinolone antibiotics, 
achieved by mutations at GyrA and ParC, as well as include the promoter and active-site 
mutations developed against folate-biosynthesis blockers, such as trimethoprim. Besides 
these mechanisms, bacteria are also capable of keeping antibacterial drugs out of their cells 
efficiently, either through efflux or by altering the permeability of the cell wall. These ‘counter-
processes’ rely either on drug-specific exporters or on multidrug efflux pumps. Alternatively, 
bacteria may prevent drug entry by reducing the permeability of the bacterial cell wall, either 
by structural changes or by the reduction of proton motive force (PMF) [101]. Moreover, high 
levels of drug resistance frequently require multiple complementary mechanisms, and in turn, 
genetic changes to evolve. 
 In general, antibiotic resistance can emerge as a result of mutations at endogenous 
chromosomal loci or may result from horizontally-transferred genetic elements. The relative 
importance of these genetic mechanisms in resistance evolution depends on the given 
antibiotic and the bacterial strain-of-interest [99,102].  
 
7. Assessing antibiotic resistance evolution 
 
Given the fundamental impact of antibiotic resistance on drug development and the treatment 
of infections caused by drug resistant pathogens, it would be imperative to accurately identify 
the possible mechanisms of resistance evolution at an early stage of antibiotic development 
[103]. However, assessing the risk of resistance development in the preclinical stage is 
especially challenging. Standard laboratory evolutionary techniques explore only a small 
fraction of the sequence space, and fail to identify exceedingly rare resistance mutations and 
their combinations [103–106]. The case of GSK 2251052, a novel antibiotic candidate 
(formerly named as epetraborole and AN3365) sheds light on the unpredictability of resistance 
mechanisms before clinical applications. GSK 2251052 blocks leucyl-tRNA synthetase in 
Gram-negative pathogens responsible for urinary tract infections, including E. coli. 
Unexpectedly, resistance to this drug candidate was identified early during its phase II clinical 
trial. Due to this early emergence of resistance, GlaxoSmithKline, the developer of GSK 
2251052 has terminated clinical development, thereby wasting its R&D costs reaching tens of 
millions of USD [107]. 
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Predicting evolutionary processes which may lead to decreased antibiotic susceptibility 
is a complex issue for several reasons. First, because a large number of molecular 
mechanisms can contribute to resistance. Second, resistance mechanisms may differ among 
different pathogenic bacteria. Third, the standard adaptive laboratory evolution assays that 
are frequently used both in basic research and in industrial laboratories to assess resistance 
evolution (such as fluctuation tests and serial passaging experiments) generally rely on natural 
mutational processes which are modest and biased in many cases [103–105,108,109]. 
Therefore, these methods explore only a fraction of potential real-life resistance mechanisms. 
For a brief visual description of these techniques see figure 3.  
 
Figure 3. Traditional laboratory methods of antibiotic resistance analysis. While 
frequency-of-resistance (FoR) assays primarily detect single-step mutations, passaging 
experiments can explore multistep mutational processes that may lead to high-level antibiotic 
resistance. 
 
As a good benchmark for identifying antibiotics which require only a single mutation to 
have their bioactivity abolished, the mutation rate and population size for predictive tests 
should be high enough to evaluate at least three mutations at 99.9% of nucleotide positions 
in the whole genetic material. This equals to assaying 2.4×1011 wild-type cells, roughly 5 
milliliters of a saturated E. coli culture, in a standard frequency-of-resistance (FoR) assay 
[103]. However, this assay generally detects only single-step mutational processes, when 
resistance against a given drug requires only a single genetic alteration to appear. 
Consequently, for antimicrobials that require more than a single mutation to evolve detectable 
resistance, the mutational space needed to be explored scales exponentially with the number 
of sites. In turn, for a drug that necessitates two mutations to evolve a resistant phenotype, 
the identification of resistance-causing mutation combinations would require screening over 
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4.5×1022 wild-type E. coli cells in a frequency-of-resistance assay [98]. Using hypermutator 
strains would reduce this number to a maximum of 3.22×105 (i.e. MP6-mutagenesis [110]), but 
this number still remains infeasible with current microbiological tests [109].  
In the other hand, however, recent genome-engineering technologies are promising 
alternatives to explore resistance processes in a more systematic and accelerated manner. 
Through the generation of diverse and unbiased mutant libraries at many defined loci, genome 
engineering allows the generation of genetic changes which otherwise would be highly unlikely 
to occur under laboratory timescales. However, technologies that enable the targeted 
mutagenesis of multiple loci in their native genomic context, and in turn the exploration of 
antibiotic resistance processes, suffer from serious limitations [111].  
Certain methods target the entire genome unselectively [112,113] and as a 
consequence, these assays result in the accumulation of undesired, off-target modifications 
with detrimental side effects. In other cases, the lengths of targeted regions are highly limited 
[74,114–117], precise adjustment of the mutation rate is unsolved [74,114], or the mutational 
spectrum is highly biased [74,89,110,114,116–119]. Finally, recently described techniques 
employing CRISPR-Cas9 nucleases and base-editors for in vivo mutagenesis require the 
presence of a protospacer adjacent motif in the vicinity of the target site, which limits the 
available targets and prohibit multiple rounds of mutagenesis to generate multistep 
evolutionary processes [26,74–76,116,120–124]. For a more detailed comparison of existing in 
vivo mutagenesis protocols, see our recent review in Current Opinion in Microbiology [24] and 
the comparison of in vivo mutagenesis methods in our article in the Proceedings of the 
National Academy of Sciences of the United States of America [125].  
Amongst the methods available for large-scale mutagenesis and phenotyping, the 
aforementioned single-stranded (ss) DNA-mediated recombineering, and specifically 
multiplex automated genome engineering (MAGE) stands out [38,61]. However, existing 
ssDNA recombineering-based techniques enable randomization of very short sequences 
(such as promoters or neighboring residues in a protein-coding sequence) by a single oligo 
[46,47,126,127], which limits the explorable sequence space. The explanation for this limitation 
is the fact that the efficiency of ssDNA-mediated recombineering depends on the oligo’s 
sequence identity to the target region [30,38,43] (see also Figure 10), i.e., the decrease of 
sequence identity for any recombineering oligo compared to its target will simultaneously 
increase the binding free energy (∆G), thus preventing their hybridization to the corresponding 
target site. Therefore, the diversification of genomic sequences longer than 30 base pairs is 
not feasible with a single oligonucleotide. Several strategies based on MAGE have been 
proposed to mutagenize the full length of individual genes in their native genomic context, 
including MAGE-seq and MO-MAGE [31,128]. However, as a common feature of these 
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methods, individual nucleotide positions are mutagenized separately by using a distinct 
oligonucleotide for each [31,128,129]. As a consequence, these methods demand the costly 
and time-consuming manufacturing of hundreds to thousands of individually designed and 
synthesized oligos even for a single prokaryotic gene [31,128]. 
To address this issue, during the eight years of my research in the Biological Research 
Centre of the Hungarian Academy of Sciences me and my colleagues have focused on 
improving ssDNA-recombineering to allow the precise and cost effective mutagenesis of 
multiple, long genomic segments in various species without unwanted, off-target modifications 
[130]. The resulting methods now enable the systematic comparison of mutational effects 
across different species, as well as the exploration of the phenotypic effects of a vast number 
of mutations in their native genetic context. Moreover, the application of these developments 
has contributed to a better understanding of microbial evolution and resistance profiles of 
antibiotics [131,132]. As a step-forward towards the predictability of antibiotic resistance, these 
developments have allowed us to predict the evolution of resistance against an antibiotic 
currently in clinical trials, and have contributed to the preclinical development of a novel class 
of antibiotic as well.  
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Objectives  
 
Our research has focused on improving bacterial genome engineering towards precision, 
increased throughput, multiplexability, and a broader host range to facilitate its applications in 
basic and applied research. Specifically, we first aimed to develop a broad host range, 
plasmid-based ssDNA-recombineering system which can efficiently operate in a wide range 
of enteric bacteria, including those frequently used in microbial fermentations or are significant 
human pathogens. Next, building on this advancement, we aimed to develop an extremely 
high-throughput genome engineering technique that efficiently generates a vast number of 
genotypic alterations in bacterial genomes in their native genetic context. Finally, we examined 
whether ssDNA-recombineering enables an accelerated analysis of microbial mutational 
processes and the directed evolution of antibiotic resistance in multiple bacterial species.  
 
To achieve these goals, our research included the following steps: 
• We characterized a dominant mutator allele of the methyl-directed mismatch repair 
system of E. coli, and analyzed the phenotypic conservancy of its effect across 
enterobacterial species. 
• We designed and constructed a broad host range, plasmid-encoded system for 
ssDNA-mediated genome engineering to allow simultaneous mismatch-repair control 
and efficient genome editing. 
• We developed a method of DNA synthesis which can introduce large genetic diversity 
into user-defined oligonucleotide strands without mutational bias in a cost-effective 
way. 
• We developed a method for ssDNA-mediated genome engineering which can 
introduce randomly distributed, random mutations and their combinations along the 
entire length of multiple long and continuous genomic segments simultaneously in 
multiple bacterial species. 
• We compared the mutational effects that give rise to antibiotic resistance phenotypes 
across phylogenetically related bacterial strains. 
• We identified evolutionary processes that can lead to antibiotic resistance to new 
antibiotic candidates that are currently under clinical development.    
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Resources and methods 
 
Oligonucleotides 
 
A full list of all DNA oligonucleotides used in this work are listed in Appendix 2 and 3. Oligos 
were ordered as standard desalting for purification from Integrated DNA Technologies or 
synthesized in-house at the Nucleic Acid Synthesis Laboratory of the Biological Research 
Centre of the Hungarian Academy of Sciences (Szeged, Hungary) according to a standard 
phosphoramidite-based DNA synthesis procedure. High-throughput sequencing primers for 
Illumina and Pacific Biosciences sequencing platforms were purified with high-performance 
liquid chromatography (HPLC) to avoid truncated variants that can interfere with precision and 
the separation of subsamples. Oligonucleotides after manufacturing, desalting, and 
subsequent lyophilization were suspended in 1 × TE buffer (10 mM Tris-HCl (pH 8.0); 0.1 mM 
ethylenediaminetetraacetic acid (EDTA)) and stored at -20 °C . 
The design of ssDNA-recombineering oligos followed a general guideline [43,133]: 
Genome editing oligonucleotides I.) were 90 nucleobases in length, II.) had minimized 
secondary structure (∆G higher than -12 kcal/mol) and III.) lacked mistargets on the target 
strain’s genome to avoid false hybridization and off-target mutagenesis. Moreover, to perform 
mutagenesis at E. coli K-12 MG1655 lacZ, malK, araB, hisB, rpsL, and cycA, oligonucleotides 
had 2 phosphorothioate bonds at each terminus in order to evade ssDNA exonucleases within 
the target cells. 
 
Synthesis of soft-randomized DIvERGE oligonucleotides 
 
Synthesis of DIvERGE and reference oligos was performed on an ABI 3900 DNA synthesizer 
(Applied Biosystems Inc), according to a modified phosphoramidite chemistry-based protocol. 
As a solid support controlled pore glass was applied, and the following synthesis cycles were 
repeated: I.) Deprotection was achieved with 3% (weight/volume) trichloroacetic acid in 
dichloromethane. II.) Incoming phosphoramidite, dissolved in 0.055 M concentration in 
anhydrous acetonitrile and premixed with the other three amidites in the defined spiking ratio 
according to the given experiment was coupled after activation with 5-ethylthio-1H-tetrazole. 
III.) Capping was done with 10% (volume/volume) acetic anhydride in anhydrous 
tetrahydrofuran and 16% (volume/volume) N-methyl-imidazole and 10% (volume/volume) 
pyridine containing anhydrous tetrahydrofuran. IV.) The oxidation step was accomplished with 
iodine. To this aim 5 g iodine was dissolved in a liter of pyridine: water: tetrahydrofuran mixture 
in a 0.5:2:97.5 ratio. Oligo synthesis cycles were repeated until the 5’ terminal position of the 
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DNA strand. Finally, DNA strands were cleaved from the solid carrier with concentrated 
aqueous ammonia solution. Crude oligos were then purified by high-performance liquid 
chromatography (HPLC). After concentration from HPLC fractions, 5’-dimethoxytrityl 
protecting groups were removed by using a PolyPak column (from Glen Research) according 
to the manufacturer’s instructions. Following elution and subsequent lyophilization, purified 
oligos were resuspended in 1×TE buffer (10 mM Tris-HCl (pH 8.0); 0.1 mM 
ethylenediaminetetraacetic acid (EDTA)). 
 
Applied bacteriological media and their compositions 
 
Unless otherwise noted, bacterial cultures were grown in Lysogeny Broth Lennox (LBL) 
medium (consisting of 10 g of tryptone, 5 g of yeast extract, 5 g of sodium chloride per 1000 
mL of water). LBL agar plates were prepared by the addition of 13.5 g agar per 1000 ml of 
culture medium (Sigma-Aldrich) before autoclaving for 20 minutes at 115 °C. Antibiotics that 
were used for either the maintenance of plasmid-constructs or the selection of mutants, were 
added to the LBL broth or agar-containing media at 55 °C. Antibiotic solutions were obtained 
from Sigma-Aldrich, unless otherwise noted, and were prepared from powder stocks and filter 
sterilized before use. AraB, LacZ, and MalK enzyme-activities were assayed on supplemented 
MacConkey agar plates (consisting of peptone 20 g, bile salts 1.5 g, sodium chloride 5 g, agar 
13.5 g, neutral red 0.03 g, and crystal violet 1.0 mg per 1000 mL of water) with either 1%  of 
arabinose for the functional analysis of AraB, 1% of lactose for LacZ, or 1% maltose for MalK 
enzymatic activities. Following electroporation, terrific-broth (TB) was applied as cell recovery 
media (yeast extract 24 g, tryptone 12 g, K2HPO4 9.4 g, KH2PO4 2 g per 1000 mL of water). 
Bacterial media were heat-sterilized by autoclaving at 115 °C for 20 minutes. Minimal salt 
medium (MS), supplemented with 0.2% glucose and 0.1% casamino acids (Difco 
Laboratories) was applied for trimethoprim drug susceptibility assays due to its low folate 
content, that would otherwise interfere with the competitive inhibition of FolA. 
 
ssDNA-recombineering protocol 
 
To perform ssDNA-recombineering and iterative Multiplex Automated Genome Engineering 
(MAGE) cycles, individual bacterial colonies were inoculated into 2 ml LBL medium in the 
presence of the corresponding antibiotic. These starter cultures were then incubated overnight 
in a shaking incubator at 30 °C and a continuous shaking of 250 rotation per minute (rpm). 
Next, these stationer phase starter cultures were diluted 100-fold in antibiotic-supplemented 
LBL medium. Each MAGE cycle consisted of the following steps: Upon reaching OD600 = 0.4-
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0.6, cells were transferred to a 42 °C shaking water bath to induce λ Red protein expression 
for 15 minutes at 250 rpm agitation. Immediately after heat induction, cells were chilled on ice 
for 10 minutes. Next, cells were made electrocompetent by washing and pelleting twice in 10 
ml ice-cold H2O in a refrigerated Eppendorf 5702R centrifuge (at 4000 rpm for 8 minutes). 
Bacterial cells were then suspended in 160 µl chilled H2O and kept on ice until electroporation. 
Unless otherwise noted, 40 µl electrocompetent bacterial cell suspension was admixed with 1 
µl of the corresponding 100 µM ssDNA oligonucleotide. For simultaneous allelic replacements 
at lacZ, malK, araB, hisB, rpsL, and cycA 1-1 µs of each oligo were admixed and 
electroporated. Electroporations were performed on a BTX  CM-630 Exponential Decay Wave 
Electroporation System (from Harvard Apparatus) within 1 mm gap electroporation cuvettes 
Pulse conditions were 1.8 kV, 200 , 25 µF. Immediately after electroporation, 1 ml TB 
medium was added to each cuvette and cells were then transferred to 5 ml TB media to 
recover and start to divide. Following 60 minutes recovery at 30 °C under constant agitation 
(250 rpm), 5 ml antibiotic containing LBL medium was added to each culture. Finally, cells 
were allowed to reach mid-logarithmic growth phase under continuous agitation. At this point, 
cells were either subjected to an additional MAGE cycle or allowed to reach stationary phase 
and were analyzed for phenotype and genotype. 
To assess the performance of ssDNA-recombineering in E. coli K-12 MG1655 , single 
recombineering cycles were performed in E. coli K-12 MG1655 + pSIM8, E. coli K-12 MG1655 
+ pORTMAGE2, and in E. coli K-12 MG1655 ∆mutS + pSIM8 by using oligonucleotides that 
introduced single base pair mismatches into lacZ and thereby generated premature stop 
codons.  
For the determination of the off-target effects during long-term MAGE experiments, E. 
coli K-12 MG1655 + pSIM8, E. coli K-12 MG1655 + pORTMAGE1, and E. coli K-12 MG1655 
∆mutS + pSIM8 cells were subjected to oligo-mutagenesis. During every MAGE cycle, lacZ, 
malK, araB, hisB, rpsL, and cycA were subsequently targeted by 4 MAGE cycles for each 
locus. Then, allelic replacement efficiencies were measured at each locus either by 
colorimetric assay or allele-specific PCRs with the following primer pairs for cycA and hisB, 
respectively: cycAASP_f and cycAASP_r, hisBASP_f and hisBASP_r. Finally, isolates that 
carried the desired mutation were verified by capillary sequencing. After the identification of 
the correct genotype, recombineering cycles targeting the next locus were initiated. After all 6 
desired allelic replacements were identified in the given clone (with the exception of hisB 
mutation in MG1655 + pSIM8 cells, which mutation was not observable even by screening 
760 distinct colonies, presumably due to the high recognition efficiency of mismatch repair for 
the corresponding mismatch type), genomic DNA (gDNA) was isolated with a GenElute 
Bacterial Genomic DNA kit from Sigma-Aldrich, according to the manufacturer’s protocol. 
These gDNA samples were subsequently subjected to whole genome sequencing. 
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DIvERGE cycling protocol 
 
DIvERGE in E. coli K-12 MG1655, E. coli UPEC CFT073, Salmonella enterica LT2, and 
Citrobacter freundii ATCC 8090 was performed according to a modified pORTMAGE3 
plasmid-based ssDNA-recombineering protocol. In our assays, E. coli K-12 MG1655 
represented a widely used laboratory E. coli strain, E. coli UPEC CFT073 represented a 
human uropathogenic strain of E. coli, Salmonella enterica LT2 served as a model for human 
pathogenic Salmonella strains, while Citrobacter freundii ATCC 8090 is the reference and type 
strain for Citrobacter freundii, an emerging opportunistic pathogen. 
In order to measure the efficiency of mutagenesis at the asnA::tetR-CAT landing pad, 
TETRM1 and TETRM3 soft-randomized oligos with randomization levels of 0.5%, 1%, and 2% 
were targeted to the landing pad on the genome of E. coli K-12 MG1655, Salmonella enterica 
LT2, and Citrobacter freundii ATCC 8090. Next, five consecutive cycles of DIvERGE were 
performed with each oligo. After the 5th mutagenesis cycle, gDNA was extracted by using 
GenElute Bacterial Genomic DNA kit from Sigma-Aldrich, and the DNA was subjected to PCR 
amplicon-based genotypic analysis on Illumina MiSeq. 
To analyze the single-step mutational landscape of FolA and its promoter, a mixture of 
eight, folA-targeting, soft-randomized oligos were electroporated into pORTMAGE3 containing 
E. coli K-12 MG1655 and E. coli CFT073 cells in triplicates. After the addition of 1 ml TB 
recovery media into each electroporation cuvettes, 0.3 ml of each cell suspension was 
admixed, separately for all replicates and allowed to recover in 5 ml TB media at 30 °C under 
constant agitation for 60 minutes at which timepoint 5 additional milliliters of LBL medium was 
added to each culture. The mutagenized cell populations were then allowed to grow until 
stationary phase at 30 °C.  
Multiplex, iterative DIvERGE mutagenesis was carried out to mutagenize folA by 
performing the genomic integration of an equimolar mixture of 8, soft-randomized oligos that 
covered the entire target site. 0.5 - 0.5 µl of each oligo were electroporated into heat-induced, 
pORTMAGE3 containing electrocompetent cells. Following electroporation, cell growth and 
recovery phases were performed according to the general ssDNA-recombineering procedure, 
and the whole procedure was repeated for five consecutive times.  
A single DIvERGE mutagenesis cycle was carried out in E. coli K-12 MG1655 to 
generate a gyrA, gyrB, parE, and parC combinatorial mutant library. After equimolarly 
admixing 130 soft-randomized oligos that covered all four loci with slight overlaps, 4 l of this 
oligo pool was electroporated into E. coli K-12 MG1655 cells that carried the pORTMAGE3 
plasmid. To increase mutant library size, electroporation was performed in 10 parallel 
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replicates, in each electroporating 40 µls of electrocompetent cells with 4 µl of this oligo pool. 
The resulted cell libraries were then pooled and was then allowed to recover in 50 ml fresh TB 
media for 1 hour at 30 °C under constant agitation. Following recovery, cells were diluted with 
50 ml LBL media and allowed to reach stationary phase at 30 °C while continuously agitating 
the library at 250 rpm.  
Finally, aliquoted samples from each experiment were mixed with 50 volume/volume% 
of 50% glycerol and then frozen and stored at -80 °C. Besides storage from each cell library, 
genomic DNA (gDNA) was also isolated from 500 µl of each population with a GenElute 
Bacterial Genomic DNA kit from Sigma-Aldrich, according to the manufacturer’s protocol. 
These gDNA samples were subsequently subjected to targeted amplicon sequencing. 
 
MP6 plasmid-based in vivo mutagenesis 
 
MP6 is a potent, L-arabinose inducible, broad-spectrum, plasmid-based mutagenesis system 
that enhances mutation rate 322 000-fold over the basal level in E. coli, thus surpassing the 
mutational efficiency of other, widely used in vivo and in vitro whole-genome mutagenesis 
methods [110]. In sum, the inducible expression of five mutator genes from the synthetic 
operon of MP6 (namely dnaQ926, dam, seqA, emrR, ugi, and cda1) alters the native cells 
proofreading, base excision repair, base selection, and mismatch repair capabilities and 
thereby exceedingly elevating mutation rate. For this assay, an MP6 (Addgene plasmid ID: 
69669) containing E. coli K-12 MG1655 starter culture was grown overnight at 30 °C in LB + 
25 g/ml chloramphenicol in the presence of 25 mM glucose and diluted 1000-fold into 12 
parallel samples in 1 ml LBL media. MP6 mutagenesis was induced by adding L-arabinose at 
a final concentration of 200 mM. As a control, wild-type E. coli K-12 MG1655 population were 
inoculated in the same manner in 12 parallel replicates. Cultures were grown overnight at 30 
°C. 
  
Construction of pORTMAGE and pZA31tetR-mutLE32K plasmids 
 
pORTMAGE1 (Addgene plasmid ID: 72680) and derivatives were constructed by introducing 
the gene encoding E. coli MutL (ecmutL) containing an E32→K mutation (ecmutLE32K) into 
the pSIM8 plasmid [57]. pSIM8 was donated by Donald L. Court (National Cancer Institute in 
Frederick, MD, USA). pORTMAGE1 and derivatives were constructed by introducing 
ecmutLE32K into pSIM8. To this aim, first, the native mutL from E. coli K-12 MG1655 was 
cloned into the λ Red operon of pSIM8, downstream of exo and upstream the tL terminator to 
yield pSIM8mutL. The correct assembly of pSIM8mutL was verified by PCR and subsequent 
capillary sequencing with LExoF and tL3R primers. Next, the introduction of ecmutLE32K was 
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achieved by whole-plasmid amplification mutagenesis. To this aim, PCRs in 50 l total volume 
were cycled 35 times at 98 °C 10 seconds, 56 °C 30 seconds and 72 °C for 5 minutes, with a 
final extension time of 6 minutes at 72 °C, using mutL32F and mutL32R as PCR primers. The 
PCR amplicon was then treated with 1 unit of DpnI restriction enzyme, directly within the PCR 
buffer for 60 minutes at 37°C, and then purified and concentrated into 12 l deionized water 
by using a Zymo DNA Clean-and-concentrator kit, according to the manufacturer’s instruction 
(Zymo Research). Finally, the circularization of the plasmid was performed at 18 °C overnight 
with T4 DNA Ligase (Thermo Scientific). The final, ligated plasmids were then 
electrotransformed into E. coli K-12 MG1655 electrocompetent cells. Correct clones were 
verified by PCR and subsequent capillary sequencing with LExoF and tL3R primers.  
pZA31tetR-mutLE32K was constructed by introducing the mutLE32K allele into 
pZA31tetR under the control of the pLtetO regulatory unit [134]. 
pORTMAGE2 (Addgene plasmid ID: 72677) was constructed by introducing a strong 
ribosomal binding site (5’-GAGAGGAGGTATATAC) upstream of the ecmutLE32K allele in 
pORTMAGE1 by whole-plasmid amplification mutagenesis. 
Next, we constructed kanamycin and chloramphenicol resistance marker-based 
variants of pORTMAGE2: pORTMAGE3, and 4, respectively. The kanamycin-resistant 
pORTMAGE3 (Addgene plasmid ID: 72679) and the chloramphenicol-resistant pORTMAGE4 
(Addgene plasmid ID: 72679) were constructed by replacing the beta-lactamase gene of 
pORTMAGE2 with either the KanR or the cat resistance marker by using Gibson-assembly. 
The plasmids were linearized by PCR amplification with pL32K frame_1, and pL32K frame_2 
primer pairs and the kanamycin-phosphotransferase gene (KanR) or chloramphenicol-
acetyltransferase (cat) gene was amplified using the Gibson Kan_Fw - Gibson Kan_rev and 
Gibson Chlo_Fw - Gibson Chlo_rev primer pairs, respectively. Assembly reactions were 
performed in Gibson Assembly Master Mix (New England Biolabs) at 50 °C for 60 minutes. 
Purified products were electroporated into E. coli DH5 electrocompetent cells and plated to 
agar plates containing the corresponding antibiotic. Plates were incubated at 30 °C overnight. 
Successful plasmid assemblies were then verified from the outgrowing colonies by colony 
PCR and capillary sequencing. 
 
Integration of landing pad sequence into the target species 
 
In order to measure allelic-replacement efficiencies uniformly across species, we integrated 
an artificial landing pad sequence into the genome of E. coli K-12 MG1655, S. enterica serovar 
Typhimurium LT2, and C. freundii ATCC 8090. This landing pad sequence was integrated into 
the endogenous asnA in every organism by utilizing dsDNA-recombineering. AsnA is one of 
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two asparagine synthetase enzymes in these species and is located at conserved genomic 
locus nearby the origin of replication in all three species. Due to the redundancy of its function 
in enterobacterial genomes, inactivation does not cause a fitness defect in rich media under 
the conditions where our assays were performed. To insert the landing pad into asnA, the 
recombineering cassette with additional 3’ and 5’ 50 nucleobase long homologous overhangs 
to the genomic target site was generated by PCR from pZA31YFPtetR, using the 
corresponding primer combinations Cint_F and Cint_R for Citrobacter freundii, Sint_F and 
Sint_R for Salmonella enterica, Eint_F and Eint_R for E. coli. Following PCRs, PCR products 
were cleaned and concentrated. Next, the insertions of the landing pad with flanking genomic 
homologies into the genome-of-interest were performed by dsDNA-recombineering with 
pORTMAGE3 plasmids. Finally, clones that successfully integrated the landing pad cassette 
were selected overnight based on their chloramphenicol resistance on LBL + 20 µg/ml 
chloramphenicol agar plates and integrations were sequence-verified by colony PCR with 
CHK_F and CHK_R primers. 
 
Selection of drug resistance from DIvERGE libraries 
 
To identify antibiotic resistance-causing variants, frozen cell libraries of E. coli K-12 MG1655 
that had undergone either DIvERGE- or MP6-mutagenesis were thawed and washed three 
times in 1 ml Minimal Salt (MS) media. Appropriate dilutions of the 5-cycle DIvERGE 
population were plated onto Minimal Salt (MS) agar plates containing 4, 11, 67, and 267-times 
the wild-type MIC concentration of the drug. The wild-type MIC of trimethoprim is 0.75 µg/ml 
on MS + casamino acid agar medium for E. coli K-12 MG1655 and CFT073 (UPEC). To 
assess the single step mutational landscape of folA DIvERGE libraries were selected in three 
replicates on agar plates that contained 4-times the wild-type, agar surface-based MIC 
concentration of trimethoprim. Highly trimethoprim-resistant variants were selected on Minimal 
Salt (MS) + casamino acid agar plates containing 1000 g/ml trimethoprim. The selection was 
also performed with the induced MP6 population on MS + casamino acid agar plates 
containing 4-times the wild-type MIC concentration of trimethoprim. Next, 800 - 1000 individual 
colonies were isolated for further genotype- and antibiotic susceptibility-analysis from all 
plates. Colonies were scraped off from agar plates in 5 ml MS medium to each plate, and from 
this cell-suspension, 0.5 ml was used to extract genomic DNA by using GeneElute Bacterial 
Genomic DNA Kit according to the manufacturer’s instructions (Sigma-Aldrich). 
E. coli K-12 MG1655 gyrA, gyrB, parE, parC libraries were selected on LBL agar plates 
containing 2-times the wild-type minimum inhibitory concentration (MIC) of ciprofloxacin (i.e., 
2 ng/mL). Following incubation for three days at 30 °C, 3000 resistant clones were isolated. 
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Colonies were scraped off as previously, and from this cell-suspension, 0.5 ml was used to 
extract genomic DNA by using GeneElute Bacterial Genomic DNA Kit (Sigma-Aldrich). 
Gepotidacin selection experiments were performed on Mueller Hinton II (from Sigma-
Aldrich) agar plates containing 2- and 12-times the wild-type MIC concentration of gepotidacin 
(i.e., 140 ng/ml). Gepotidacin was obtained from MedChemExpress, China (HY-16742) and 
the molecular structure and purity of the drug were verified by nuclear magnetic resonance 
(NMR) spectroscopy. The frequency of resistant cells according to the standard frequency-of-
resistance (FoR) protocol was assayed by plating 1010 E. coli K-12 MG1655 cells to 145 mm 
agar plates containing 50 ml Mueller Hinton II agar with the corresponding gepotidacin 
concentration. Colony counts were determined after 3 days of incubation at 30 °C. DIvERGE-
generated, gepotidacin resistant variants were isolated from DIvERGE mutant libraries on 
Mueller Hinton II Agar (Sigma-Aldrich) plates containing 12-times the wild-type MIC 
concentration of gepotidacin. Gepotidacin selection experiments were performed in triplicates. 
 
Assessing the allelic replacement efficiency of MAGE and pORTMAGE 
 
The efficiency of ssDNA-recombineering in E. coli, Salmonella enterica, and Citrobacter 
freundii was assayed by high-throughput amplicon sequencing on Illumina MiSeq. High-
throughput amplicon sequencing provided an unbiased and scalable method to read-out allelic 
composition in multiple strains without the need of a readily selectable marker gene-based 
allelic replacement assay (e.g., lacZ). To compare efficiencies of ssDNA-recombineering 
across strains and conditions pSIM8 containing C. freundii ATCC 8090 asnA::TET-CAT_OFF 
cells, pORTMAGE2 containing E. coli K-12 MG1655 asnA::TET-CAT_OFF, S. enterica 
serovar Typhimurium asnA::TET-CAT_OFF and pORTMAGE3 harboring C. freundii ATCC 
8090 asnA::TET-CAT_OFF cells were subjected to ssDNA-recombineering according to our 
general ssDNA-recombineering protocol. Following a single cycle of recombineering, gDNAs 
were isolated from ~108 bacterial cells from each stationary phase culture and subjected to 
bulk amplicon-sequencing.  
Specifically, we assessed allelic compositions at the landing pad in each strain – 
condition pair by the high-throughput bulk sequencing of a 436 base pair long PCR amplicon. 
This PCR amplicon covered the landing pad region that was targeted by oligo-recombineering. 
From each gDNA sample, 200 ng DNA was used as a template to amplify this target region 
with tetDS1 and tetDS2 PCR primers. PCRs were performed uniformly 50 l Phusion Hot Start 
II High-Fidelity PCR mixture (Thermo Scientific) with Phusion High-Fidelity buffer to maximize 
PCR’s fidelity. To increase DNA amplicon quantities, PCRs were performed in 3 × 50 l. PCRs 
were cycled 26 times at 98 °C for 10 seconds, 57 °C for 30 seconds, and 72 °C for 30 seconds, 
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with a final extension time of 3 minutes at 72 °C. PCR products were assayed by agarose gel 
electrophoresis to ensure that only a single, specific PCR amplicon was generated and 
quantified by using a TapeStation instrument (Agilent). Next, sequencing libraries from the 
436 base pair long amplicons were prepared and sequenced at SeqOmics Biotechnology Ltd. 
(Mórahalom, Hungary) by using NEBNext DNA Library Prep Master Mix and NEBNext 
Multiplex Oligos for Illumina (New England Biolabs). Sequencing libraries were prepared 
according to the manufacturer’s instructions with minor modifications: initial fragmentation was 
skipped, and purifications were performed with Agencourt AMPure XP beads (Beckman 
Coulter). Finally, libraries were sequenced using MiSeq Reagent Kit v2 for a 250 base pair 
paired-end sequencing on an Illumina MiSeq sequencer.  
Following sequencing, raw Illumina sequencing reads were processed by using CLC 
Genomics Workbench ver. 8.0.1. On the course of processing, sequencing reads were first 
trimmed to an error probability threshold of 5%. Next, overlapping read pairs were merged to 
reconstruct the 436 base pair long landing pad template. To identify mutations compared to 
the wild-type sequence of the landing pad, sequencing reads were then mapped to the landing 
pad’s sequence. This mapping data was then exported from CLC Genomics Workbench and 
pysamstats (https://github.com/alimanfoo/pysamstats) was used to extract coverage and 
nucleobase composition for each DNA position of the PCR amplified landing pad region. In all 
samples, every nucleotide at the corresponding landing pad positions was sequenced at least 
120 000-times. Finally, allelic replacement efficiencies at each targeted nucleotide position 
was quantified by measuring the distribution of nucleotide variants at each nucleotide position.  
Library generation in E. coli K-12 MG1655, Salmonella enterica serovar Typhimurium, 
and Citrobacter freundii ATCC 8090 was assayed by targeting asnA with ssDNA-
recombineering that carried six randomized nucleotide position. Randomization in this context 
meant the equimolar representation of A, C, T, and G nucleobases at a given randomized 
nucleotide position. To compare the ability of ssDNA-recombineering across strains and 
conditions, heat-induced E. coli K-12 MG1655 + pSIM8, S. enterica serovar Typhimurium + 
pSIM8, C. freundii ATCC 8090 + pSIM8KAN, E. coli K-12 MG1655 + pORTMAGE2, S. 
enterica serovar Typhimurium + pORTMAGE2, C. freundii ATCC 8090 + pORTMAGE3 cells 
were electroporated with the corresponding strain-specific recombineering oligos according to 
the general ssDNA-recombineering protocol. Following oligo integration for five 
recombineering cycles, gDNA from each population was extracted and amplified according to 
the protocol described for the landing-pad assay by using CHK_F and CHK_R primers. Next, 
the library composition at asnA in each species was assayed by Illumina high-throughput 
sequencing as described above. 
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Whole genome sequencing to assess off-target effects of ssDNA-recombineering  
 
After 24 iterative recombineering cycles, we selected one independently edited clone from E. 
coli K-12 MG1655 + pORTMAGE, MG1655 ΔmutS + pSIM8, and MG1655 + pSIM8. Next, 
each selected clone and their corresponding parental strains (E. coli K-12 MG1655 wild-type 
and MG1655 ΔmutS) were inoculated into 1 ml LBL medium and grown until stationary phase 
at 30 °C. Genomic DNA was isolated from 500 µl of each culture with GenElute™ Bacterial 
Genomic DNA kit from Sigma-Aldrich, according to the manufacturer’s protocol.  
To quantify off-target mutations, the genomes of these parental and the MAGE-derived 
clones were then whole-genome sequenced. To this aim, sequencing libraries were 
constructed from genomic DNA using NEBNext Fast DNA Fragmentation & Library Prep Set 
kit for Ion Torrent (New England Biolabs) according to manufacturer's instructions. Ion Xpress 
Barcode Adaptors (Life Technologies) were then ligated, and the template-fragments were 
size-selected by using AmPure beads (Agencourt). Adaptor-ligated fragments were then PCR 
amplified and cleaned by using AmPure beads and quality checked on TapeStation (Agilent). 
Finally, sequencing libraries were quantitated by using an Ion Library TaqMan Quantitation Kit 
(Life Technologies). These sequencing libraries were prepared for sequencing by using Ion 
OneTouch reagents according to the manufacturer’s instructions (Life Technologies). Finally, 
template-positive sequencing beads were deposited to an Ion 318 chip and sequencing was 
performed with the Ion Hi-Q Sequencing Kit on an Ion Personal Genome Machine System 
(Life Technologies).  
Following sequencing, nucleobase calling from the raw sequencing data was carried 
out within the Ion Torrent Suite. The tmap read mapper module of Torrent Suite was used to 
align sequencing reads to the E. coli K-12 MG1655 genome (NCBI reference sequence: 
U00096.3). Next, single nucleotide substitutions, small insertions, and deletions were detected 
compared to the reference E. coli genome by the Torrent Variant caller (i.e., the tvc) module. 
Only mutations that were represented at least on 12 sequencing reads and on at least 66% of 
all sequencing reads that aligned to the given reference position were voted as true mutations. 
Moreover, only those variants were taken into account that was supported by sequencing on 
both strands of the sequencing read. Mutations that were not targeted by recombineering and 
were detected only in the edited clones, besides being absent in the parental strains were 
voted as off-target mutations. For a detailed list of off-target mutations see Appendix 5. 
 
High-throughput sequencing of soft-randomized oligos 
 
To analyze the characteristics and mutational spectrum of soft-randomization-based oligo 
synthesis for DIvERGE, we synthesized 90 nucleotide long soft-randomized oligos that were 
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complementary to the landing pad sequence. Within these oligos, each nucleotide position 
was soft-randomized with up to 2% of all 3 possible mismatching nucleobases. However, as 
the library preparation step (i.e. the NEBNext DNA Library Prep Master Mix from New England 
Biolabs) of Illumina sequencing accepts only dsDNA fragments, we had to develop a PCR-
free method to convert soft-randomized DNA oligonucleotides to dsDNA strands before we 
have been able to analyze nucleotide composition. To this aim, we made each oligo double-
stranded by annealing each soft-randomized strand to their non-randomized reverse 
complement that was chemically synthesized under identical conditions. Therefore, we 
equimolarly mixed complementary oligo pairs in 50 µl of H2O and mixed with 2.5 µl of 1 M 
NaCl. Samples were then heated to 95 °C for 5 minutes and slowly allowed to cool to room 
temperature within 120 minutes. Next, 650 ng of these annealed dsDNA oligos were 5’ end 
phosphorylated with T4 DNA polynucleotide kinase. Ligase reactions were then cleaned with 
AMPure XP beads (Beckman Coulter), and the DNA was eluted in nuclease-free H2O. Next, 
dsDNA oligos were dA-tailed by using a NEBNext DNA Library Prep kit. During dA tailing, end 
repair was excluded because we observed the additional removal of mismatching 
nucleobases at the end of hybridized strands that falsely generated mutation-free oligo-ends. 
After the purification of dA-tailed products with AMPure XP beads, 10 µls of this dA-tailed 
samples were ligated with sequencing adaptors. To minimize adaptor dimer formation, dA-
tailed DNA:adaptor concentration was set to 1:2. Library preparation and sequencing was then 
performed by using NEBNext DNA Library Prep Master Mix Set for Illumina (New England 
Biolabs) according to the manufacturer’s instructions. Finally, the sequencing of at least 105 
oligonucleotides from each sample was achieved by using a MiSeq Reagent Kit v2 for paired-
end sequencing on an Illumina MiSeq sequencer. However, it should be noted that this 
sequencing-library preparation protocol resulted in the removal of mismatching nucleobases 
from the last terminal 2 positions at both the 3’ and 5’ ends, due to the lack of adaptor-ligation 
if mismatches at those positions destabilized the ends of dsDNA oligonucleotides. Therefore 
these positions were excluded from further library-composition analyses. 
 
Illumina sequencing-based analysis of folA and landing pad libraries  
 
To quantify the distribution and spectrum of mutation at folA and at the landing pad in 
DIvERGE experiments, we developed a PCR amplicon deep sequencing-based mutational 
assay. This assay, in conjunction with subsequent Illumina sequencing and strict sequencing 
noise removal on the course of sequence data processing, allowed us to precisely identify 
mutations at the target site.  
Our protocol relied on the high preciosity PCR amplification of the target locus. In order 
to minimize PCR mutagenesis during amplicon preparation, previously isolated gDNA 
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samples were subjected to the minimum number of PCR that generated enough amplicon 
template for sequencing reactions (i.e., between 200 – 500 ng). This was usually achievable 
by 18 – 20 subsequent cycles of PCR. To achieve the possible lowest error rate, PCRs were 
performed in 50 ul of Phusion High-Fidelity PCR Master Mix (Thermo Fisher Scientific) using 
the corresponding primer pairs. Next, PCR amplicons that contained the entire target locus 
were digested using NEBNext dsDNA Fragmentase (New England Biolabs) for 12 - 15 
minutes to yield approximately 190 base pair fragments. Digested amplicons were then 
purified, and sequencing libraries were prepared as described previously for landing pad 
libraries. Finally, sequencing was done by using MiSeq v2 reagent kit for 250 base pair paired-
end sequencing run on a MiSeq Illumina sequencer. 
Fragmentation allowed us to decrease the error rate on the course of Paired-end 
Illumina MiSeq sequencing: Prior analyses demonstrated that the fidelity of Illumina MiSeq 
sequencing substantially decreases after the 3’ 200th nucleotide in the sequencing read. 
Thereby, limiting the length of sequencing reads below 200 nucleobases increased the 
probability of correct base-calling [135]. To this aim, on the course of bioinformatic analyses 
of raw sequence data, based above the 200th nucleobases in each sequencing read were also 
excluded from analyses.  
 
Assessing mutational profiles with Pacific Biosciences Single Molecule Real-Time 
sequencing 
 
Illumina sequencing, however, is not suitable to precisely analyze the allelic composition and 
the combination of distant mutations at loci that are longer than ~400 base pairs. This limitation 
arises due to the inherent error rate of sequencing and the mediocre read lengths of current 
Illumina sequencing methods [135,136]. Currently, only single molecule long read sequencing 
methods, i.e., Pacific Biosciences Single Molecule Real-Time (SMRT)-, Oxford Nanopore, and 
10X Genomics synthetic long-read sequencing are suitable to accurately assess the genotype 
of DNA strands that are longer than 600 nucleotides [137–139]. Therefore and based on its 
superior error rate, the availability of multiplex PCR amplicon sequencing methods, and the 
ease of sequencing library preparation, we relied on Pacific Biosciences single molecule real-
time (SMRT) sequencing to assess the genotypic composition of folA, DNA gyrase, and 
topoisomerase IV variant libraries. To access Pacific Bioscences sequencing service, we built 
up a fee-for-service collaboration with the Norwegian Sequencing Centre (NSC UiO), a 
national sequencing technology platform hosted by the University of Oslo in Norway. 
Specifically, to assess the genotypic composition of genomic libraries at folA, gyrA, 
gyrB, parE, and parC in multiple species we relied on Pacific Biosciences RSII Single Molecule 
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Real-Time (SMRT) circular-consensus amplicon sequencing. In order to minimize PCR-
induced mutagenesis during sequencing library preparation, previously isolated gDNA 
samples (200 ng) served as a template for Phusion High-Fidelity PCR with the corresponding 
species and sample specific barcoded primer pairs (Appendix 3). These barcodes allowed us 
to pool and sequence up-to 80 distinct sequencing sample in a single sequencing reaction. 
PCR reactions were performed in 50 l reaction volumes according to the following 
parameters: 98 °C initial denaturation for 3 min, 18-22 cycles of (98 °C 20 seconds; 63 °C 0.5 
minutes; 72 °C 1.5 minutes), and final extension for 5 minutes at 72 °C. On the course of PCR 
amplicon preparation, to minimize overamplification that can cause biases in library-
composition, and to avoid amplicon-chimera formation, PCR reactions were stopped at the 
mid-exponential phase of amplification. Finally, PCR amplicons were purified by using a Zymo 
DNA Clean and Concentrator kit (Zymo Research) and eluted in 30 µl 0.5× TE buffer. PCR 
amplicons were then mixed at an equimolar ratio and shipped to the Norwegian Sequencing 
Centre on dry ice. The preparation of sequencing libraries (the ligation of SMRTBell adapters) 
and their sequencing on Pacific Biosciences RSII SMRT cells was performed by the 
Norwegian Sequencing Centre (Norway) on a Pacific Biosciences RSII sequencer. 
 
Mutational analysis of landing pad libraries and DIvERGE oligo pools 
 
The analysis of Illumina MiSeq sequencing data was performed in collaboration with Balázs 
Bálint, Bálint Márk Vásárhelyi, and István Nagy (SeqOmics Biotechnology Ltd). Specifically, 
sequencing data were analyzed by using a bioinformatics pipeline that we developed to 
increase sequencing-accuracy and reduce sequencing noise. Briefly, to remove sequencing 
read-ends that have a higher error rate, paired-end Illumina MiSeq reads were first trimmed 
to 190 nucleotides. Next, trimmed reads were further trimmed based on sequencing quality 
and all nucleotides that had an error probability that was higher than 0.1% were excluded from 
follow-up analysis. Next, overlapping paired-end sequencing read pairs were merged into a 
single read by using CLC Genomics Workbench 9.0. Following read pre-processing, 
sequencing data analysis was carried out based on the sample-source of the data. When 
analyzing landing pad libraries following DIvERGE-mutagenesis, sequencing reads were 
aligned to the wild-type sequence of the landing pad by using CLC Genomics Workbench 9.0. 
When we assessed the sequence composition of soft-randomized DIvERGE oligos and their 
corresponding genomic targets after genomic integration, BWA-MEM was applied. Following 
alignment, it was necessary to filter out erroneous sequencing reads and alignment-artifacts. 
To this aim, erroneous alignments were removed with SAMtools version 0.1.19-96b5f2294a 
and NGSUtils version 0.5.7-e98ddfa. Next, sequencing reads that do not span the entire 
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TETRM oligo-target region were removed with JVarkit. Finally, the number of nucleobase 
alterations between mapped sequencing reads and their target region were reported with 
BLASTn and alterations, as compared to the wild-type target sequence, were summarized 
with Pysamstats version 0.24.2. In all cases, mutation frequency at every nucleotide position 
was calculated as the ratio of reads that contained substitutions, insertions, or deletions at the 
given nucleotide position. Diversified target positions within the landing pad were defined as 
the nucleotide positions where mutation frequency exceeded 6-times the standard deviation 
of the background sequencing noise. Sequencing noise for this purpose was measured in 
each sequencing sample at an untargeted region within the landing pad, between the target 
site of TETRM1 and TETRM3 oligos. 
 
 
Mutation composition analysis of folA libraries based on Illumina sequencing 
 
To identify mutations and assess the nucleotide composition of folA libraries from E. coli K-12 
MG1655 and E. coli CFT073, we have developed a custom Python program-package with 
built-in filters for Illumina sequencing error reduction. Similarly to the previously described 
landing pad libraries, Illumina sequencing reads were first trimmed to 190 nucleotides to 
remove erroneous bases. Next, these trimmed reads were further trimmed based on 
sequencing quality. All nucleotides that had an error probability that was higher than 1‰ were 
excluded from further analysis and removed with BBduk. Next, the resulted overlapping 
sequencing read-pairs were merged, and sequencing reads that contained any ambiguous 
nucleotide (i.e., N) and reads that were shorter than 72 nucleobases were also removed. 
These filtered sequencing reads were subsequently mapped with BWA-MEM to their 
corresponding genomic targets. Finally, Pysamstats version 0.24.2 was used to measure 
mutation frequency and to generate a nucleotide composition table for each targeted reference 
position. The single-step mutational landscape of folA from scanning DIvERGE libraries was 
determined based on sequencing reads that displayed exactly and only one nucleobase 
substitution compared to their genomic target sequence. These reads were translated to 
amino acid sequences. These peptides were then compared to their corresponding coding 
sequence to analyze amino acid composition for each reference position. This final program 
was made publicly available and is now accessible at http://group.szbk.u-
szeged.hu/sysbiol/EvGEn/diverge-2018-script.html under the name 
DIvERGE_Illumina_script.zip. All Illumina and Pacific Biosciences DNA sequencing data is 
available in Appendix 6. 
 
34 
 
Assessing mutation profiles in folA libraries based on Pacific Biosciences 
sequencing 
 
Following sequencing, raw Pacific Biosciences RSII sequencing data was processed by the 
Norwegian Sequencing Centre to demultiplex samples based on their unique, symmetric 16 
base pair long barcode sequence that we attached on the course of library. Demultiplexing 
and circular consensus read generation were performed by SMRT Analysis 2.3 from Pacific 
Biosciences. Next, circular consensus sequencing reads were imported to CLC Genomics 
Workbench 9.0 and mapped to their corresponding genomic target region. Reads with an 
ambiguous nucleotide and reads that were shorter than 80% of their wild-type genomic target 
or had less than 90% sequence identity to their target were discarded. This ensured the 
removal of erroneous sequencing reads. On the course of alignment, reads were individually 
mapped to their target sequence either on Escherichia coli K-12 MG1655 (NCBI Reference 
Sequence: NC_000913.3), or on Escherichia coli CFT073 (NCBI Reference Sequence: 
NC_004431.1), or on the chromosome of Salmonella enterica LT2 (NCBI Reference 
Sequence: NC_003197.1), according to their origin. Finally, nucleotide substitutions in each 
sequencing read were determined simultaneously with any associated amino acid alterations 
compared to the reference sequence. On the course of variant analysis, only mutations that 
had an error probability that was lower than 1% were considered. DNA gyrase allele frequency 
values were plotted on the crystal structure of topoisomerase protein complex from 
Mycobacterium tuberculosis (Protein Data Bank identifier: 5BS8). 
 
Genomic integration of defined mutations 
 
Defied mutations within the chromosomes of E. coli K-12 MG1655, E. coli UPEC CFT073, 
Citrobacter freundii ATCC 8090, and Klebsiella pneumoniae ATCC 10031 were constructed 
within the wild-type parental strains by using pORTMAGE3 recombineering according to our 
previously described ssDNA-recombineering protocol (see ssDNA-recombineering protocol, 
and reference [130]). To construct defined mutations, ssDNA oligonucleotides that carried the 
mutation-of-interest were designed and synthesized to target the replicating lagging-strand of 
gyrA, parC or folA in the corresponding bacterial strain. The corresponding oligonucleotides 
for mutant reconstructions and PCR-based allele confirmations are listed in Appendix 3. 
Mutants were generated by performing a single ssDNA-recombineering cycle with 
pORTMAGE3 according to the general ssDNA-recombineering protocol. Mutant clones were 
then plated to agar plates, and the presence of the corresponding mutations were confirmed 
by colony-PCR and subsequent capillary sequencing of the oligo-target region. 
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In vitro growth rate measurements 
 
We measured bacterial fitness as growth rates in a rich bacterial medium (LBL) under aerobic 
conditions. To investigate interferences between mutagenesis and cell viability, we measured 
30, randomly chosen E. coli K-12 MG1655 wild-type, MP6-mutagenized E. coli K-12 MG1655, 
and DIvERGE-mutagenized E. coli K-12 MG1655 trimethoprim-resistant isolates in LBL 
medium. Cultures of these mutants were cultured in LBL broth and incubated at 30 °C until 
they reached stationary phase. Then we transferred approximately 1000 cells from each 
mutant into 96-well plates, containing 0.1 ml LBL medium. Following inoculation, cells were 
grown at 30 °C in a Powerwave XS2 (Biotek) automated microplate spectrophotometer under 
continuous agitation. Growth curves were recorded by measuring the optical density of the 
cultures (OD600 nm) at every 7 minutes for 24 hours. Finally, growth rates were calculated from 
the obtained growth curves [140,141]. 
 
Antibiotic drug susceptibility measurements 
 
To select variant libraries and assess the susceptibility of bacterial strains under selective 
conditions, we measured antibiotic susceptibilities under different growth conditions. Minimal 
Salt + casamino acid agar-surface-based minimum inhibitory concentrations (MICs) of 
trimethoprim for E. coli K-12 MG1655, E. coli CFT073, and Salmonella enterica LT2 were 
assessed by using E-test strips according to the manufacturer’s protocol (bioMerieux). 
Trimethoprim susceptibility was determined in Minimal Salt media + casamino acid (without 
thiamine). Trimethoprim resistance of individually isolated bacterial strains were quantified as 
the 75 % inhibitory concentration of trimethoprim (IC75) in Minimal Salt + casamino acid broth. 
Specifically, the IC75 value of the given bacterial isolate was calculated as the trimethoprim 
concentration at which the area under the growth curve of the given cell population was equal 
to 25% of a control cell population of the same strain that was grown without antibiotic. To 
obtain growth curves, bacterial isolates were grown in the presence of an increasing 
trimethoprim concentration gradient, according to our general protocol for in vitro growth rate 
measurements. All IC75 measurements were performed in triplicates. 
To assess the maximal IC75 values within pooled mutant libraries, we performed a 
competition-based antibiotic susceptibility measurement. Compared to the drug susceptibility 
testing of individual genotypes, competition experiments enriched the least drug-susceptible 
variant from a library of different genotypes and assessed its IC75 value. To perform 
competition, 100 – 150 distinct bacterial colonies from the given, trimethoprim-selected library 
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were scraped off, and the IC75 values were determined for approximately one million cells 
from these pooled cell populations. Competition experiments were performed in triplicates.  
Ciprofloxacin and gepotidacin MICs for wild-type E. coli K-12 MG1655, Citrobacter 
freundii ATCC 8090, Klebsiella pneumoniae ATCC 10031, and their corresponding isogenic 
mutants were determined by a microdilution-based MIC assay. Microdilution-based MIC 
assays were performed in triplicates in 96-well plates according to the general EUCAST 
protocol at 30 °C [142]. Ciprofloxacin susceptibilities were determined in LBL broth, while 
gepotidacin MICs were assayed in cation-adjusted Mueller Hinton II broth (Sigma-Aldrich) 
following 18 hours of incubation. 
 
Mutation rate measurements 
 
We measured the phenotypic effect of the plasmid-based expression of E. coli MutL E32→K 
(ecmutL E32→K) on the mutation rates of E. coli K-12 MG1655, Salmonella enterica serovar 
Typhimurium LT2, Citrobacter freundii ATCC 8090, Edwardsiella tarda ATCC 15947, and 
Escherichia hermannii HNCMB 35034 in a rifampicin frequency-of-resistance and subsequent 
fluctuation assay. First, strains, harboring the anhydrotetracycline-inducible pZA31tetR-
mutLE32K plasmid for ecMutL E32→K overexpression were inoculated into 1 ml 20 µg/ml 
chloramphenicol-containing LBL broth. Strains were grown separately either in the presence 
or in the absence of 100 ng/ml anhydrotetracycline that induced the overexpression of ecMutL 
E32→K. After overnight growth at 30 °C, 104 cells from each of these starter cultures were 
transferred into 10 separate tubes that contained 1 ml chloramphenicol-supplemented LBL 
broth with or without 100 ng/ml anhydrotetracycline, respectively. Next, these individual 
cultures were allowed to reach stationary phase by incubating them at 30 °C under constant 
agitation. Diluted samples from these cultures were then spread onto both LBL agar plates 
and LBL agar plates containing 100 μg/ml rifampicin. Agar plates were then incubated at 37 
°C, and the number of colonies were determined after 1 day of incubation. These mutation 
frequency assays were performed in duplicates. Finally, mutation rate was calculated from the 
frequency of rifampicin resistant colonies in each culture by using the Ma-Sandri-Sarkar 
maximum-likelihood method within the FALCOR analysis tool [143] available at 
http://www.mitochondria.org/protocols/FALCOR.html. 
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Results 
 
Characterization of a dominant negative allele of E. coli MutL 
 
As the first step, we have characterized the phenotypic effect of a previously described allele 
of E. coli MutL (ecMutL E32→K) by Aronshtam A et. al. [144]. When expressed from a plasmid, 
this variant is known to induce a mutator phenotype even in the presence of the wild-type 
methyl-directed mismatch repair (MMR) system of E. coli. Therefore, by using standard 
cloning techniques, we have reconstructed and cloned this mutant allele into the 
anhydrotetracycline-inducible pZA31tetR expression vector. Next, we have measured the 
mutation rates in wild-type E. coli K-12 MG1655 cells with and without the induction of ecMutL 
E32→K overexpression. The induced overexpression of ecMutL E32→K resulted in an over 
30-fold increase in mutation rate in wild-type E. coli cells as measured by rifampicin frequency-
of-resistance assay and subsequent fluctuation tests [143] (Figure 4). Also, we have 
demonstrated that in the presence of ecMutL E32→K, the mutation rate approached that of 
an E. coli MG1655 strain lacking the functional MMR machinery (i.e. a mutS mutant) 
[130,145]. Moreover, these findings indicate that the wild-type genomic copy of mutL is not 
able to suppress the effect of the dominant negative variant. Based on these results, we have 
concluded that the controlled overexpression of ecMutL E32→K would enable the controlled 
on-off switch of MMR repair, fully accomplished by a plasmid-based expression system and 
without the inactivation of the genomic copy of mutL. 
 
Figure 4. Mutation rate of E. coli K-12 MG1655 harboring the anhydrotetracycline-
inducible pZA31tetR-mutLE32K plasmid which overexpresses ecMutL E32→K, a 
dominant negative mutator allele of E. coli MutL. Mutation rates were assessed by the 
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rifampicin frequency-of-resistance assay and subsequent fluctuation tests. Error bars 
represent 95% confidence intervals based on 20 replicates for each sample. 
 
Construction of a plasmid-based MAGE system with mismatch repair control 
 
We hypothesized that the plasmid-based overproduction of the dominant negative ecMutL 
E32→K allele would allow a transient and controllable switch from a non-mutator to a mutator 
phenotype. Moreover, as the effect of the ecMutL E32→K allele cannot be suppressed by the 
native wild-type copy of mutL, thus no disruption of the genomic allele would be required.  
The traditional MAGE method uses a temperature-regulated expression system which 
is controlled by the temperature-inducible cI857 repressor–pL promoter system [34]. This 
expression platform enables an exceptionally rapid and high-level overexpression of λ Red 
proteins. Based on this desirable feature, we hypothesized that by constructing a synthetic 
bacterial operon that encodes and co-expresses ecMutL E32→K and the necessary genes of 
λ recombineering (exo, bet, gam), the construction of a plasmid-based MAGE system would 
be feasible.  
To test the functionality of co-expression, we have constructed a synthetic operon that 
contained all three genes of λ recombineering and mutL E32K on a broad host-range vector. 
This plasmid included the pBBR1 broad host-range origin-of-replication, isolated originally 
from Bordetella bronchiseptica [146], and finally resulting in the development of pORTMAGE 
plasmids (Figure 5). In this synthetic operon the expression of E. coli mutL E32K, as well as 
exo, bet, and gam were under the control of the cI857 temperature-sensitive λ repressor-
regulated pL promoter.  
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Figure 5. General structure of the pORTMAGE plasmids. Expression of ecMutL E32→K in 
conjunction with the three λ recombinase genes (exo, bet, and gam) is controlled by the cI857 
temperature-sensitive λ repressor regulated pL promoter-based induction system. 
 
Next, to investigate the effect of the expression of the dominant MutL allele on the efficiency 
of ssDNA-recombineering, we have employed a previously characterized test system in E. coli 
K-12 MG1655 [62,147]. This system relies on the genomic introduction of a diverse set of 
single nucleotide mismatches (A:G, T:T, A:A, G:A, C:T, G:T, G:G, and C:A, according to the 
given chromosomal to synthetic nucleobase mismatch) into the genomic copy of lacZ at 
specific locations. In turn, the incorporation of these mutations induces a premature stop 
codon. Thus, these mutations result in the premature termination of LacZ, so the frequency of 
allelic replacements can be detected easily by a colorimetric assay that visualizes the 
enzymatic function of LacZ. LacZ (beta-galactosidase) hydrolyzes the terminal non-reducing 
beta-D-galactose residues into beta-D-galactosides.  
Based on single pORTMAGE cycles in E. coli K-12 MG1655 performed individually with each 
lacZ-targeting oligo, we have found that in all cases, pORTMAGE allowed of a highly efficient 
oligo incorporation, while the plasmid lacking the expression of ecMutL E32→K (pSIM8) 
produced highly biased oligo-incorporation. Moreover, the efficiency of pORTMAGE to 
incorporate single-nucleotide mismatches was comparable to the efficiency of the traditional 
MAGE protocol [38,62] (Figure 6).  
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Figure 6. Allelic replacement efficiencies of oligos inducing various types of single 
nucleotide mismatches in the chromosome of E. coli K-12 MG1655 in the presence of the 
wild-type mismatch repair machinery (pSIM8, a plasmid that solely expresses λ Red 
recombinases) and ecMutL E32→K-controlled MMR from pORTMAGE. The frequency of 
allelic replacement was estimated as the number of LacZ-inactivated cells per the total number 
of cells on MacConkey agar plates. The values are the means of two independent 
measurements. Error bars represent the standard error of the mean. 
 
Genome engineering with pORTMAGE avoids off-target mutagenesis 
 
In each MAGE cycle, the expression of λ Red recombinases is induced by a single temporal 
temperature shift lasting for 15 minutes [38]. In each genome engineering cycle, decreased 
MMR activity is only required during the period of oligo annealing and incorporation. Therefore, 
by coupling λ recombinase and ecMutL E32→K expression on pORTMAGE to rapidly switch 
the cell’s phenotype between mutator and non-mutator states immediately before oligo 
incorporation, we hypothesized that the application of pORTMAGE would minimize the time 
when bacterial cells display a mutator phenotype. In turn, the use of pORTMAGE would lower 
the time-frame when engineered bacteria are susceptible to the accumulation of off-target 
mutations. This would be highly advantageous compared to the traditional MAGE procedure 
which necessitates a permanently inactivated mismatch repair. 
To investigate the performance of pORTMAGE and off-target mutagenesis 
simultaneously on the course of iterative MAGE cycles, we have carried out a long-term 
multiplex genome editing project. Three strains, and in turn, three distinct genome engineering 
41 
 
approaches were compared: (I) an E. coli K-12 MG1655 MutS mutator strain carrying the 
control pSIM8 plasmid which solely expressed the λ Red recombinases [57] (representing the 
traditional MAGE method); (II) the wild-type E. coli K-12 MG1655 strain carrying pORTMAGE, 
and (III) the wild-type E. coli K-12 MG1655 strain carrying a control pSIM8 plasmid.  
To investigate the long-term accumulation of off-target mutations, we iteratively 
performed 24 consecutive cycles of MAGE while targeting six different, widely distributed loci 
across the genome of E. coli K-12 MG1655. These loci were individually targeted for 4 
consecutive MAGE cycles by oligos which introduced a specific type of mismatch (Table 1).  
 
Gene Genomic position Mismatch 
Corresponding 
oligo 
araB 69999 A:A araB_AA 
lacZ 364878 T:T LacZ_TT_v7 
hisB 2091657 G:T hisB_GT 
rpsL 3472447 A:C rpsL_AC 
malK 4245058 C:C MalK_CC_v1 
cycA 4428025–4428026 AA:AC cycA_AAAC 
 
Table 1. Genomic positions of the six marker genes targeted for recombineering on the 
chromosome of E. coli K-12 MG1655 (NCBI sequence identifier: NC_000913.3). The 
introduced modifications are marked as nucleotide mismatches, in chromosomal to synthetic 
order. Table adapted from Nyerges, Á. et al. Conditional DNA repair mutants enable highly 
precise genome engineering. Nucleic Acids Research 42, e62–e62 (2014) [67]. 
 
Following 4 cycles of ssDNA recombineering targeting each locus, allelic replacement 
efficiencies were determined at all loci-of-interest either by colorimetric MacConkey agar-
assays or allele-specific PCRs. Finally, as a confirmation, the clones carrying the desired 
alteration were also verified by capillary sequencing. 
As expected, in E. coli K-12 MG1655 cell with λ Red recombinase expression only (i.e. 
pSIM8) and without the inactivation of MMR, the allelic replacement efficiency was very low in 
most cases. LacZ A652→T and malK C252→G are being exceptions as the corresponding 
mutations are poorly recognized by the cells endogenous methyl-directed mismatch repair, 
and thereby their incorporation is not hindered by the presence of the native mismatch repair 
machinery. On the contrary to what we observed in E. coli MG1655 cells + pSIM8, E. coli K-
12 MG1655 with pORTMAGE-based recombineering generally displayed highly efficient allelic 
replacement, approaching the efficiency observed with traditional MAGE which uses 
permanent MMR inactivation (E. coli K-12 MG1655 mutS + pSIM8) (Table 2). 
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 Allelic replacement efficiency (%) 
E. coli strain 
lacZ 
A652T 
malK 
C252G 
araB 
T50A 
hisB 
C166T 
rpsL 
A128G 
cycA 
AA139TG 
MG1655 
+ pORTMAGE 
54.58 61.56 39.76 22.92 33.76 22.92 
MG1655 mutS 
+ pSIM8 
51.32 60.23 62.87 39.58 38.91 41.67 
MG1655  
+ pSIM8 
45.31 51.82 1.56 < 0.1 0.72 1.04 
 
Table 2. Allelic replacement efficiencies in E. coli K-12 MG1655 + pSIM8, MG1655 ΔmutS 
+ pSIM8, and MG1655 + pORTMAGE after four consecutive ssDNA-recombineering cycles 
targeting each given locus. Allelic replacement efficiencies represents the ratio of cells (in %) 
carrying the corresponding mutations within the entire cell population that underwent 
mutagenesis. Allelic replacement efficiencies were determined at all loci either by colorimetric 
MacConkey agar-assays or allele-specific PCRs (see Methods). 
 
Next, we have investigated the accumulation of off-target mutations. After 24 iterative 
recombineering cycles, we have selected one independently edited clone from E. coli K-12 
MG1655 + pORTMAGE, MG1655 ΔmutS + pSIM8, and MG1655 + pSIM8, respectively. To 
quantify off-target mutagenesis, the whole genomes of the parental cell and the MAGE-derived 
clones were sequenced. Sequence analysis revealed that E. coli K-12 MG1655 + pSIM8, 
without mismatch repair inactivation, had accumulated only two off-target mutations. In 
contrast, E. coli K-12 MG1655 ΔmutS + pSIM8, the strain that was engineered according to 
the traditional MAGE protocol, had mutated at 84 non-targeted positions. This observation is 
in line with previous studies [52,65]. Remarkably, we have found no off-target mutations in 
wild-type E. coli K-12 MG1655 which had been engineered with pORTMAGE.  
In summary, these results have demonstrated that pORTMAGE facilitates highly 
efficient allelic replacement, coupled with a remarkably reduced rate of off-target mutations. 
 
pORTMAGE allows rapid genome editing in a range of bacterial species 
 
Phylogenetic comparison of MutL sequences indicate that glutamic acid (E) at the 32nd position 
of EcMutL is conserved in a wide range of species, ranging from MutL sequences in 
Proteobacteria to the homologous MLH1 in Saccharomyces cerevisiae [130]. We therefore 
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assumed that the dominant mutation E32→K at this amino acid residue could have a similar 
phenotypic effect in a broad range of bacterial species.  
To investigate this concept in details, we have tested the impact of the dominant 
EcMutL E32→K allele on mutation rates in several enterobacterial species. We have selected 
the human pathogen Salmonella enterica serovar. Typhimurium, the fish pathogen 
Edwardsiella tarda, the opportunistic pathogen Escherichia hermanii, Citrobacter freundii, and 
the biotechnologically relevant production-host E. coli BL21(DE3) as target organisms. In 
agreement with our hypothesis, the overexpression of E. coli MutL E32→K from the 
anhydrotetracycline-inducible plasmid pZA31tetR-mutLE32K largely increased mutation rates 
in all species (see Appendix 4). Also, the level of increase in mutation rate was comparable to 
the mismatch repair deficient variants of these strains. These results suggest that the co-
expression of the dominant MutL allele from E. coli and the λ Red recombinases from 
pORTMAGE would have a similar effect in all phylogenetically related strains.  
Therefore, to further test this assumption, we have compared the allelic replacement 
efficacy of pORTMAGE in E. coli K-12 MG1655 and its relatives, Salmonella enterica and 
Citrobacter freundii which diverged from E. coli approximately 100 - 200 million years ago 
[148,149]. Also, to broaden the potential applications of pORTMAGE, we have engineered 
three modified pORTMAGE plasmids with different antibiotic resistance markers (termed 
pORTMAGE3 and 4). To characterize the performance of pORTMAGE uniformly across these 
target species, we have constructed a landing pad sequence and have integrated it into the 
aspartate-ammonia ligase gene (asnA) of the host genome. Next, we have utilized this 
genomically integrated landing pad as the target sequence for recombineering (Figure 7). The 
application of this identical landing pad sequence at a fixed position on the bacterial 
chromosome nearby the origin of replication (oriC) has allowed us to avoid sequence-context-
specific effects in recombineering. To perform recombineering at the landing pad, we have 
designed five, 90-nucleotide-long mutagenizing oligos that introduced all possible single 
nucleobase mismatches at five different positions within the landing pad. 
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Figure 7. General map of the landing pad sequence inserted into E. coli K-12 MG1655, 
S. enterica and C. freundii. The green region represents the target sequence for allelic 
replacement treated with a set of five oligos shown in the targeting box. For each of the five 
genome editing oligonucleotides, degenerate bases (Ns) are shown in red. The cat 
(chloramphenicol acetyltransferase) gene that confers resistance to chloramphenicol has 
allowed us to introduce the landing pad into the genome via double-stranded DNA-
recombineering. 
 
Next, allelic replacement efficiencies were measured by performing a single ssDNA-
recombineering cycle using these 5 oligos admixed into a single pool. As in our previous 
experiments, we have compared the efficiencies characteristic of (I) the wild-type strain 
carrying the pSIM8 plasmid, (II) wild-type mismatch repair proficient cells carrying a 
pORTMAGE plasmid, and (III) the mutS mutator strain carrying only pSIM8. To accurately 
measure the efficiency of oligo integration into the landing pad within the resulting cell library, 
we have developed an Illumina MiSeq-based deep-sequencing method that precisely 
assesses allelic composition within the bacterial population.  
Allelic replacement efficiencies in the wild-type cells carrying only pSIM8 for λ Red 
recombinase-expression was found to vary substantially across E. coli, S. enterica, and C. 
freundii (Figure 8A-C). These results, in turn, suggest strain-specific variations in mismatch 
repair. Also, mutations introducing the same mismatch at different genomic positions 
frequently showed differences in their integration efficiency, indicating the DNA sequence 
context dependency of mismatch repair.  
In the other hand, however, the allelic replacement executed by pORTMAGE was in certain 
cases nearly 100-fold more efficient and largely unbiased in all three species compared to the 
wild-type control (Figure 8A-C). In E. coli K-12 MG1655, allelic replacement efficiencies with 
pORTMAGE approached the efficiencies obtained in the corresponding mutS variant. In C. 
freundii, pORTMAGE showed a similarly robust performance as in E. coli and S. enterica 
(Figure 8C). 
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Figure 8. Allelic replacement efficiencies at the landing pad in (A) E. coli K-12 MG1655, 
(B) Salmonella enterica serovar Typhimurium LT2, and (C) Citrobacter freundii ATCC 
8090. Figure displays the means of the results of two independent Illumina deep-sequencing 
assays. Error bars represent the standard error of the mean (n = 2). Star (*) denotes oligos 
generating the same mismatch as another oligo to demonstrate context dependency of allelic 
replacement. MutS(-) denotes strain carrying a deletion of mutS. 
 
pORTMAGE efficiently generates mutant libraries in multiple bacterial species 
 
To characterize pORTMAGE, we have introduced sequence diversity at a specific genetic 
locus in multiple bacterial species. Specifically, we have randomized six individual 
nucleobases within the endogenous asnA of three phylogenetically related species, E. coli, S. 
enterica, and C. freundii. Using organism-specific, 90-base-long oligos carrying six 
randomized positions, we have carried out five cycles of MAGE with and without mismatch 
repair control in all target species. Next, genomic DNA was isolated from the resulting cell 
library and the oligo target region was amplified by PCR. Finally, these PCR fragments were 
subjected to Illumina sequencing to analyze the allelic composition within each bacterial 
population. In all three species, allelic replacement efficiencies with pORTMAGE were at least 
an order of magnitude higher at all targeted positions than the frequencies obtained with 
pSIM8 (Figure 9). Additionally, pORTMAGE substantially reduced the biases in oligo-
incorporation which allowed for a more uniform representation of each mutant within the 
population. Importantly, by using pORTMAGE, we obtained a bias-free mutant library at the 
target locus in all species. Moreover, sequence analysis suggested that all possible single-
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step mutations and their combinations, approximately 4000 variants, were represented at a 
reasonable frequency within the resulting cell library.  
 
A 
 
B 
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Figure 9. Mutant library generation at asnA in (A) E. coli K-12 MG1655, (B) S. enterica 
serovar Typhimurium, and (C) C. freundii ATCC 8090. The first stacked column at each 
position indicates mutant library generation by using pSIM8, while the second column 
indicates mutagenesis that were performed by pORTMAGE (indicated with “+pMAGE”). The 
asnA genomic positions of each randomized nucleotide is displayed relative to the first 
nucleotide of the gene. The wild-type genomic nucleotide is indicated in parentheses. Values 
are based on a single Illumina amplicon deep-sequencing assay for each. 
 
These results suggest that pORTMAGE, after the transformation of a single plasmid, 
allows the rapid generation of large, unbiased sequence libraries carrying random mutations 
at desired positions in multiple enterobacterial species. In our follow-up work, this feature 
served as an enabling technology to scale-up oligo-recombineering in order to analyze 
mutational effects in a massively parallel manner within multiple bacterial species. 
 
Development of a method for the in vivo targeted mutagenesis of long genomic 
segments 
 
Single-stranded (ss) DNA-mediated recombineering is a highly versatile tool for multiplex 
bacterial genome engineering [11]. However, existing ssDNA recombineering-based 
techniques enable the randomization of very short sequences only (such as neighboring 
residues in a protein-coding sequence) [38,46,47]. This limitation is of great significance, as 
the efficiency of ssDNA-mediated recombineering depends on the oligo’s sequence identity to 
its target region. Thereby increasing the number of mismatches within a single oligonucleotide 
exponentially decreases the efficiency of oligo-incorporation during recombineering [38,43] 
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(Figure 10). Therefore, diversification of genome sequences which are longer than 
approximately 30 base pairs is not feasible with a single oligonucleotide [38,126]. This, in turn, 
hinders the exploration of the combinatorial sequence space and targeting extended genomic 
loci [129]. 
 
 
Figure 10. The relation between the level of soft-randomization of a 90-nucleobase-long 
oligonucleotide, the number of mismatches, and the efficiency of ssDNA-mediated 
genome editing. High level of randomization (i.e. 25% A : 25% T : 25% G : 25% C, marked 
with the letter N, the IUPAC code of degenerated nucleotide) generates a pool of sequences 
with limited homology to their target site. Soft-randomization (i.e. 94% of the wild-type 
nucleotide admixed with 2–2% of the other 3 possible nucleotides, termed as 2% soft-
randomization) mainly produces highly homologous sequences compared to their target. As 
the number of mismatching bases is logarithmically related to allelic-replacement (AR) 
efficiency, increasing oligo-randomization level during DNA synthesis rapidly abolishes the 
efficiency of ssDNA-mediated genome editing. Figure is based on data from Wang, H. H. & 
Church, G. M. Meth. Enzymol. 498, 409–426 (2011) and optMAGEv0.9, available at 
http://arep.med.harvard.edu/optMAGE. 
 
Although a strategy has been proposed where the individual nucleotide positions are 
mutagenized separately by using a distinct oligo for each nucleotide position or amino acid 
encoding codon (i.e. MAGE-Seq and MO-MAGE) [31,90], these protocols require hundreds to 
thousands of individual oligos even for a single gene or regulatory sequence. Moreover, these 
methods do not allow of the simultaneous exploration of epistatic interactions across mutation 
combinations in a bias-free manner. Consequently, their application hinders a cost-effective 
genome engineering and the in-depth investigation of the phenotype-to-genotype landscape. 
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Thus, a cost effective method that does not necessitate high-throughput DNA synthesis to 
systematically explore mutational effects and perform targeted mutagenesis is eagerly 
needed.  
Therefore, we have developed an ssDNA-mediated, recombineering-based method 
which utilizes pools of partially overlapping, soft-randomized oligonucleotides and allows of 
up to a million-fold increase in mutation rate at multiple targets. This novel method, termed 
directed evolution with random genomic mutations (DIvERGE) (Figure 11), enables the 
exploration of vast numbers of combinatorial genetic alterations in their native context, while 
off-target mutagenesis is minimized [111]. 
To develop DIvERGE, based on the relation between the number of mismatches 
compared to a genomic target and the incorporation pattern of mutations from oligonucleotides 
with MAGE, we hypothesized that covering chromosomal segments with partially overlapping, 
mutagenizing oligonucleotides allows a uniform mutagenesis of the target segments. 
Additionally, by adjusting the randomization level in each oligonucleotide on the course of 
chemical DNA synthesis on a way to limit the number of mismatches compared to the target 
sequence would allow for an efficient integration of long mutagenizing oligos into their 
corresponding target site. Limiting the level of randomization during DNA synthesis would also 
ensure that all possible mutations and their combinations are represented in the synthesized 
oligo pool. Importantly, such randomized oligos can be straightforwardly synthesized using a 
soft-randomization-based phosphoramidite DNA synthesis protocol on most automated DNA 
synthesizers [150,151]. Soft-randomization-based synthesis would also enable the precise 
control of the rate and spectrum of mutations within each oligonucleotide. In fact, soft-
randomization can be described as the chemical DNA synthesis method that introduces a 
small amount of nucleotide-mixture at specific variable positions of the wild-type sequence 
[150,151]. To generate soft-randomized oligos in our case, oligos for recombineering were 
manufactured with soft-randomization along their entire sequence. It thereby generated oligos 
with randomly positioned random mutations along their entire length. As a practical advantage, 
the application of soft-randomized DNA synthesis also circumvents the need for expensive 
massively-parallel oligonucleotide synthesis, and reduces the costs to as little as 35 EUR (~40 
USD) for a single oligonucleotide library, which is two orders of magnitude lower than that for 
large-scale DNA synthesis methods [26,31,152].  
Based on the utility of this method to introduce genetic diversity at multiple genomic 
loci, we termed it ‘directed evolution with random genomic mutations’, or DIvERGE for short 
(Figure 11). 
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Figure 11. Schematic overview of directed evolution with random genomic mutations 
(DIvERGE). Soft-randomized DNA oligo synthesis precisely controls the rate and spectrum of 
mutations in partially overlapping oligos. These oligos fully cover the locus of interest (LOI) 
and induce mutagenesis at this target site after incorporation with pORTMAGE. By building 
on the cyclic workflow of pORTMAGE, DIvERGE proceeds via cell growth (1), oligo delivery 
and incorporation (2) and subsequent mutagenesis (3) that leads to a high genetic diversity at 
the target locus (4). Iterative repetition of this workflow (5) highly elevates genetic diversity 
within the mutagenized cell population. Figure is adapted from Nyerges, Á. et al. (2018) 
Directed evolution of multiple genomic loci allows the prediction of antibiotic resistance. 
Proceedings of the National Academy of Sciences, 115, E5726–E5735 [125]. 
 
Uniform and adjustable mutagenesis of selected genomic targets by soft-randomized 
oligos  
 
To test our hypothesis, we first tested whether the soft-randomized synthesis of DNA oligos 
can keep mutation rate and the mutational spectrum uniform along a defined sequence. 
Therefore, we synthesized 90-nucleotide-long soft-randomized oligos which were 
complementary to the previously designed landing pad [130]. Within these oligos, each 
nucleotide position was soft-randomized with 0 to 2% of all 3 possible mismatching 
nucleobases. This ratio of soft-randomization was defined as the fraction of mismatching 
nucleobases at each nucleotide position.  
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Next, the nucleotide composition within the resulting oligo was assayed by Illumina 
sequencing. In line with our expectations, soft-randomization induced a balanced distribution 
of mutations compared to the wild-type sequence of the landing pad, along the entire length 
of the oligonucleotide (Figure 12). 
 
 
Figure 12. Mutation frequency along a soft-randomized, 90-nucleotide-long 
oligonucleotide, TETRM3_05. The oligonucleotide was synthesized at each nucleotide 
position along its entire length of sequence by using a 0.5% nucleoside-phosphoramidite soft-
randomization (i.e. 98.5% of the wild-type nucleotide admixed with the other 3 possible 
nucleotides, 0.5% of each). Mutation frequencies are based on Illumina MiSeq sequencing of 
5×104 individual oligonucleotide strands. 
 
Next, we examined the genomic incorporation of soft-randomized ssDNA oligos at the 
landing pad sequence by pORTMAGE (Figure 13). Using two soft-randomized oligos, we have 
simultaneously targeted two 90-basepair-long regions within the landing pad, and performed 
five iterative pORTMAGE genome editing cycles with an equimolar mixture of both oligos 
(TETRM1 and TETRM3). Mutation frequency and the distribution of mutations at the genomic 
target were determined by Illumina sequencing. Sequence analysis of the two genomic loci 
revealed that soft-randomized oligos had successfully mutagenized their targets. Moreover, 
mutagenesis from a single 90-nucleotide-long oligo was extended to 78 nucleobases which is 
over 2.5-times longer than the maximum range of mutagenesis demonstrated by previous 
ssDNA-recombineering methods [38,126] (Figure 13). The decrease of recombineering 
efficiency at the oligo-termini is possibly due to the destabilizing effects of mismatches at these 
regions that subsequently prevents integration of mutations. This hypothesis is also supported 
by the detected mutation-integration pattern along the length of MAGE-oligos [40]. 
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Figure 13. Genomic mutation frequency of DIvERGE in E. coli K-12 MG1655 after 5 
cycles of mutagenesis. Two 90-basepair-long genomic regions separated by an 
intermediate region of 70 base pairs were targeted for mutagenesis with two pools of 2% soft-
randomized oligos (TETRM1_2 and TETRM3_2). The target sites are indicated as black lines 
beneath the x axis. A cut-off value of 0.2 % (dashed line) was used as a threshold to qualify 
diversified positions. Mutation frequencies are based on Illumina amplicon deep sequencing. 
 
Reassuringly, no major bias in mutational spectrum was detected along the target 
region, and the frequency of each individual substitution type fell between 13.8 and 22.4% in 
the genomic mutant library (Table 3). Moreover, the extent of sequence diversity of the 
population was tunable by the nucleotide admixing rate of the oligo pool used for soft-
randomization based DNA synthesis (Figure 14). 
 
 
Mutational bias 
indicator 
Oligonucleotide Genomic 
 Frequency (%) 
Standard 
deviation 
Frequency (%) 
Standard 
deviation 
A→G, T→C 13.8 0.8 13.8 0.4 
G→A, C→T  22.4 1.5 22.2 1.8 
A→T, T→A 15 1.1 17.1 1.4 
A→C, T→G 12.9 0.5 13.8 0.2 
G→C, C→G 14.2 0.4 14.8 1.1 
G→T, C→A 21.7 0.2 18.2 0.6 
 
Table 3. Mutagenic spectrum indicators of DIvERGE mutagenesis. Table shows the 
spectrum of substitutions in a 0.5% soft-randomized oligo, TETRM1_05, after 
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phosphoramidite-based DNA synthesis, and the resultant spectrum of mutations at the 
genomic target after five cycles of DIvERGE mutagenesis in E. coli K-12 MG1655. 
Frequencies and standard deviations are calculated from Illumina sequencing-based 
mutational composition analysis. 
 
 
Figure 14. Frequency of substitutions within the landing pad in the course of DIvERGE 
mutagenesis as the function of nucleotide admixing ratio (termed ‘spiking’) during DNA 
soft-randomization. Samples represent the allelic composition at the landing pad in E. coli 
K-12 MG1655 after 5 iterative DIvERGE mutagenesis cycles with oligos of the corresponding 
soft-randomization (i.e. ‘spiking’) ratio [151]. ‘Normal synthesis’ represents mutagenesis with 
a non-randomized oligo. Values are based on Illumina amplicon deep sequencing. 
 
Performing 5 DIvERGE cycles with medium-level soft-randomization, i.e. introducing 2-2-2% 
of admixed mismatching nucleobases within the oligo sequence at every position, resulted in 
an over one million-fold increase in the mutation rate at the oligo target compared to the 
background level. This corresponds to an increase from 2.2×10-10 to 2.4×10-4 mutations per 
nucleotide per generation, as measured by Illumina sequencing of the landing pad, and 
compared to the wild-type mutation rate of E. coli K-12 MG1655 [130]. Importantly, the 
mutation rate of non-targeted regions, which was measured at the non-targeted regions of the 
landing pad, remained low (Figure 13). Overall, DIvERGE enabled an efficient control of 
sequence diversification at the target loci of interest by the recombineering-based integration 
of soft-randomized ssDNA oligos. 
 
55 
 
Soft-randomized oligos efficiently mutagenize multiple bacterial species 
 
Based on the broad host-range functionality of pORTMAGE [125], we hypothesized that 
DIvERGE could also be applicable to distant relatives of E. coli as well. To test our hypothesis, 
again we selected Salmonella enterica serovar. Typhimurium LT2 and Citrobacter freundii 
ATCC 8090 as models. To characterize the efficiency of DIvERGE in a uniform manner across 
these species, we utilized our previously established landing pad assay. Similarly to our prior 
tests to characterize pORTMAGE, our landing pad system allowed us to assess the 
performance of DIvERGE by using the same set of oligos and the same protocol as in E. coli 
K-12 MG1655.  
To test the functionality of DIvERGE in both strains we relied on our general 
pORTMAGE protocol and integrated two soft-randomized oligos (TETRM03 and TETRM03) 
into the genomic landing pad of Salmonella and Citrobacter. As expected, the iterative 
integration of these oligos efficiently induced mutagenesis in both species (Figure 15) 
Moreover, we were able to achieve a mutation rate of at least 105-times higher at the target 
sequence in both species compared to their corresponding wild-type mutation rates (Table 4). 
 
A 
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Figure 15. DIvERGE is applicable to multiple bacterial species. Figure shows the increase 
in genomic mutation frequency, measured as the frequency of mutations occurring at a given 
nucleotide position after 5 consecutive DIvERGE cycles in (A) Salmonella enterica serovar. 
Typhimurium LT2 and (B) C. freundii ATCC 8090. Two 90-basepair-long genomic regions, 
separated by an intermediate region of 70 base pairs, were targeted for mutagenesis with two 
pools of 2% soft-randomized oligos (TETRM1_2 and TETRM3_2). The target sites of oligos 
are indicated as black lines beneath the x axis. The dashed line indicates a cut-off value of 
0.2% which served as a qualification marker of diversified positions. Mutation frequencies are 
based on Illumina amplicon deep sequencing. 
 
Table 4. Locus-specific elevation of mutation rates in Salmonella enterica, E. coli K-12 
MG1655, and C. freundii ATCC 8090 by DIvERGE mutagenesis at the landing pad. 
Strain 
Wild-type mutation rate 
(mutation/locus/generation) 
DIvERGE mutation rate 
(mutation/locus/generation) 
Fold increase in 
mutation rate 
induced by 
DIvERGE 
E. coli K-12 
MG1655 
1.10×10-8 1.22×10-2 1.11×106 
Salmonella 
enterica LT2 
6.37×10-8 0.92×10-2 1.44×105 
Citrobacter 
freundii 
ATCC 8090 
1.13×10-8 1×10-2 8.9×105 
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DIvERGE can mutagenize extended genomic regions  
 
Based on the observed incorporation pattern of soft-randomized oligos at the landing pad, we 
hypothesized that covering long genomic segments with multiple, partially overlapping soft-
randomized oligos would enable the uniform mutagenesis of extended targets. Therefore, we 
increased our genomic target site to 560 base pairs by designing and synthesizing multiple 
overlapping oligos where each oligo overlapped with the adjacent one, and thereby covered 
the entire target (as shown in figure 11). For the target loci we chose folA, which encodes the 
enzyme dihydrofolate reductase (FolA, or alternatively DHFR), and its promoter region. 
The enzyme encoded by folA provides the major dihydrofolate reductase activity in the 
tetrahydrofolate biosynthetic pathway. FolA catalyzes the reduction of dihydrofolate to 
tetrahydrofolate via hydride transfer from NADPH to the pteridine ring, using NADPH as a 
reducing cofactor [153,154]. E. coli FolA is a monomeric protein containing 159 amino acids. 
Tetrahydrofolate is an essential intermediate in the biosynthesis of proteins and nucleic acids, 
and therefore FolA is essential for cell division and growth. Thus, FolA is a frequent drug 
target: numerous approved drugs widely used in therapy are characterized by this mechanism 
of action, and have antitumor, antibacterial or antimalarial properties [154–156] (e.g. the 
antibiotic trimethoprim).  
 
 
 
Figure 16. Dihydrofolate reductase (FolA) of E. coli (Protein Data Bank ID: 1RH3) and 
the distribution of trimethoprim resistance-conferring amino acid positions on the 
surface FolA. Reported mutations conferring trimethoprim resistance are located at the active 
site of the enzyme and around the binding site for the NADPH cofactor (green). The figure is 
based on trimethoprim IC75 values of folA mutations as were reported in Nyerges, A et al., 
2018, PNAS.  
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Studying the evolutionary processes of folA has profound clinical importance, not only 
because dihydrofolate reductase is the target of the widely used antimicrobial drug 
trimethoprim, but also because it serves as a target for developing novel antibiotics (e.g. 
iclaprim [157]). Trimethoprim is also routinely used in therapy to treat E. coli infections [158]. 
Concerning E. coli, prior studies have demonstrated that under prolonged trimethoprim 
selection the evolution of antibiotic resistance develops predominantly through mutations at 
folA (Figure 16) or is caused by horizontally transferred, trimethoprim-insensitive folA variants 
[158–163]. Based on its role in trimethoprim resistance and the fact that folA mutants can 
easily be selected on antibiotic-containing agar plates, bacterial dihydrofolate reductases has 
been extensively studied to understand the evolution of antibiotic resistance and involved 
evolutionary mechanisms [164–166].  
Therefore, in order to investigate the utility of DIvERGE to rapidly evaluate 
trimethoprim resistance-conferring mutations of folA we have performed mutagenesis on the 
entire resistance-determinant locus of E. coli. As prior studies had demonstrated that 
trimethoprim resistance frequently results from mutations in both the folA promoter [161] and 
the protein-coding region of the gene [162,165,167], we have decided to mutagenize both 
regions in E. coli K-12 MG1655 by the simultaneous use of eight overlapping soft-randomized 
oligos. Based on the previously observed incorporation pattern of mutations induced by soft-
randomized DIvERGE oligos (Figure 13 and 15), we have applied 18-nucleotide-long overlaps 
between adjacent oligos to ensure uniform mutagenesis at all nucleotide positions. Overall, 
one DIvERGE oligo targeted the promoter region, while seven targeted the 480-basepair-long 
protein-coding sequence of folA. 
Using an equimolar mixture of these overlapping soft-randomized oligos, we first 
generated folA variant libraries with single point mutations at the target sequence. To achieve 
that we electroporated each of the soft-randomized oligos separately into pORTMAGE-
containing E. coli K-12 MG1655 cells. Resulting mutant libraries were then subjected to 
trimethoprim selection pressure on agar plates containing 3 µg/ml trimethoprim, and the 
resistant colonies were collected. Subsequently, the genotypes of pooled resistant colonies 
were determined by Illumina amplicon deep sequencing at the folA locus. Variants with more 
than one mutation were excluded from this sequence data analysis. Thus, we solely focused 
on the single-step adaptive mutational landscape of folA and its promoter sequence. We have 
found that 81% of the identified point mutations reside in the protein-coding region, primarily 
localized at the active site, as well as at the NADPH binding site of FolA as reported in literature 
[163], while the rest is located at the promoter region. DIvERGE has induced 17 previously 
described [160–163,165,166] mutations that are already known to be linked to trimethoprim 
resistance. Besides, we have also revealed at least 7 new substitutions. Next, we have 
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individually reconstructed each of these mutations in E. coli MG1655 and confirmed their 
resistance phenotype (Figure 23).  
 
Consecutive DIvERGE and selection cycles rapidly evolve high-level antibiotic 
resistance  
 
High-level resistance to trimethoprim generally demands multiple mutations at folA and its 
promoter. These mutations jointly act to up-regulate gene expression and/or decrease the 
drug molecule’s binding to its target site [156].  
To investigate the ability of DIvERGE to model, and thus to enable the analysis of 
multistep evolutionary processes, we have subjected E. coli K-12 MG1655 cells to consecutive 
cycles of DIvERGE mutagenesis. Using eight soft-randomized oligos, five rounds of oligo-
integrations were carried out with pORTMAGE, simultaneously targeting all nucleotide 
positions in the folA promoter and in the protein-coding region. Sequence analysis of the 
resulting mutant libraries revealed that the iterative integration of these eight oligos has 
successfully randomized the entire target (Figure 17 A), and has successfully generated 
higher-order mutational combinations as well (Figure 17 B).  
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Figure 17. DIvERGE mutagenesis along the full length of the drug target of 
trimethoprim. (A) Mutation frequency at E. coli K-12 MG1655 folA after five consecutive 
cycles of DIvERGE. Positions 0 and 480 refer to the first nucleotide position of the start and 
the last position of the stop codon of folA, respectively. Mutation frequency is defined as the 
background-normalized frequency of substitutions occurring at a given nucleotide position, 
analyzed by Pacific Biosciences Single Molecule Real-Time sequencing. (B) Naïve library 
composition at folA after five cycles of DIvERGE mutagenesis targeting the E. coli MG1655 
K-12 folA locus. The figure is based on Pacific Biosciences Single Molecule Real-Time 
sequencing reads, showing the frequency of each allele with the corresponding number of 
nucleobase substitutions within the oligo-target region. 
 
 
After five cycles of DIvERGE mutagenesis, we identified folA mutants characterized 
with an up to 895.7-fold increase in the 75% inhibitory concentration (IC75) of trimethoprim 
compared to the wild-type parental strain (Table 5). IC75 is a generally accepted measure of 
quantifying bacteriostatic antibiotic activity, referring to the drug concentration that inhibits 
bacterial growth by 75% compared to the drug-free condition, thus we have chosen IC75 to 
characterize trimethoprim resistance in our experiments [166]. 
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Strain 
folA regulatory 
mutation(s) 
FolA mutation(s) 
Trimethoprim IC75 
value (g/ml) 
Fold change 
of IC75 
compared to 
wild-type 
E. coli K-12 
Strain 1 
C-58T A26T, L28R, P39R 1254 895.7 
E. coli K-12 
Strain 2 
C-58T, T-74A P21P, L28R, N147D 447.5 319.6 
E. coli K-12 
Strain 3 
C-58T L28R 610 492.8 
E. coli K-12 
Strain 4 
C-43T, C-58T A26D, L28R, H45R 794 567.1 
 
Table 5. Susceptibility of individually selected E. coli K-12 MG1655 folA mutants to 
trimethoprim after five cycles of DIvERGE mutagenesis. Data represent the 75% inhibitory 
concentrations (IC75) based on the average of three independent measurements. 
Trimethoprim-specific IC75 of the wild-type equals to 1.4 g/ml. 
 
Whether DIvERGE can be applied to multi-round directed evolution using only a single 
set of soft-randomized oligos generated at the beginning of an experiment is a significant issue 
regarding the potential application of DIvERGE in adaptive laboratory evolution experiments. 
One may argue that oligos designed to target the wild-type folA, may revert mutations which 
had accumulated at an earlier stage of laboratory evolution [90]. To address this question, we 
focused on a folA variant which was generated in our 5-cycle DIvERGE experiment and 
contained three mutations within folA. Next, we carried out five additional DIvERGE cycles on 
this mutant with the soft-randomized oligo pool designed to target the wild-type sequence, and 
subsequently we sequenced the resulting library. Reassuringly, sequence randomization was 
successful along the whole length of the target sequence, and no substantial decrease in the 
level of nucleotide variation was observed (Figure 18). The only exceptions were the 
nucleotides which were directly adjacent to the three pre-existing mutations. Importantly, 
compared to the parental allele, novel genotypes could be selected which displayed an 
extremely high level of trimethoprim resistance. Selected genotypes showed an over 3900-
fold increase in the relative IC75 value of trimethoprim as compared to wild-type E. coli K-12 
MG1655 (Table 6). 
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Figure 18. Library composition of an E. coli K-12 MG1655 folA variant, differing in three 
substitutions at the nucleotide positions 58, 90, and 132 as compared to the wild-type 
sequence, after five additional cycles of DIvERGE mutagenesis using an oligo pool designed 
for the wild-type sequence. Allelic composition was determined by Illumina sequencing. 
 
 
Table 6. Susceptibility of individually selected E. coli K-12 MG1655 folA mutants to 
trimethoprim after five plus five cycles of DIvERGE mutagenesis. Multi-round DIvERGE-
generated folA alleles selected at agar plates treated with 1000 g/ml trimethoprim displayed 
an extremely high level of trimethoprim resistance and contained additional mutation 
combinations compared to the parental variant resulting from the first five cycles of DIvERGE. 
The parental variant generated after the first 5 cycle of DIvERGE contained C-58A; as well as 
W30C and/or C132G as same-sense mutations at folA. Data represent the 75% inhibitory 
concentrations (IC75) based on the average of three independent measurements. 
 
Overall, DIvERGE was capable of generating a diverse set of trimethoprim-resistant 
variants while simultaneously retaining mutations that were introduced prior to the second 
round of mutagenesis-selection cycles. As we employed the same oligo pool during the whole 
course of the experiment, this result indicates that there is no need for a new set of soft-
randomized oligos after each round of mutagenesis. Therefore, iterative DIvERGE 
Strain ID folA regulatory mutation Amino acid change (or same-sense SNP) IC75 (-fold change compared to wild-type)
8 C-58A A26S, L28R, W30C, (C132G) >3900
11 C-58A A26T, L28R, W30C >3900
12 C-58A A26T, L28R, (C132G), M88L 2140
23 C-58A A26T, L28R, (C132G) 1430
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mutagenesis-selection cycles can be run rapidly, without interruptions, and can be potentially 
scaled up towards many parallel allelic variants. 
Taken together, these results indicate that DIvERGE rapidly generates higher-order 
mutational combinations that induce high-level antibiotic resistance; a result that would be 
otherwise inaccessible via single mutational steps. In fact, it should be noted that adaptive 
laboratory evolution experiments relying on natural mutagenesis frequently require over one 
week to achieve a similar level of trimethoprim resistance [162,165,167], indicating that 
standard methods for adaptive laboratory evolution are outperformed by DIvERGE. 
Accordingly, when the main targets of bacterial selection are known, DIvERGE is a highly 
useful tool to accelerate laboratory evolution. 
 
DIvERGE outperforms a state-of-the-art method for whole genome mutagenesis 
 
We next compared the performance of DIvERGE to an established in vivo mutagenesis 
method called MP6 mutagenesis [110]. MP6 is an inducible plasmid-based system which can 
upregulate genomic mutation rate up to 322 000-fold, and thereby surpasses the mutational 
efficiency of other widely used in vivo methods. We compared three key aspects of 
mutagenesis: (I) the level of resistance achieved in the mutagenized populations, (II) the 
spectra of mutations and their combinations, and finally (III) the extent and consequences of 
off-target mutagenesis. As MP6 mutagenesis was developed for use in E. coli, we compared 
DIvERGE and MP6 in E. coli K-12 MG1655.  
 Bacterial populations were subjected to MP6-based whole-genome mutagenesis and 
then to five consecutive cycles of folA-targeted DIvERGE. Experimental conditions, including 
the estimated population size and time-frame, were comparable in the two protocols. Following 
mutagenesis, the resulting cell libraries were exposed to mild, medium and high levels of 
trimethoprim stress. The fraction of consequent resistant cells was determined and the 
resistant clones, approximately 1000 resistant mutants for each trimethoprim concentration, 
were sequenced by Pacific Biosciences Single Molecule Real-time sequencing to read out the 
genotypic information for folA. Library composition analysis revealed that, compared to MP6, 
DIvERGE resulted in an 83-fold higher fraction of resistant clones under mild trimethoprim 
stress. Moreover, the level of resistance reached in DIvERGE-treated populations was 37.6-
fold higher than in the MP6-treated population (Figure 19).  
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Figure 19. DIvERGE promotes the in vivo evolution of antibiotic resistance compared 
to MP6 mutagenesis. (A) Genotypic analysis of 1000 trimethoprim-resistant variants, 
generated by MP6 and DIvERGE mutagenesis in E. coli K-12 MG1655. Libraries were 
selected at trimethoprim concentrations 4- (green), 67- (blue), and 267-fold (yellow) higher 
compared to the IC75 of trimethoprim in wild-type E. coli K-12 MG1655. Sequence analysis of 
each individual variant was performed by amplicon sequencing of the folA target site on a 
Pacific Biosciences RSII instrument in circular-consensus sequencing (CCS) mode. Library 
composition analyses were performed in duplicates and error bars are calculated as the 
standard error of the mean for the two replicates. Bar diagrams indicate various levels of 
trimethoprim stress including trimethoprim concentrations of 4- (green), 67- (blue), and 267-
fold (yellow) higher compared to the IC75 of trimethoprim in wild-type E. coli. (B) The maximal 
IC75 values of trimethoprim in E. coli K-12 MG1655 populations mutagenized with 5 DIvERGE 
cycles targeting the folA locus compared to MP6 mutagenesis.  
 
 Sequence analyses of the resistant clones also revealed that under low trimethoprim 
stress, 89.5 % of the MP6 generated variants contained a single mutation only. By contrast, 
under the same circumstances, DIvERGE frequently resulted in variants with multiple 
mutations of different combinations (Figure 20).  
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Figure 20. Distribution of the number of substitutions within MP6 and DIVERGE-
generated trimethoprim resistant folA variants (n = 1000) in E. coli K-12 MG1655. Error 
bars represent the standard error of the mean of two replicates. 
 
Finally, as DIvERGE utilizes the pORTMAGE system for an efficient allelic 
replacement, we expected that off-target mutations would be minimized in this procedure. To 
investigate the extent of off-target mutagenesis, we measured the fraction of rifampicin-
resistant cells in MP6 and DIvERGE-mutagenized cell populations as a measure of off-target 
mutagenesis. Importantly, the rifampicin resistance-conferring locus (rpoB [168]) was not 
targeted by DIvERGE. As expected, the frequency of rifampicin-resistant cells increased 
significantly in the MP6-treated cell populations, causing an over 1000-fold increase in the 
frequency of rifampicin-resistant cells. In contrast, DIvERGE-mutagenized cells showed no 
significant increase in the frequency of rifampicin-resistant cells compared to the untreated 
wild-type population (Figure 21). These findings confirm our earlier results on the shortage of 
undesired mutations in non-targeted regions of the landing pad sequence (Figure 13).  
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Figure 21. Off-target effects of mutagenesis as indicated by the fraction of rifampicin-
resistant cells (representing off-target mutagenesis) and trimethoprim-resistant cells (targeted 
by DIvERGE) in DIvERGE and MP6-treated E. coli K-12 MG1655 populations compared to 
the wild-type E. coli K-12 MG1655 control. Error bars denote the standard error of the mean 
for 12 biological replicates.  
 
As another important issue, the accumulation of undesired, off-target mutations may 
interfere with the phenotypic effects of the engineered target modifications. Indeed, resistant 
clones derived from MP6 mutagenesis showed a 19.8% reduction in growth rate (fitness) in 
the absence of trimethoprim stress (Figure 22). Of note, this finding does not reflect a potential 
fitness cost of the MP6 plasmid, as MP6 was removed prior to these fitness measurements. 
In contrast, no significant fitness decline was observed in DIvERGE-generated, trimethoprim-
resistant clones (Figure 22), indicating the lack of fitness-decreasing off-target mutations. 
Thus, these results suggest again that DIvERGE could be a useful and practical tool to 
selectively and efficiently target predefined genomic loci, while minimizing off-target effects. 
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Figure 22. Fitness effects of the different mutagenesis strategies. Growth rate 
measurements were performed on MP6-generated variants (representing whole-genome 
mutagenesis) selected using 3 g/ml trimethoprim, as well as on two, 3 g/ml (DIvERGE 1) 
and 50 g/ml (DIvERGE 2) trimethoprim-selected DIvERGE-generated variants, analyzing 30 
individual isolates for each. T-tests were conducted for each strain compared to the wild-type 
E. coli K-12 MG1655 control (MG1655 wt). Star indicates significance of p < 0.05. 
 
Differences in the evolution of antibiotic resistance between closely related bacterial 
strains  
 
Concerning the predictability of antibiotic resistance, it is an important question whether and 
how closely related bacterial strains evolve resistance to specific antibiotics, and whether 
these processes differ between close relatives on the phylogenetic tree. This is an issue of 
special importance, because most of our knowledge about drug resistance evolution is 
originating from laboratory experiments which were performed on non-pathogenic, laboratory 
model strains. DIvERGE allowed us to investigate this issue for the first time, due to its 
exceedingly high mutagenesis rate and the ability to systematically and comprehensively 
compare mutational effects of entire resistance determinants.  
To evaluate resistance evolution in two closely related bacterial strains, we have 
targeted folA and its promoter sequence in a uropathogenic E. coli (UPEC) CFT073 strain, a 
close relative of E. coli K-12 MG1655. Importantly, trimethoprim is frequently used against 
uropathogenic E. coli infections in the clinical practice, as this antibiotic is excreted to urine by 
the kidneys, thus reaches high concentrations at the infection’s site [154,158,169]. As the 
protocol we employed to mutagenize UPEC was quantitatively the same as the one we had 
previously applied in the case of E. coli K-12 MG1655, the mutagenesis of folA gave an 
opportunity to compare single-step resistance processes in both strains. As for E. coli K-12 
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MG1655, we performed a single round of DIvERGE mutagenesis to generate cell libraries with 
single point mutations at folA. Next, as for E. coli K-12 MG1655, approximately 3000 resistant 
clones were selected at mild (3 µg/ml) trimethoprim stress, and were subsequently sequenced 
using Illumina MiSeq.  
Comparison of adaptive mutations in E. coli CFT073 has revealed novel resistance 
mutations compared to the non-pathogenic strain, E. coli K-12 MG1655. Despite a folA 
sequence similarity of 99% and almost the same mutation frequently between E. coli K-12 
MG1655 and the UPEC strain, the conferred relative resistance levels frequently differed 
between the two strains (Figure 23). Most notably, one of the identified mutations, FolA 
Ala7→Ser displayed resistance phenotype only in the uropathogenic isolate. This mutational 
effect is especially interesting, as this alanine amino acid in the gene product protein directly 
interacts with trimethoprim during the drug’s mode of action [156]. One explanation for this 
strain-specific effect could be the importance of 5’ mRNA secondary structure on translation 
[170] and in turn, FolA expression. Thereby, due to slight differences in the sequence-context, 
the expression of the drug-target can differ between the two isolates. 
These results highlight that mutational effects may differ even between closely related 
strains of the same species, and in turn, the analysis of evolutionary processes in genotypes 
beyond the given strain of interest may be misleading in some cases. This finding indicates 
that for reliable information mutational processes should be directly analyzed in the specific 
strain of interest. DIvERGE, however, offers a practical method to investigate evolutionary 
processes directly in these strains of interest, due to its broad host-range functionality. 
 
Figure 23. Comparison of relative susceptibility to trimethoprim associated with 
selected folA alleles in E. coli K-12 MG1655 (E. coli K-12, in blue) and CFT073, a 
uropathogenic E. coli strain (UPEC, in red). Data represent fold-change in IC75 compared 
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to the corresponding wild-type strain. Results are based on the average of three independent 
measurements. Error bars denote standard deviation based on three replicates. 
 
Mutagenesis along the full length of multiple drug targets to predict resistance 
 
As indicated by our results using the FolA-inhibitor trimethoprim, DIvERGE is a versatile tool 
to explore resistance-conferring mutations at a predefined drug target. As DIvERGE has 
allowed of an exceptionally deep and rapid analysis of trimethoprim resistance, we have 
anticipated that it could be utilized to evaluate resistance-conferring mutations induced by 
other antibiotics of various classes as well. From a practical point of view this is especially 
relevant, as DIvERGE could serve as a tool to forecast resistance evolution to antibiotic 
candidates at an early stage of development by predicting potential resistance mutations. 
Therefore, we next investigated whether DIvERGE can mutagenize longer genomic regions 
with a comparable resolution, and thereby, whether resistance processes for other drug 
classes can be evaluated successfully. Importantly, other methods for in vivo mutagenesis do 
not enable an exhaustive combinatorial mutagenesis of genomic loci longer than a few 
hundred base pairs. 
  For our experiments, we have chosen DNA gyrase and topoisomerase IV inhibitor 
antibiotics. Studying resistance mechanisms against existing and novel DNA gyrase and 
topoisomerase IV inhibitors is of special importance, especially because 25% of all antibiotic  
drug candidates currently in clinical trials (11 out of the 44) target these bacterial proteins 
[95,171]. In fact, topoisomerase-targeting antibacterial drugs, namely the quinolone group, 
were introduced into the therapy in 1962 [171,172]. Since then they have become the most 
widely used synthetic antibiotics, and are also extensively studied as a potential source of 
novel antibiotic development. In Gram-negative bacteria, such as E. coli, the primary target of 
quinolone drugs is the enzyme DNA gyrase [172]. However, quinolone antibiotics also tend to 
have affinity to topoisomerase IV [173] which is a bacterial enzyme homologous to DNA 
gyrase. As the test compound, we have chosen ciprofloxacin, a fluoroquinolone drug widely 
used in clinical practice, and already known to be concerned by resistance [174,175]. 
Furthermore, as ciprofloxacin resistance poses a significant clinical challenge [91,176], 
ciprofloxacin seemed to be a rational target to compare the resistance processes discovered 
by DIvERGE in laboratory strains to real-life resistance processes resulting in actual, clinically-
significant resistance mutants. 
To seek mutations at the genomic targets that may influence the target-binding of 
ciprofloxacin, we mutagenized gyrA, gyrB and parC, parE loci along the full lengths of their 
protein coding sequences in E. coli K-12 MG1655. GyrA and GyrB proteins constitute a DNA 
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gyrase heterodimer, while ParC and ParE form topoisomerase IV. These 4 loci altogether are 
more than 16-times longer than folA mutagenized in our previous tests. To induce 
mutagenesis, we scaled up DIvERGE and performed a single round of ssDNA-recombineering 
in E. coli K-12 MG1655 by using a mixture of 130 soft-randomized oligos, covering a total of 
9503 base pairs. The resulting mutant libraries were then subjected to ciprofloxacin stress 
using a ciprofloxacin concentration of two-fold higher than the MIC of ciprofloxacin (i.e. 3 
ng/ml) in the wild-type E. coli K-12 MG1655. Next, by exploiting the precision and throughput 
of Pacific Biosciences Single Molecule Real-Time sequencing, the genotypes at all four loci in 
3000 resistant clones were determined. Sequence analysis indicated that the majority of the 
identified mutants carried single mutations only. Mutations were detected in gyrA and gyrB, 
but were not present in parC and parE. Detected genotypes were dominated by mutations at 
Ser 83 and Asp 87, and their combinations, known to confer ciprofloxacin resistance in clinical 
practice [174,177]. Most notably, the analysis revealed a novel 46-aminoacid-long region of 
GyrB, which was found to be mutated in more than 22% of the analyzed mutants. To 
understand the role of this region on GyrB, we subsequently performed protein structure 
analyses which demonstrated that this region is in the close proximity of GyrA, and forms the 
binding site of fluoroquinolone antibiotics [178,179] (Figure 24).  
 
 
Figure 24. Map of DIvERGE-induced mutations conferring ciprofloxacin resistance at 
DNA gyrase protein complex, the primary target of ciprofloxacin in E. coli K-12 MG1655. 
Figure shows the detected mutational hot-spots based on simultaneous Pacific Biosciences 
Single Molecule Real-Time sequencing of the gyrA (red) and gyrB (blue) loci (Protein Data 
Bank ID: 5BS8). Furthermore, the fluoroquinolone drug molecule is illustrated in yellow and 
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the double strand DNA is shown in magenta. Mutated amino acid positions with a mutation 
frequency of over 0.5% were qualified as resistance-conferring mutations and were plotted on 
the crystal structure of the protein complex from Mycobacterium tuberculosis (Protein Data 
Bank identifier: 5BS8). 
 
Also, it should be noted that the lack of resistance-conferring mutations at ParC and 
ParE is in-line with previous observations [175]. Mutations accounting for the first step of 
fluoroquinolone resistance are generally localized to the primary drug target, and mutations in 
ParC and ParE rely on epistatic interactions with mutations in GyrA [180]. Considering that for 
fluoroquinolone compounds, the interaction with either target enzyme is sufficient to block 
bacterial growth, the level of susceptibility of the wild-type bacterium is determined by the more 
sensitive target of these two [175,181]. In Gram-negative bacteria, mutations accounting for 
the first step of fluoroquinolone resistance are located at DNA gyrase, the drugs’ primary 
target, while mutations concerning the less sensitive secondary target (i.e. topoisomerase IV) 
do not induce resistance on their own. This phenomenon is explained by the dominance of 
the interaction between the drug and its primary target [172]. Thus, in the hierarchical 
acquisition of high-level fluoroquinolone resistance, the secondary target’s level of sensitivity 
sets a limit to the resistance level conferred by mutations in the primary target. As secondary 
mutations at the secondary target (topoisomerase IV) may occur only once the primary target 
is mutated, these secondary mutations are essential to abolish the bioactivity of 
fluoroquinolone antibiotics. To investigate this co-evolution of high-level fluoroquinolone 
resistance involving both protein targets, we are planning to further investigate this topic, and, 
based on our experimental findings with iterative DIvERGE-mutagenesis and trimethoprim 
selection cycles, we expect that DIvERGE will be able to explore multi-step resistance 
acquisition as well. 
 
Analysis of resistance to an antibiotic currently in human clinical trials 
 
Findings from our experiments with these two distinct classes of antibiotics indicate that 
DIvERGE-induced mutagenesis with subsequent antibiotic selection and mutant-genotyping 
can identify resistance mechanisms in a high-throughput manner. Moreover, it is capable of 
highlighting the binding site(s) of antibiotics. Therefore, we have investigated whether 
DIvERGE is applicable to identifying or predicting resistance to antibiotics with unexplored 
resistance mechanisms, or even in cases where the exact mode-of-action is to be clarified. 
As a first step into this direction, we focused on gepotidacin (GSK2140944), an 
antibiotic candidate currently in human Phase II clinical trials (ClinicalTrials.gov registry 
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number: NCT02045797 and NCT02294682) [182–184]. It selectively inhibits bacterial DNA 
gyrase and topoisomerase IV via a unique mechanism of action, different from that of any 
other approved antibiotics [185]. A recent study has failed to identify resistant mutants to this 
drug in Neisseria gonorrhoeae [186], but this finding may only reflect the limitations of standard 
microbial assays for the detection of resistance processes. Thus, no literature data was 
available on the mutations that may cause resistance to gepotidacin in Gram-negative 
bacteria. To investigate this issue in details, we have attempted to generate resistance-
conferring variants by exposing as many as ten billion wild-type E. coli K-12 MG1655 cells to 
gepotidacin stress according to standard frequency-of-resistance assays [187]. No resistant 
variants were observable after 72 hours. By contrast, when we subjected the four potential 
target gene loci of gepotidacin (gyrA, gyrB and parC, parE) to DIvERGE mutagenesis, and 
selected the resulting cell library on agar plates containing gepotidacin, we identified resistant 
clones in three days. All of these DIvERGE-generated E. coli variants showed a similar, ~560-
fold decrease in gepotidacin susceptibility compared to the wild-type parental strain (Table 7). 
Sequence analyses of three independently isolated clones showed that the combination of 
only two specific mutations (GyrA Asp82→Asn and ParC Asp79→Asn) induced a high level 
of gepotidacin resistance. Moreover, the simultaneous introduction of the same mutation 
combination into the genomes of E. coli CFT073 (UPEC), Citrobacter freundii ATCC 8090, 
and Klebsiella pneumoniae ATCC 10031 revealed that these mutations together highly 
decrease susceptibility to gepotidacin in human pathogenic isolates as well. 
 
Strain 
Gepotidacin MIC 
(µg/ml) 
 Fold change in MIC  
compared to the corresponding 
wild-type 
Escherichia coli CFT073 >150  >750 
Citrobacter freundii  
ATCC 8090 
>150 >330 
Klebsiella pneumoniae  
ATCC 10031 
125 2080 
 
Table 7. Gepotidacin-susceptibility of human pathogenic bacteria containing the 
mutation combination of GyrA Asp82→Asn and ParC Asp79→Asn. The minimum 
inhibitory concentrations (MICs) of gepotidacin in the wild-type E. coli CFT073, C. freundii 
ATCC 8090, and K. pneumoniae ATCC 10031 equal to 200, 450, and 60 ng/mL, respectively. 
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These findings indicate the applicability of DIvERGE to explore rare combinations of 
resistance-causing mutations which would otherwise remain undetected with standard 
methods of laboratory evolution. We anticipate that our new method will be a useful tool for 
rapid resistance screening both at the early stages of drug design and during lead optimization 
of novel antibiotic candidates. Also, we hope that it could offer a practical support to identify 
novel molecular entities prone to resistance, and thus it could successfully direct lead 
optimization to mitigate drug-to-target interactions that are promoting resistance. 
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Discussion 
 
Methods of bacterial genome engineering offer an unprecedented opportunity to 
systematically interrogate phenotype-to-genotype relationships. However, available tools for 
bacterial genome engineering suffer from limitations. Previous methods have been optimized 
for a few laboratory model strains only (such as E. coli K-12 MG1655, the “work-horse” strain 
of laboratory and biotechnological research) or demand the extensive modification of the host 
genome, labor-intensive cloning steps, or DNA synthesis prior to genome editing. Moreover, 
most methods lead to the accumulation of undesired, off-target modifications which, in 
extreme cases, may outnumber the desired edits and may mask the effect of intentional 
engineering. These issues have serious implications on the widespread applicability of 
genome engineering in both basic and applied research [24,29,130].  
Our research work has specifically addressed these issues in consecutive projects. 
 
Dominant mismatch repair control allows precise genome editing 
 
As our first step, we aimed to extend the most high-throughput microbial genome engineering 
method (multiplex automated genome engineering, shortly MAGE [38]) towards 
straightforward applicability in multiple bacterial species. To achieve that, we first 
characterized a dominant mutation in MutL, a key protein [144] of the methyl-directed 
mismatch repair system, and utilized its dominant effect to precisely control mismatch-repair 
processes in target cells. We have demonstrated that this MutL E32→K mutant of E. coli 
rapidly abolishes mismatch repair activity even in the presence of the wild-type protein. By 
integrating this MutL E32→K variant into the MAGE workflow, we have developed a plasmid-
based system, termed pORTMAGE, for genome engineering, and we have successfully 
demonstrated its applicability for high-throughput genome editing at multiple loci [130]. 
Importantly, whole-genome sequencing has revealed that the pORTMAGE-modified strains 
lack off-target mutations, which is a significant improvement compared to prior MAGE-based 
methods. 
 
Conserved functionality across various strains and species 
 
Exploiting the highly conserved nature of bacterial methyl-directed mismatch repair, the 
application of the dominant MutL E32→K provided a unique solution for the interspecies 
portability in MAGE. The dominant mutator phenotype of MutL E32→K was conserved across 
a diverse set of enterobacteria [130]. Also, follow-up studies after the introduction of 
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pORTMAGE pointed out that the very same mutation confers a dominant effect in Vibrio 
cholerae, thereby permitting efficient recombineering in this strain as well [188,189].  
Finally, by placing the entire synthetic operon encoding all necessary elements of 
MAGE and mismatch repair control to a vector of broad host-range, we have successfully 
adapted ssDNA-recombineering to a wide range of biotechnologically and clinically relevant 
enterobacteria. In turn, pORTMAGE has allowed of the rapid generation of specific mutations, 
and thus the development of large, unbiased mutant libraries mutagenized at desired positions 
in these species. 
The spectrum of species in which the functionality of pORTMAGE has been 
demonstrated so far enlists multiple strains including Escherichia, Salmonella, Citrobacter, 
and Klebsiella genera [125,130]. Moreover, since the introduction of pORTMAGE, other 
research laboratories and our follow-up collaborations have demonstrated that the rationale 
behind pORTMAGE is generally applicable. Until now, pORTMAGE has been implemented in 
more than 100 laboratories worldwide, and its utilization has contributed to studies that focus 
on clinical and biotechnological issues. Moreover, through to the discovery of novel 
recombinases which allow efficient genome editing in phylogenetically more distant species, 
we have also adapted ssDNA-recombineering to the biotechnologically important species 
Pseudomonas putida [190]. 
 
Systematic analysis of phenotype-to-genotype associations 
 
The systematic investigation of genotype-to-phenotype associations for complex traits, 
however, still remained a significant challenge at that point, partly because the evolution of 
such evolutionary innovations frequently require the acquisition of multiple, rare mutations at 
the same time [69,71]. In turn, the availability of genome engineering tools which enable the 
targeted combinatorial mutagenesis of multiple loci is an inherent prerequisite for these goals 
to be met. However, current in vivo genome engineering and mutagenesis methods suffer 
from serious limitations in this regard. In most cases, the length and/or the number of targeted 
loci are severely limited. As a consequence, the attainable throughput and achievable library 
sizes are generally moderate. Also, certain methods target the entire genome unselectively, 
and in turn, lead to the accumulation of undesired, off-target modifications with detrimental 
side effects. Last but not least, most methods are limited to single microbial species or strains 
which prevents evolutionary investigations beyond model species [125,24]. 
Previous attempts to address these shortcomings rely on CRISPR/Cas-mediated 
genome engineering and CRISPR/Cas-guided base-editors to achieve high specificity 
[26,74,114,116]. Although they represent a major step forward, these techniques still produce 
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limited library sizes, frequently due to toxicity, and have limitations in terms of target sequence 
length and the number of simultaneous targets [26]. Moreover, they result in considerable bias 
regarding the types of mutations generated, and are all hindered by the availability of a 
protospacer adjacent motif (PAM) required for Cas recognition. 
 
Directed evolution with random genomic mutations 
 
To address the aforementioned shortcomings, we have advanced pORTMAGE-based 
recombineering to allow the systematic multiplex mutagenesis of long genomic segments. By 
building on the efficiency, multiplexability and throughput of multiplex automated genome 
engineering (MAGE) and the cross-species portability of pORTMAGE, as well as by combining 
these with a method for mutagenic chemical DNA synthesis, we have managed to advance 
recombineering to meet specific expected criteria. Thus, this new method termed directed 
evolution with random genomic mutations or DIvERGE for short (I) targets multiple, user-
defined genomic regions, (II) has a broad and controllable mutagenesis spectrum for each 
nucleotide position, (III) allows of up to a million-fold increase in mutation rate at the target 
sequence, (IV) enables multiple rounds of mutagenesis and selection in a fast and continuous 
way, (V) is applicable to a wide range of enterobacterial species without the need for prior 
genomic modification(s), (VI) avoids off-target mutagenesis, and (VII) is also cost-effective, as 
it relies on soft-randomized oligos which can easily be manufactured at a modest cost. In 
summary, DIvERGE offers a versatile solution for high-precision directed evolution at multiple 
loci in their native genomic context. As a significant advantage, it utilizes soft-randomized 
ssDNA oligos, coupled to pORTMAGE-based ssDNA-recombineering, to allow for the in-depth 
exploration of the sequence space [132,125]. 
 
Soft-randomized oligos randomize extended targets 
 
First, we have demonstrated that DIvERGE can mutagenize multiple, distinct genomic 
segments at nucleotide level precision, without affecting non-targeted regions (Figure 13 and 
15). A unique application of soft-randomized oligos has enabled us to extend the target 
sequence undergoing mutagenesis up to 87% of the length of an entire oligonucleotide, by 
using only a single oligo. Next, the partially overlapping design of such oligos, as well as the 
coverage of entire genes and their regulatory regions permitted rapid protein engineering 
through random mutagenesis (Figure 17). Importantly, DIvERGE has the advantage to place 
no constraint on the target sequence regarding the availability of a protospacer adjacent motif, 
which is a strict requirement for CRISPR/Cas-based mutagenesis techniques. 
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Precise control of mutagenesis 
 
Second, modifications of the parameters for soft-randomized oligo synthesis have made it 
possible to execute an unbiased introduction of mutations at each targeted nucleotide position 
(Table 3), resulting in a more comprehensive generation of combinatorial mutants. This is a 
significant advantage of DIvERGE over techniques where the mutational spectrum is biased, 
such as those relying on CRISPR/Cas-directed base-editors or E. coli DNA polymerase I, or 
other recombineering-based methods [115,116,119]. Besides the types of introduced 
sequence alterations, the rate of mutagenesis can also be precisely adjusted by controlling 
the parameters and composition of soft-randomization of the oligos during synthesis, as well 
as by the number of iterative DIvERGE cycles. Thereby, mutation rate can be upregulated to 
achieve an increase of up to a million-fold compared to wild-type mutation rates at the targeted 
loci, a range exceeding that of most in vivo methods.  
 
Iterative cycles of recombineering accelerate laboratory evolution 
 
Third, we have demonstrated that DIvERGE can be performed iteratively using the same oligo 
pools which are designed at the beginning of a given experiment. Thereby it permits multiple 
rounds of directed evolution (consisting of iterative mutagenesis and selection steps), which 
has been demonstrated to facilitate the rapid attainment of bacterial variants highly resistant 
to trimethoprim in our case. By performing multi-round directed evolution of folA, we have 
successfully demonstrated the rapid generation of variants containing up to 10 mutations. This 
feature is particularly important, as it facilitates the combination of independently generated 
mutations whose co-occurrence would normally be highly unlikely under laboratory conditions, 
and would require time-consuming laboratory evolution protocols [71,162,165,166]. Thereby, 
DIvERGE accelerates the laboratory evolution of slowly evolving traits. 
 
Broad-host mutagenesis identifies strain-specific mutational effects 
 
Fourth, we have demonstrated the portability of DIvERGE by mutagenizing multiple 
enterobacterial species, including biotechnologically and clinically relevant organisms. 
DIvERGE has enabled us to explore the in vivo evolution of drug resistance in pathogen 
bacteria, in a much faster and more comprehensive manner compared to prior techniques. 
Using DIvERGE, we have identified numerous previously undetected resistance-conferring 
mutations. Moreover, we have also demonstrated that phenotypic effects of certain 
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trimethoprim resistance-associated mutations vary considerably across phylogenetically 
related strains. Despite the 99% sequence similarity of folA between E. coli K-12 MG1655 and 
the uropathogenic strain E. coli CFT073, the relative resistance level induced by the very same 
mutation differed between the two strains. One of the identified mutations, FolA Ala7→Ser 
was associated with a decreased trimethoprim susceptibility only in the uropathogenic isolate. 
Although the reason for this strain-specific effect is yet to be explored, it might be explained 
by the different mRNA stability-effects of the same mutation within the two strains. These 
results also have implications on the utility of previous laboratory evolutionary experiments of 
drug resistance which were performed in non-pathogenic, laboratory model strains. Also, 
these results have shed light on the possibility on strain-specific antibiotic resistance 
processes. 
 
High-throughput recombineering is well suited to analyze antibiotic resistance 
evolution 
 
Together, pORTMAGE and DIvERGE are paving the way towards the high-throughput in vivo 
exploration of fitness landscapes of endogenous genes or gene networks in multiple species. 
In a direct clinically relevant application, these methods have allowed us to explore the 
evolutionary routes which induce target-specific antibiotic resistance in multiple bacterial 
species. As the new method executes an exceptionally high mutation rate at the drug’s target, 
and also lacks mutational biases, using DIvERGE we have comprehensively generated 
resistance-conferring mutations at specific drug targets. We have successfully demonstrated 
that DIvERGE is capable of rapidly identifying mutations which contribute to the development 
of resistance against three distinct antibiotic classes. Utilizing DIVERGE we have identified 
several previously described mutations conferring resistance against trimethoprim and 
fluoroquinolone antibiotics: the predominant folA and gyrA mutations evolved by DIvERGE 
have already been observed to arise in E. coli under laboratory settings, and have also been 
reported in the clinical practice in patients treated with trimethoprim or fluoroquinolone 
medications [174,181]. Moreover, using DIvERGE we have also revealed several previously 
unknown mutations conferring trimethoprim resistance.  
By exploiting the ability of DIvERGE to explore the combinatorial mutational space at long 
genomic segments, we have identified a combination of two specific mutations at gyrA and 
parC that might lead to clinically significant resistance against a novel antibiotic that is under 
clinical development (gepotidacin, GSK2140944) in the near future. This higher sensitivity of 
DIvERGE has also contributed to the detection of resistance-mutations to antibiotics which 
have previously been described as resistance-proof based on conventional techniques (i.e. 
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gepotidacin). Importantly, as DIvERGE can mutagenize a large fraction of genes that are 
targets of antibiotics currently being developed or clinically utilized, it could be a useful tool for 
the massively parallel discovery of mutations conferring resistance against multiple classes of 
antimicrobial agents, and it could be executed in a faster way and with higher resolution 
compared to alternative methods. 
 
Conclusion 
 
To address the shortcomings of currently available genome editing and in vivo directed 
evolution techniques, we have developed a plasmid-based method for broad host-range 
genome engineering (pORTMAGE), and based on pORTMAGE, a method for in vivo directed 
evolution. This new method, termed DIvERGE (directed evolution with random genomic 
mutations) allows the systematic multiplex mutagenesis of long genomic segments. DIvERGE 
has numerous advantages over the alternative techniques, including (I) the possibility to target 
multiple, user-defined genomic regions; (II) it has a broad and controllable mutagenesis 
spectrum for each nucleotide position; (III) it allows of up to a million-fold increase in mutation 
rate at the target sequence; (IV) it enables multiple rounds of mutagenesis and selection in a 
fast and continuous manner; (V) it is applicable to a wide range of enterobacterial species 
without the need for prior genomic modification(s); (VI) it avoids off-target mutagenesis, and 
(VII) it is also cost-effective as it relies on soft-randomized oligos which can easily be 
manufactured at a modest cost. In summary, DIvERGE offers a versatile solution for high-
precision directed evolution at multiple loci in their native genomic context. Due to these 
favorable characteristics, DIvERGE is especially well-suited to study bacterial evolution 
leading to antibiotic resistance. 
The standard protocols currently used by pharmaceutical companies to predict the speed at 
which antibiotic resistance would emerge against a new drug candidate are frequently 
inadequate and give inaccurate information because of their limited throughput to explore the 
sequence space. This is a significant problem, as antibiotics developers are frequently 
plagued by the waste of considerable efforts and funding as rapid resistance evolves to new 
antimicrobial agents. Clearly, high-throughput mutagenesis platforms are required to identify 
antibiotics with the promise of extended clinical efficacy, and these should be utilized from the 
very early stage of drug development. DIvERGE implements a significant improvement in this 
direction. Although the genes for targeted mutagenesis need to be defined in advance, once 
these genes of interest are known, DIvERGE allows of a reliable exploration and prediction of 
resistance processes in clinically relevant pathogens. Coupled to subsequent fitness and 
virulence assays, DIvERGE offers an opportunity to identify antimicrobial agents with a 
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potential of extended clinical efficacy, even at an early stage of drug development. Regarding 
this direction, our experiments have already demonstrated the feasibility of resistance 
analyses for novel antimicrobial agents [125,191]. 
In the future, we hope that our DIvERGE strategy would be adaptable to other 
organisms, including yeasts and mammalian cells, in which ssDNA-mediated recombineering 
would be expected to function efficiently. As a first step in this direction, we have already 
developed a modified version of DIvERGE which is applicable to the eukaryotic species 
Saccharomyces cerevisiae [132]. 
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Összefoglaló  
 
Az evolúciós folyamatok vizsgálatára és a genotípus fenotípusra gyakorolt hatásának 
tanulmányozására a nagy áteresztőképességű genommérnökség páratlan lehetőséget kínál. 
Az örökítő anyag nagyszámú, tervezett változatát, mutációját létrehozva és hatását hasonló 
áteresztőképességgel vizsgálva a komplex, több mutációt igénylő evolúciós folyamatok is 
laboratóriumi időlépték alatt vizsgálhatóvá válnak. Mindezen evolúciós lépések azonban 
hagyományos laboratóriumi evolúciós módszerekkel nem, vagy csak igen hosszú idő alatt 
válnának tanulmányozhatóvá. Mindezek ellenére a genommérnökség eszköztára súlyos 
hiányosságoktól szenved, mely egyes biológiai kérdések megválaszolását hátráltatja. Ennek 
oka, hogy az elérhető módszerek java mindösszesen néhány laboratóriumi modellszervezetre 
(például a széles körben alkalmazott Escherichia coli K-12 bélbaktériumra) optimalizált, vagy 
kiterjedt genommódosítást, DNS szintézist, és időigényes klónozási lépéseket igényel – 
ezáltal praktikusságukat és áteresztőképességüket csökkentve. Továbbá az elérhető 
módszerek java nem kívánt, háttér-mutációk felhalmozódásához vezet, mely egyes 
esetekben akár a célzott genommódosítás hatást is elfedheti.  
Kutatásunk ennek következtében a genommérnöki módszerek hátrányainak 
leküzdésére irányult. Ennek eléréséhez, munkánk során a jelenleg elérhető legnagyobb 
áteresztőképességű genommérnöki módszert, az egyes szálú DNS-rekombináción alapuló 
multiplex génmérnökség (MAGE) módszerét fejlesztettük tovább számos baktérium fajban 
történő alkalmazásra. Ezen túl pedig a nem kívánt háttérmutációk megjelenését is 
nagyságrendekkel csökkentettük, a módszer precíz alkalmazása érdekében. Ezen új eljárás, 
melyet pORTMAGE-nek neveztünk el, precíz és könnyen alkalmazható eszközt kínál számos 
bélbaktérium genomjának gyors és célzott módosítására. Ezt követően a pORTMAGE 
módszerét alapul véve olyan eljárást fejlesztettünk ki mely elsőként teszi lehetővé kiterjedt 
genomi szakaszok átfogó, célzott in vivo mutagenezisét – és ezáltal az evolúciós folyamatok 
korábbiaknál gyorsabb tanulmányozását. 
 Első célunk elérése érdekében, azaz, hogy a káros háttér-mutációk számának 
minimalizálása mellett egy széles gazdaspecifitású genommérnöki módszert fejlesszünk ki, 
egy általánosan alkalmazható, plazmid alapú eljárást dolgoztunk ki. Ennek megvalósítását az 
Escherichia coli metiláció-függő DNS hibajavítását végző egyik fehérje, a MutL domináns 
mutátor mutánsa tette lehetővé. A MutL a metiláció által irányított hibás bázispárosodás 
kijavítás („methyl-directed mismatch repair”, MMR) útvonalának tagja, mely a MutHLS 
komplex részeként a MutH endonukleáz DNS-hibához való vonzásában vesz részt. 
Vizsgálataink során megfigyeltük, hogy Escherichia coli MutL fehérjéjének a E32→K mutációt 
hordozó változata a sejt mutátor állapotát indukálja, azaz a MutHLS komplex működését 
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meggátolja, vad típusú változatának jelenléte esetén is. Ezen domináns hatást biztosító allél 
lehetővé tette a bakteriális metiláció által irányított hibás bázispárosodás kijavítás 
szabályozását a genom módosítása nélkül, mindösszesen egyetlen, plazmid alapú 
fehérjetermelési rendszer sejtbe juttatásával. Mindezt kihasználva, a genommódosítást és 
DNS hibajavítás szabályozását együttesen megvalósító, plazmid alapú genommódosítási 
rendszert hoztunk létre, melyet pORTMAGE-nek neveztünk el.  
A pORTMAGE egyszerre képes szabályozottan a bakteriális genommódosításhoz 
szükséges rekombinációs fehérjék és a domináns MutL E32→K variáns termelésére, melyet 
hőmérséklet-szabályozható módon a λ bakteriofágból származó  cI857 represszor – pL 
promóter-alapú fehérjetermelési rendszer révén valósít meg. A pORTMAGE rendszere 
számos hasonlóságot mutat MAGE korábbi módszerével, így a korábbi módosított MAGE-
módszerekben is átalakítás nélkül alkalmazható. Azonban míg a MAGE tradicionális 
módszere csupán limitált számú bakteriális törzsre volt alkalmazható melyekben előzetesen 
a DNS hibajavítás metiláció-függő útvonalát el kellett távolítani, addig a pORTMAGE 
alkalmazása egyetlen plazmid sejtbe juttatásával azonnal lehetővé tette a hatékony 
genommódosítást. A pORTMAGE alapú genommódosítás során a rekombinációt katalizáló 
fehérjék és a domináns MutL allél termelése egyetlen rövid hősokk segítségével indukálható, 
mely egyúttal a sejtek MutHLS rendszerének inaktiválásához is vezet. Ezáltal a 
genommódosítást végző DNS oligonukleotidok beépülésének idejére a sejtek metiláció által 
irányított hibás bázispárosodás kijavítási rendszere kikapcsolt állapotban marad, így 
egyformán hatékony mutációbeépítést tesz lehetővé legyen szó bármilyen genomi módosítás 
típusról. Ezen felül azonban a domináns mutátor MutL allél szabályozható termelése további 
előnyt is kínált. Segítségével a sejtek mutátor állapota a genommódosítás teljes folyamata 
során rövid időperiódusára vált korlátozhatóvá, ezáltal csökkentve a sejtosztódások számát 
melyet a sejt háttérmutációk felhalmozódására érzékeny állapotban tölt. Kísérleteink ezen 
elmélet helyességét igazolták. Ismételt pORTMAGE-genommódosítási ciklusokat követően a 
sejtek teljes genomját szekvenciaanalízisnek alávetve a módszer segítségével kapott sejt-
változatok nem mutattak háttérmutációkat a bakteriális genomon. Ezzel szemben azonban a 
tradicionális módszerrel módosított sejtek több mint 80 nemkívánt mutációt halmoztak fel.  
 Végezetül pedig, a MutHLS rendszer erős konzerváltságát kihasználva a domináns 
MutL E32→K allél felhasználása a pORTMAGE általános alkalmazását is lehetővé tette. 
Ennek oka, hogy az Escherichia coli-ból eredő MutL E32→K allél számos bélbaktériumban 
hasonló, domináns DNS hibajavításra gyakorolt hatást mutatott, ezáltal pedig a pORTMAGE 
hatékony működését lehetővé tette az Escherichia, Salmonella, Citrobacter, Klebsiella 
nemzettség számos fajában is, melyek jelentős biotechnológiai és klinikai mikrobiológiai 
szereppel bírnak. 
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 Ezt követően, hogy lehetővé tegyük a mutációk hatásának szisztematikus analízisét 
kiterjedt genomi régiók esetén is, az egyes szálú DNS-rekombináción alapuló multiplex 
génmérnökséget módszerét tovább fejlesztve olyan eljárást dolgoztunk ki mely képes kiterjedt 
genomi szakaszok egyenletes in vivo mutagenezisére. A jelenlegi in vivo mutagenezis 
módszerek erre nem adnak lehetőséget. Ennek oka, hogy az elérhető módszerek mutációs 
rátája vagy limitált, vagy épp nem specifikus, ezáltal nemkívánt háttér-mutációkat generálnak. 
Ezen túl egyes módszerek esetén pedig a szakasz, melyre mutáció vihető be erősen limitált. 
Ennek következtében pedig ezen módszerek nem teszik lehetővé a szekvenciatér hatékony 
feltérképezését, amely azonban elengedhetetlen lenne az evolúciós folyamatok hatékony 
vizsgálata érdekében. Ezen probléma megoldása érdekében a pORTMAGE alapú oligo-
rekombináció módszerét olyan DNS szintézis eljárással kapcsoltuk össze, mely képes a 
rekombinációban felhasznált DNS oligonukleotidok teljes hosszán random elhelyezkedésű és 
típusú mutációkat létrehozni.  Mindezt egy módosított foszforamidit-kémia alapú DNS 
szintézis eljárással sikerült elérnünk, mely képes volt a genommérnökség során felhasznált 
oligonukleotidok teljes hosszán a lehetséges nukleotid-szubsztitúciók egyenletes 
létrehozására. 
Ezen új eljárás, melyet DIvERGE-nek (mely a ’directed evolution with random genomic 
mutations’ megnevezésből képzett mozaikszó) neveztünk el, képes a pORTMAGE előnyös 
tulajdonságainak kihasználása mellett (precizitás, gyorsaság, pontosság, széles 
gazdaspecifitás) nagyszámú mutáció és mutáció-kombináció bakteriális genomba építésére. 
Kutatásaink során sikerrel igazoltuk, hogy a DIvERGE módszere során alkalmazott mutagén 
oligonukleotidok nukleotid pontossággal képesek genomi célpontjuk mutagenezisére, akár 
egymilliószoros mutációs ráta emelkedést elérve a sejtek természetes mutációs 
folyamataihoz képest. A DIvERGE fejlesztése során bizonyítottuk, hogy ezen mutagén 
oligonukleotidok részlegesen átfedő alkalmazásával és genomba építésével teljes gének, 
illetve azok szabályázásáért felelős szekvenciák is egyidejűleg mutagenizálhatók. Mindezt 
kihasználva pedig sikeresen értünk el egyenletes mutáció-bevitelt több mint 9500 bázispárnyi, 
négy teljes bakteriális gént (gyrA, gyrB, parE, parC) kódoló genomi szekvencián. Ezt követően 
pedig az egyenletes mutagenezis és igen magas mutációs ráta segítségével sikerrel 
demonstráltuk, hogy a DIvERGE módszere kiválóan alkalmas bakteriális jellegek irányított 
evolúciójára, olyan esetekben is, mely korábbi laboratóriumi evolúciós stratégiák 
felhasználásával nem vagy csak igen hosszú idő alatt vált volna megvalósíthatóvá. 
 Ennek egy praktikus példájaként DIvERGE segítségével sikeresen térképeztük fel a 
bakteriális antibiotikum rezisztencia kialakulása mögött meghúzódó genomi mutációs 
folyamatokat, több antibiotikum család esetén is. A DIvERGE segítségével megvalósított 
célzott mutagenezis laboratóriumi körülmények között sokszorosára gyorsította az 
antibiotikum-célfehérje mutációi által megjelenő rezisztencia kialakulását, ezáltal pedig 
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átfogóan vizsgálhattunk olyan antibiotikum rezisztencia folyamatok megjelenését is, melyek a 
tradicionális mikrobiológiai módszerekkel felfedezetlenek maradtak: nagyáteresztőképességű 
mutagenezis segítségével mindösszesen néhány nap időtartam alatt nagyszámú trimetoprim 
és fluoroquinolon-antibiotikum ellenes mutációt is sikerült felfednünk, mely közül számos a 
klinikai gyakorlatban is előfordult. Továbbá kihasználva a pORTMAGE széles gazda-
specifitását, ezen antibiotikum rezisztenciafolyamatok hatását rokon bakteriális törzsek között 
is összehasonlítottuk. Az azonos körülmények között összehasonlított rezisztencia folyamatok 
tanulmányozásából kiderült, hogy egyes mutációk hatása az antibiotikum toleranciára az 
anyatörzs genotípusától függően jelentős eltéréseket mutathat, továbbá törzs-függő 
rezisztenciafolyamatokat is feltártunk. 
 Végezetül pedig, a DIvERGE egyik legfontosabb gyakorlati előnyeként, sikerrel 
igazoltuk, hogy egy, ismert célponttal rendelkező, fejlesztés alatt álló antibiotikum 
(gepotidacin) feltételezett támadáspontjait mutagenizálva az ellene megjelenő 
rezisztenciafolyamatok még a klinikai alkalmazása előtt felfedhetők. Így feltételezéseink 
szerint a DIvERGE alkalmazása mind az alapkutatásban – az evolúciós folyamatok 
korábbiaknál átfogóbb vizsgálata révén -  mind az alkalmazott kutatásban - a hatékonyabb 
irányított evolúciós stratégiák lehetővé tétele által - jelentős előnyökkel szolgál majd. 
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Summary 
 
Methods for large-scale manipulation of organismal genomes offer an unprecedented 
opportunity to understand phenotype-to-genotype relationships, and thereby systematically 
map fitness landscapes. In turn, microbial genome engineering is a promising and powerful 
tool to analyze evolutionary processes that would otherwise require exceedingly time-
consuming laboratory experiments or would even be infeasible with current techniques. 
However, the available genome engineering methods suffer from limitations that prevent the 
widespread application of microbial genome engineering. These methods are either optimized 
for a few laboratory strains (such as Escherichia coli K-12) or demand labor-intensive cloning 
steps, DNA synthesis and/or extensive genome manipulation prior to genome editing. 
Moreover, most methods lead to the accumulation of undesired, off-target mutations whose 
effects may mask the results of intentional engineering.  
Here we present significant advancements at these challenging fronts. As our first step, we 
have improved the currently available, most high-throughput and multiplexable genome 
engineering method, ssDNA-based recombineering (recombination-based genetic 
engineering), to achieve broad host-range functionality and to reduce off-target effects to 
negligible levels. This new method, termed pORTMAGE offers an all-in-one tool for 
enterobacterial genome engineering. Next, we have further advanced genome engineering to 
allow the systematic mutagenesis of extended genomic segments.  
To achieve our first aim, i.e. to overcome prior limitations of genome engineering 
associated with off-target mutagenesis and the lack of interspecies portability, we have 
developed a generalized, plasmid-based method for ssDNA-recombineering. The tool 
enabling these advancements was a dominant-negative mutator allele of mutL encoding an 
indispensable component of the methyl-directed mismatch repair system of E. coli. MutL is a 
component of the MutHLS protein machinery which is responsible for methyl-directed 
mismatch removal and acts by recruiting MutH endonuclease to the site of DNA replication 
error. Importantly, we have noticed that the mutator effect of a particular MutL variant, MutL 
E32→K, cannot be complemented by the native, genomically-expressed MutL protein when 
the dominant protein is overexpressed from an extra-chromosomal vector. Based on this 
ability, we have decided to incorporate this dominant allele into the workflow of ssDNA-based 
recombineering to abolish mismatch repair activity when it is required during the process of 
genome editing. To achieve that, we have constructed a set of plasmids (termed pORTMAGE) 
expressing the λ Red recombinase enzymes, as well as the dominant-negative mutator allele 
of MutL, all under the control of the cI857 temperature-sensitive λ repressor-pL expression 
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system. During genome engineering, the expression of this synthetic operon is induced by a 
brief, temporal temperature shift, which in turn produces the necessary recombinases and the 
dominant-negative mutator allele of MutL which suppresses mismatch repair for the brief 
period of oligo-mediated genome editing. Thereby pORTMAGE has allowed efficient genome 
engineering and unbiased oligo incorporation, with a performance comparable to that of prior 
ssDNA-based recombineering protocols. Also, as pORTMAGE allows a rapid switch between 
mutator and non-mutator phenotypes, pORTMAGE has minimized the length of time when the 
bacterial population is susceptible to the accumulation of off-target mutations (i.e. it limited the 
time of mutator state). In line with this characteristic, whole-genome sequencing has revealed 
that the pORTMAGE-modified strain lacks observable off-target mutagenesis, which is a 
significant improvement compared to prior ssDNA-recombineering methods.  
Finally, the phylogenetically highly conserved nature of MutL also offered a solution for 
interspecies portability. The expression of E. coli MutL E32→K was found to suppress 
mismatch repair even in relatives of E. coli. Thus, pORTMAGE has allowed of an efficient 
genome engineering and mutant library generation in numerous biotechnologically and 
clinically relevant bacterial species, including ones from the Escherichia, Salmonella, 
Citrobacter, and Klebsiella genera. 
Next, to enable the systematic analyses of fitness landscapes and mutational effects, 
we have advanced ssDNA-recombineering to mutagenize extended genomic loci. The 
rationale behind this step is that the throughput and library sizes attainable with existing in 
vivo long-range mutagenesis methods are generally either moderate or lead to the 
accumulation of undesired, off-target modifications with detrimental side effects. Thus, these 
methods do not allow to explore of sequence space at extended genomic loci, which would 
be important for evolutionary investigations. Therefore, we further advanced our pORTMAGE-
based recombineering in a way to utilize pools of partially overlapping, soft-randomized ssDNA 
oligonucleotides, and as a consequence, to achieve an increase of an up to a million-fold in 
mutation rate at defined genomic targets.  
This novel method, termed directed evolution with random genomic mutations 
(DIvERGE), has enabled us to explore a vast number of combinatorial genetic alterations in 
their native genetic context. By using DIvERGE, we have demonstrated that the application of 
soft-randomized oligos during ssDNA-recombineering can mutagenize multiple genomic loci 
with nucleotide precision and without affecting off-target sites. Thereby, genomic mutation 
rates can be upregulated to achieve up to a million-fold increase compared to the wild-type 
mutation rate of the target loci. Next, by partially overlapping such oligos and covering entire 
genes and their regulatory regions, we have performed rapid directed evolution at genomic 
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loci consisting of over 9500 base pairs. Furthermore, we have demonstrated that DIvERGE 
can be performed iteratively, using the same oligo pools designed at the beginning of a given 
experiment. Thereby, DIvERGE has permitted multiple rounds of mutagenesis and selection, 
facilitating the rapid attainment of highly drug-resistant bacterial variants which would 
otherwise require time-consuming laboratory evolution protocols. Thus, DIvERGE is capable 
for accelerating the laboratory evolution of slowly evolving phenotypes. Exploiting the multi-
species functionality of pORTMAGE, we have also demonstrated that DIvERGE functions 
efficiently in multiple species, as confirmed by our experiments of mutagenizing 
biotechnologically and clinically relevant enterobacteria. Thus, DIvERGE has enabled us to 
rapidly explore the in vivo evolution of drug resistance directly in human pathogens. During 
sequence analyses, we have identified numerous, previously undetected resistance-
conferring mutations. Moreover, we have demonstrated that phenotypic effects of certain 
antibiotic resistance-associated mutations vary considerably across closely related bacterial 
strains. In a direct clinically relevant application, our new method has allowed us to explore 
the evolutionary routes promoting antibiotic resistance. 
As a highly relevant practical achievement, we have demonstrated that DIvERGE is 
capable for rapidly identifying mutations that contribute to the evolution of resistance to three 
distinct antibiotic classes, and we have executed these studies in a much faster way and with 
a higher throughput compared to alternative methods. By utilizing DIVERGE we have 
identified previously described mutations responsible for resistance against trimethoprim and 
fluoroquinolone antibiotics: the predominant FolA and GyrA mutations evolved by DIvERGE 
have already been observed to arise in E. coli under laboratory settings, and have also been 
reported in the clinical practice in patients treated with trimethoprim or fluoroquinolone 
medications. Moreover, using DIvERGE we have also revealed several previously unknown 
mutations conferring trimethoprim resistance, which induce resistance to ciprofloxacin as well, 
and we have revealed major differences in mutational effects across related strains. By 
exploiting the ability of DIvERGE to explore the combinatorial mutational space at long 
genomic segments, we have identified a combination of two specific mutations that might lead 
to resistance against a novel antibiotic that is under clinical development (gepotidacin). 
In the future, we hope that our DIvERGE strategy will be adaptable to other organisms, 
including yeasts and mammalian cells, in which ssDNA-mediated recombineering would be 
expected to function efficiently. As a first step in this direction, we have already developed a 
modified version of DIvERGE which is applicable to the eukaryotic species Saccharomyces 
cerevisiae.  
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Appendix 
Appendix 1. Bacterial strains used in our research 
Strains used in this study  
Strain Genotype Note  
Escherichia coli K-12 MG1655 Wild-type   
Escherichia coli BL21(DE3) Wild-type   
Salmonella enterica serovar Typhimurium LT2 Wild-type from S. Datta et al. / Gene 379 (2006) 109–115  
Salmonella enterica serovar Typhimurium TS616 
derived from Salmonella enterica serovar 
Typhimurium LT2 
from S. Datta et al. / Gene 379 (2006) 109–115  
Citrobacter freundii ATCC 8090 Wild-type from Microbiologics  
Escherichia hermannii HNCMB 35034 Wild-type 
from the Hungarian National Collection of Medical 
Bacteria (HNCMB) 
 
Edwardsiella tarda ATCC 15947 Wild-type 
from the Hungarian National Collection of Medical 
Bacteria (HNCMB) 
 
Escherichia coli ∆mutS ∆mutS 
mutS permanently deleted, from T. Fehér et al. / 
Mol Biol Evol (2012) 29(10):3153-3159 
 
Escherichia coli DH5  Wild-type    
    
Appendix 2. List of oligonucleotides for ssDNA-recombineering 
Oligo name Sequence Description 
LacZ_M9_v5 
5'-
A*T*GATTACGGATTCACTGGCCGTCGTTTTACAACGTCGTGACTGAGAAAACCCTGGCGTTACCCAACTTAATCGCCTTG
CAGCACATC*C*C 
Oligonucleotide for the introduction 
of C:A mismatch to lacZ gene 
LacZ_GG_v3 
5'-
A*T*AACAATTTCACACAGGAAACAGCTATGACCATGATTACGGATTGACTGGCCGTCGTTTTACAACGTCGTGACTGGGAA
AACCCTGG*C*G 
Oligonucleotide for the introduction 
of G:G mismatch to lacZ gene 
LacZ_AA_v1 
5'-
G*G*AAACAGCTATGACCATGATTACGGATTCACTGGCCGTCGTTTAACAACGTCGTGACTGGGAAAACCCTGGCGTTACC
CAACTTAAT*C*G 
Oligonucleotide for the introduction 
of A:A mismatch to lacZ gene 
MAGELacZ 
5'-
G*G*AAACAGCTATGACCATGATTACGGATTCACTGGCCGTCGTTTGACAACGTCGTGACTGGGAAAACCCTGGCGTTACC
CAACTTAAT*C*G 
Oligonucleotide for the introduction 
of A:G mismatch to lacZ gene 
LacZ_TT_v7 
5'-
T*G*TGGCGGATGAGCGGCATTTTCCGTGACGTCTCGTTGCTGCATTAACCGACTACACAAATCAGCGATTTCCATGTTGC
CACTCGCTT*T*A 
Oligonucleotide for the introduction 
of T:T mismatch to lacZ gene 
LacZ_GA_v4 
5'-
A*T*AACAATTTCACACAGGAAACAGCTATGACCATGATTACGGATTAACTGGCCGTCGTTTTACAACGTCGTGACTGGGAA
AACCCTGG*C*G 
Oligonucleotide for the introduction 
of G:A mismatch to lacZ gene 
LacZ_GT_v2 
5'-
G*G*AAACAGCTATGACCATGATTACGGATTCACTGGCCGTCGTTTTATAACGTCGTGACTGGGAAAACCCTGGCGTTACC
CAACTTAAT*C*G 
Oligonucleotide for the introduction 
of G:T mismatch to lacZ gene 
LacZ_CT_v6 
5'-
A*T*GATTACGGATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGTAAAACCCTGGCGTTACCCAACTTAATCGCCTTGC
AGCACATC*C*C 
Oligonucleotide for the introduction 
of C:T mismatch to lacZ gene 
MalK_CC_v1 
5'-
C*C*AAATGACATGTTTTCTGCTACTGACAGGTGGGGATAGAGCGCCTAAGACTGAAACACCATACCAACGCCGCGTTCTG
CTGGCGGAG*T*G 
Oligonucleotide for the introduction 
of C:C mismatch to malK gene 
araB_AA 
5’-
A*T*GGCGATTGCAATTGGCCTCGATTTTGGCAGTGATTCTGTGCGAGCTTAGGCGGTGGACTGCGCTACCGGTGAAGAG
ATCGCCACCA*G*C 
Oligonucleotide for the introduction 
of A:A mismatch to araB gene 
cycA_AAAC 
5’-
A*A*TGATCATATAAACGAAAATGATCGACGGCCCGGCAAGGCTAATCGTTCAGCCAGACCCCATAAACAACCCCGTACCA
ATGGCACCG*C*C 
Oligonucleotide for the introduction 
of AA:AC double mismatch to cycA 
gene 
hisB_GT 
5’-
C*T*GAAGCTGCAAAAAGCGGGCTACAAGCTGGTGATGATCACTAATTAGGATGGTCTTGGAACACAAAGTTTCCCACAGG
CGGATTTCG*A*T 
Oligonucleotide for the introduction 
of G:T mismatch to hisB gene 
rpsL_AC 
5’-
G*T*CAGACGAACACGGCATACTTTACGCAGCGCGGAGTTCGGTTTTCTAGGAGTGGTAGTATATACACGAGTACATACGC
CACGTTTTT*G*C 
Oligonucleotide for the introduction 
of A:C mismatch to rpsL gene 
ECASN 
5'-
G*A*CGAGAAAAGTGAGATTTCACGAAGCTAATTNGACGTNGTTTGNCAATGNAAGCGNTTTTCNTTTTTTATACTCCTGCG
TCCTGTTG*C*T 
Oligonucleotide for asnA 
mutagenesis 
SEASN 
5'-
G*C*TGGCGAGAGAAATGTGATTTCACGAAGCTAATTNGACGTNGTTTGNCAATGNAAGCGNTTTTCNTTTTTTTACTCCTG
CGTCCTGT*T*G 
Oligonucleotide for asnA 
mutagenesis 
CFASN 
5'-
C*T*GGCGAGAAAAATGAGATTTTACGAAGCTAATTNGACGTNGTTTGNCAATGNAAGCGNTTTTCNTTATGTGTACTCCTG
TGTCCTGT*T*G 
Oligonucleotide for asnA 
mutagenesis 
TET_DT 
G*T*AATAACGCTAAAAGTTTTAGATGTGCTTTNCTAAGTCATCGCGATGGAGCAAAAGTACATTTAGGTACACGGCCTACA
GAAAAACA*G*T 
TET landing-pad targeting 
oligonucleotide for Illumina deep-
sequencing based MAGE 
performance assay 
TET_DC 
G*T*AATAACGCTAAAAGTTTTAGATGTGCTTTACTAANTCATCGCGATGGAGCAAAAGTACATTTAGGTACACGGCCTACA
GAAAAACA*G*T 
TET landing-pad targeting 
oligonucleotide for Illumina deep-
sequencing based MAGE 
performance assay 
TET_DG 
G*T*AATAACGCTAAAAGTTTTAGATGTGCTTTACTAAGTCATCGNGATGGAGCAAAAGTACATTTAGGTACACGGCCTACA
GAAAAACA*G*T 
TET landing-pad targeting 
oligonucleotide for Illumina deep-
sequencing based MAGE 
performance assay 
TET_DA 
G*T*AATAACGCTAAAAGTTTTAGATGTGCTTTACTAAGTCATCGCGATGGAGCAAAAGNACATTTAGGTACACGGCCTACA
GAAAAACA*G*T 
TET landing-pad targeting 
oligonucleotide for Illumina deep-
sequencing based MAGE 
performance assay 
TET_DC2 
G*T*AATAACGCTAAAAGTTTTAGATGTGCTTTACTAAGTCATCGCGATGGANCAAAAGTACATTTAGGTACACGGCCTACA
GAAAAACA*G*T 
TET landing-pad targeting 
oligonucleotide for Illumina deep-
sequencing based MAGE 
performance assay 
* represents phosphorothioate bonds 
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Oligo ID Sequence (5'-3') Description
TETRM1_01 TTAGATAAAAGTAAAGTGATTAACAGCGCATTAGAGCTGCTTAATGAGGTCGGAATCGAAGGTTTAACAACCCGTAAACTCGCCCAGAAG Spiked-oligonucleotide with 0,1% spiking, targeting the Landing pad
TETRM3_01 TTGAGATGTTAGATAGGCACCATACTCACTTTTGCCCTTTAGAAGGGGAAAGCTGGCAAGATTTTTTACGTAATAACGCTAAAAGTTTTA Spiked-oligonucleotide with 0,1% spiking, targeting the Landing pad
TETRM1_05 TTAGATAAAAGTAAAGTGATTAACAGCGCATTAGAGCTGCTTAATGAGGTCGGAATCGAAGGTTTAACAACCCGTAAACTCGCCCAGAAG Spiked-oligonucleotide with 0,5% spiking, targeting the Landing pad
TETRM3_05 TTGAGATGTTAGATAGGCACCATACTCACTTTTGCCCTTTAGAAGGGGAAAGCTGGCAAGATTTTTTACGTAATAACGCTAAAAGTTTTA Spiked-oligonucleotide with 0,5% spiking, targeting the Landing pad
TETRM1_1 TTAGATAAAAGTAAAGTGATTAACAGCGCATTAGAGCTGCTTAATGAGGTCGGAATCGAAGGTTTAACAACCCGTAAACTCGCCCAGAAG Spiked-oligonucleotide with 1% spiking, targeting the Landing pad
TETRM3_1 TTGAGATGTTAGATAGGCACCATACTCACTTTTGCCCTTTAGAAGGGGAAAGCTGGCAAGATTTTTTACGTAATAACGCTAAAAGTTTTA Spiked-oligonucleotide with 1% spiking, targeting the Landing pad
TETRM1_2 TTAGATAAAAGTAAAGTGATTAACAGCGCATTAGAGCTGCTTAATGAGGTCGGAATCGAAGGTTTAACAACCCGTAAACTCGCCCAGAAG Spiked-oligonucleotide with 2% spiking, targeting the Landing pad
TETRM3_2 TTGAGATGTTAGATAGGCACCATACTCACTTTTGCCCTTTAGAAGGGGAAAGCTGGCAAGATTTTTTACGTAATAACGCTAAAAGTTTTA Spiked-oligonucleotide with 2% spiking, targeting the Landing pad
TETRM1rv CTTCTGGGCGAGTTTACGGGTTGTTAAACCTTCGATTCCGACCTCATTAAGCAGCTCTAATGCGCTGTTAATCACTTTACTTTTATCTAA Reverse complement of TETRM1
TETRM3rv TAAAACTTTTAGCGTTATTACGTAAAAAATCTTGCCAGCTTTCCCCTTCTAAAGGGCAAAAGTGAGTATGGTGCCTATCTAACATCTCAA Reverse complement of TETRM3
TETRM1 TTAGATAAAAGTAAAGTGATTAACAGCGCATTAGAGCTGCTTAATGAGGTCGGAATCGAAGGTTTAACAACCCGTAAACTCGCCCAGAAG Reference-oligonucleotide without spiking, targeting the Landing pad
TETRM3 TTGAGATGTTAGATAGGCACCATACTCACTTTTGCCCTTTAGAAGGGGAAAGCTGGCAAGATTTTTTACGTAATAACGCTAAAAGTTTTA Reference-oligonucleotide without spiking, targeting the Landing pad
folORM1_05 ATCGGCAGGCAGGTTCCACGGCATGGCGTTTTCCATGCCGATAACGCGATCTACCGCTAACGCCGCAATCAGACTGATCATTGAGATTTC Spiked-oligonucleotide with 0,5% spiking, targeting the folA locus of E. coli K12 MG1655
folORM2_05 ACCGATTGATTCCCAGGTATGGCGGCCCATAATCACGGGTTTATTTAAGGTGTTGCGTTTAAACCAGGCGAGATCGGCAGGCAGGTTCCA Spiked-oligonucleotide with 0,5% spiking, targeting the folA locus of E. coli K12 MG1655
folORM3_05 CACCCACGTTACGCGATCGTCCGTACCCGGTTGACTGCTGAGGATAATATTTTTGCGTCCTGGCAACGGACGACCGATTGATTCCCAGGT Spiked-oligonucleotide with 0,5% spiking, targeting the folA locus of E. coli K12 MG1655
folORM4_05 AACGCGACCGCCGCCAATCACCATGATTTCTGGTACGTCACCACACGCCGCGATGGCTTCATCCACCGACTTCACCCACGTTACGCGATC Spiked-oligonucleotide with 0,5% spiking, targeting the folA locus of E. coli K12 MG1655
folORM5_05 GGTGTCGCCTTCCACTTCTGCGTCGATATGCGTCAGATACAGTTTTTGCGCTTTTGGCAAGAACTGTTCATAAACGCGACCGCCGCCAAT Spiked-oligonucleotide with 0,5% spiking, targeting the folA locus of E. coli K12 MG1655
folORM6_05 GTTCTGCGCATCAGCATCGTGGAATTCGCTGAATACCGATTCCCAGTCATCCGGCTCGTAATCCGGGAAATGGGTGTCGCCTTCCACTTC Spiked-oligonucleotide with 0,5% spiking, targeting the folA locus of E. coli K12 MG1655
folORM7_05 GCATCCGGCGCTAGCCGTAAATTCTATACAAAATTACCGCCGCTCCAGAATCTCAAAGCAATAGCTGTGAGAGTTCTGCGCATCAGCATC Spiked-oligonucleotide with 0,5% spiking, targeting the folA locus of E. coli K12 MG1655
folPRM1_05 ACTGATCATTGAGATTTCCCGATAAAAAAAATTGTCGCCACTATACGTAAAGCGTAAACCGTCGTCGACTGGTGCGAGGATGATGTTGAG Spiked-oligonucleotide with 0,5% spiking, targeting the folA locus of E. coli K12 MG1655
CfolORM1 ATCGGCAGGCAGGTTCCACGGCATGGCGTTTTCCATGCCGATAACGCGATCTACCGCTAACGCCGCAATCAGACTGATCATTGAGATTTC Spiked-oligonucleotide with 0,5% spiking, targeting the folA locus of E. coli CFT073
CfolORM2 ACCGATGGATTCCCAGGTATGGCGGCCCATAATCACGGGTTTATTTAAAGTGTTGCGTTTAAACCAGGCGAGATCGGCAGGCAGGTTCCA Spiked-oligonucleotide with 0,5% spiking, targeting the folA locus of E. coli CFT073
CfolORM3 CACCCACGTTACGCGATCGTCCGTACCCGGTTGACTGCTGAGGATAATATTTTTGCGTCCTGGCAACGGACGACCGATGGATTCCCAGGT Spiked-oligonucleotide with 0,5% spiking, targeting the folA locus of E. coli CFT073
CfolORM4 AACGCGACCGCCGCCAATCACCATGATTTCTGGTACGTCACCACACGCCGCAATGGCTTCATCCACCGACTTCACCCACGTTACGCGATC Spiked-oligonucleotide with 0,5% spiking, targeting the folA locus of E. coli CFT073
CfolORM5 GGTGTCGCCTTCCACTTCCGCGTCGATATGCGTCAGATACAGTTTTTGCGCTTTCGGCAGGAACTGCTCATAAACGCGACCGCCGCCAAT Spiked-oligonucleotide with 0,5% spiking, targeting the folA locus of E. coli CFT073
CfolORM6 GTTCTGCGCATCGGCATCGTGGAATTCGCTGAATACCGATTCCCAGTCATCCGGCTCGTAATCCGGGAAATGGGTGTCGCCTTCCACTTC Spiked-oligonucleotide with 0,5% spiking, targeting the folA locus of E. coli CFT073
CfolORM7 GTATCAGTGATGCCGGAATTCTAATATACAAAATTACCGCCGCTCCAGAATCTCAAAGCAATAGCTGTGAGAGTTCTGCGCATCGGCATC Spiked-oligonucleotide with 0,5% spiking, targeting the folA locus of E. coli CFT073
CfolPRM1 ACTGATCATTGAGATTTCCCGATAAAAAAAATTGTCGCCACTATACGTAAAGCGTAAACCGTCGTCGACTGGTGCGAGGATGATGTTGAG Spiked-oligonucleotide with 0,5% spiking, targeting the folA locus of E. coli CFT073
MgyrA.PRM_0.5 gtcgctcatctaaccgctatccctctactgtatcccggattcaaaggtcgcaaattataacacagccgcgcagtttgaggtaaacctata Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM1_0.5 CGACATCGCATAATCCAGATAGGAGCTCTTCAGCTCTTCCTCAATGTTGACCGGTGTAATTTCTCTCGCAAGGTCGCTCATCTAACCGCT Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM2_0.5 GGCGTAAAGTACGCGACGGTGTACCGGCTTCAGGCCATCTCGGACATCTGGCAGCGCACGGCCAACAATGACCGACATCGCATAATCCAG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM3_0.5 ACCGATTACGTCACCAACGACACGGGCAGATTTTTTATAGGCTTTGTTCCAGTCATTGCCTAGTACGTTCATGGCGTAAAGTACGCGACG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM4_0.5 ACGCAGCGAGAATGGCTGCGCCATGCGGACGATCGTGTCATAGACCGCCGAGTCACCATGGGGATGGTATTTACCGATTACGTCACCAAC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM5_0.5 CGTATAACGCATTGCCGCCGCAGAGTCGCCGTCGATAGAACCGAAGTTACCCTGACCGTCTACCAGCATATAACGCAGCGAGAATGGCTG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM6_0.5 ATCAACGAAATCGACCGTCTCTTTTTCGAGATCGGCCATCAGTTCATGGGCAATTTTCGCCAGACGGATTTCCGTATAACGCATTGCCGC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM7_0.5 AGAACCGTTCACCAGCAGGTTAGGAATTTTGGTTGGCATGACGTCCGGAATTTTTTCCGTGCCGTCATAGTTATCAACGAAATCGACCGT Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM8_0.5 CAGACAACCGTTGATGACTTCCGTCAGGTTGTGCGGCGGGATGTTGGTTGCCATACCTACGGCGATACCGGAAGAACCGTTCACCAGCAG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM9_0.5 CGTCGGGAAGTCCGGCCCCGGGATGTGTTCCATCAGCCCTTCAATGCTGATGTCTTCATCATCAATATACGCCAGACAACCGTTGATGAC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM10_0.5 GCGGATATACACCTTGCCGCGACCGGTACGGTAAGCTTCTTCAATACCGCGACGACCGTTAATGATTGCCGCCGTCGGGAAGTCCGGCCC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM11_0.5 CTGATACGGAATTTCGTGGACGATAATGGTTTCACGACCGGTTTTGGCGTCAACTTCCACTTCTGCGCGAGCGCGGATATACACCTTGCC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM12_0.5 CGCGCTGATGCCTTCCACGCGTTTTTCTTTTACCAGTTCCGCAATCTTCTCGATCAGGCGCGCTTTGTTTACCTGATACGGAATTTCGTG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM13_0.5 AACTTCACCGACCGCATCGCGTTTCACTTCAATCACGATGCGCATACCGTCTTTGTCAGACTCGTCACGCAGCGCGCTGATGCCTTCCAC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM14_0.5 ATGGTGCAATGCCACCATGTTGATACCGAAAGAAACCTGCAACTGGGTCTGGGAGTAGAGGTTGTTGAGCACAACTTCACCGACCGCATC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM15_0.5 GGTCACCACTTCACGGCGGTGACGAACAAACGCCGCGATGATGTCTTTCAGGTTCATGATCTTCGGCTGACCATGGTGCAATGCCACCAT Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM16_0.5 CAGCGCCACGGCTAATGCTTCAAGGATATGAGCACGATCGCGAGCTTTACGCAGTTCGAAAATAGTACGACGGGTCACCACTTCACGGCG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM17_0.5 AACCAGCGCAGTTTTCGCTTCTGCAGGCGTCGGCGCATGACGGATCAGTTCGATGATCGGGTCGATGTTCGCCAGCGCCACGGCTAATGC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM18_0.5 TTCCGGACGCGCAGCATCGTCGCCAGCACGTTCGAGCATCGCGGCAACGTTGCCCAGCTGCCACGGATTAGCAACCAGCGCAGTTTTCGC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM19_0.5 CAGAATCGCCTGAGCTTGCTGTTCGGTCAGGTAGTACAGACCATCACGCACGCCGAACTCTGGCTCCAGCCATTCCGGACGCGCAGCATC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM20_0.5 ATCCAGCAGCTCTTTGTATTCGTCGAGCAGTTTTTCGTGCTCAAGACCGGTCAGTTTCTGCAAACGCAGATCCAGAATCGCCTGAGCTTG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM21_0.5 CTCCAGCTCTTCACGGATCACTTCCATCAGACGATCGGCGCTACCAAGAATACGCAACAGTTCCGCGATCTGATCCAGCAGCTCTTTGTA Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM22_0.5 TTCCAGGTTGATGTCTGCGCTGTTGGCGGTGATTTCAGTACGACGTTTGTCACCGAACTGTTCACGAACCAGCTCCAGCTCTTCACGGAT Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM23_0.5 AGAAAGCGGCTGATACTTAACGTAGCCCTGGTGAGAGAGCGTCACGACCACATCTTCCTGGGTGATCAGATCTTCCAGGTTGATGTCTGC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM24_0.5 GTCGATAAAGTCTTCTTCTTTAATACGTGCGGCAGATTTACCTTTCCCGCCACGACGCTGCGCTTCGTATTCAGAAAGCGGCTGATACTT Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM25_0.5 TTTCATCGAATAGACGCGACCACGGCTGGAGAAGCACAGAATATGGTCGTGAGTGTTCGCCACCAGCAGTCGGTCGATAAAGTCTTCTTC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM26_0.5 CTGCTCCAGCGGCAGCAGGTTGACGATCGGACGACCGCGCGCGCCACGAGTGGCTTCCGGCAACTGATAAACTTTCATCGAATAGACGCG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM27_0.5 AGCGGTCGCCATGAAGACTTTCACGCCTTCTTCAAACTCGGTCACTGGCAGGATCGCAGTGATACGTTCGTCCTGCTCCAGCGGCAGCAG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM28_0.5 TTTGATCGCCACTTTACCGGCGGTACGCAGACGGTTGAACTCGGTGAGGACAGTTTTCTTCACGGTACCGTTAGCGGTCGCCATGAAGAC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM29_0.5 AGCGGAGAACAGCATTACTTCGTCTTCGCCGCTGGTCAGGTCAACGCCGATCAGCTCATCGCCGTCAACCAGTTTGATCGCCACTTTACC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM30_0.5 ACCGCGAACACCGGTGGTGTTGCAGCCCATCGCACGGACAGAAGACTCTTTAAAGCGCACCACTTTACCTTCAGCGGAGAACAGCATTAC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM31_0.5 TGCGGTGAGGATTGCGCCATCGCCACGAGGCACGATCAGAGAGACGACTTTATCGCCTTCACCTAAGCGAATACCGCGAACACCGGTGGT Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM32_0.5 AACCCCTTTCGTCGCACGCGACTTGGTTGGGTATTCCGCCACTGCGGTACGTTTACCGTAACCGTTTTGCGTTGCGGTGAGGATTGCGCC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM33_0.5 GATCTGGTCGCAGTCATCTACCTGTACCGCGCCAACAACTAAACCGTTACGTTCGGTAACCTTGATGGAGATAACCCCTTTCGTCGCACG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM34_0.5 GGTGTTACGGCCCACGATGCTGATTTCCGAAACGCGAGTACGTACCAGCGTACCGGCATCGGTGATCATCATGATCTGGTCGCAGTCATC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM35_0.5 AACCGGTTCAGCAACACGTTGCAGACCCACTACGTTTTCATCTTCCGCAGTACGGATGAGGATCACGCCCTGGGTGTTACGGCCCACGAT Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM36_0.5 GTCCACTTCCGGAGCGATTTCATCGTCCCCTTCCGCGGCACTGCCGTCGATGGTATCCAGATCTTCCTCGTCAACCGGTTCAGCAACACG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrA.ORM37_0.5 ATTCAAACAAGGGAGATAGCTCCCTTTTGGCATGAAGAAGTAAAATTATTCTTCTTCTGGCTCGTCGTCAACGTCCACTTCCGGAGCGAT Spiked-oligonucleotide with 0,5% spiking, targeting the gyrA locus of E. coli K-12 MG1655
MgyrB.ORM1_0.5 TTACGCACCGCATCCAGCCCTTTCAGGACTTTGATACTGGAGGAGTCATAAGAATTCGACATCAACGTTTCTCGCTCATTTATACTTGGG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM2_0.5 TCTACCACCTCGAATACCATGTGGTGCAGACCGGTGCCGTCATCCGTGTCGCCGATATACATACCCGGGCGCTTACGCACCGCATCCAGC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM3_0.5 ACAGAGTTATCGGCGTGAATGGTGACGATAATTTCTTTACAGTGACCCGCGAGCGCTTCGTCGATAGCGTTATCTACCACCTCGAATACC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM4_0.5 ACTTCCGCCGCCGATACGCCCTCTTCCGGGTGAATACCGGTCGGAATGCCGCGCCCGTCATCCTGTACAGAGACAGAGTTATCGGCGTGA Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM5_0.5 CCGTGCAGACCGCCGGACACTTTATAGGAGTTATCGTCAAATTTACCGCCTGCGTGCAGAACGGTCATGATCACTTCCGCCGCCGATACG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM6_0.5 TGAATTTTACCCTCGCGCTGGATAACCAGCTCCAGTTTTTGCGACAGGGCGTTTACTACCGAAACACCAACGCCGTGCAGACCGCCGGAC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM7_0.5 GTGCCGGTTTTTTCAGTCTCGCCGGTAACCGCCAGCGGGGCCTGCGGTACACCGTGTTCGTAGATCTGACGGTGAATTTTACCCTCGCGC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM8_0.5 TTCGCCAGAATTTCATATTCGAACTCGGTCACATTGGTGAAGGTTTCGAGGCTGGGCCAGAAACGCACCATGGTGCCGGTTTTTTCAGTC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM9_0.5 TCTTTGCCGTCGCGCTTGTCGCGCAGACGAATGGAAACGCCGGAGTTGAGGAACGACAACTCACGCAGACGTTTCGCCAGAATTTCATAT Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM10_0.5 TGGATCGGCGTTTTGTTCTTGTTCAGATATTCAACGAACGCCTTGATGCCGCCTTCATAGTGGAAGTGGTCTTCTTTGCCGTCGCGCTTG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM11_0.5 CCATCGTTCCACTGCAACGCCACTTCGACGCCAATACCGTCTTTTTCAGTGGAGAAGTAGAAGATATTCGGGTGGATCGGCGTTTTGTTC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM12_0.5 AAGCCTGCCAGGTGAGTACCGCCGTCACGCTGCGGAATGTTGTTGGTAAAGCAGTAGATGTTTTCCTGGAAGCCATCGTTCCACTGCAAC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM13_0.5 CTGACTTTGGCTTTTTTGCTGTAGCCTTCTTTGTCCATGTAGGCGTTCAGGGTACGGGTCATCGCCGCACGGAAGCCTGCCAGGTGAGTA Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM14_0.5 GAGAATTTCGGGTCCGGCACTTTCACGGAAACGACCGCAATCAGGCCTTCACGCGCATCGTCACCGGTGGCGCTGACTTTGGCTTTTTTG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM15_0.5 AGCAGTTCGTTCATCTGCTGTTCAACCGCCGATTTCACCTCAGAAGAAACCAGTTTGTCTTTGGTCTGGGAGGAGAATTTCGGGTCCGGC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM16_0.5 GCACGGGCAGCATCGATAATTTTGCCAACCACGATTTTCGCGTCGGTTGGGTTTTCCAGCAGGTATTCTGCCAGCAGTTCGTTCATCTGC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM17_0.5 CCCGGCAGGCCCGCTAAGTCGAGCGCACCTTTACGGCGGGTCATTTCACGCGCGCGACGCGCCGCTTCACGGGCACGGGCAGCATCGATA Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM18_0.5 CCCGCGGAGTCCCCTTCCACCAGGTACAGTTCGGAAAGCGCCGGATCGCGTTCCTGGCAGTCTGCCAGTTTGCCCGGCAGGCCCGCTAAG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM19_0.5 ACGTTGAGGATTTTACCCTTCAGCGGCAGAATCGCCTGGTTCTTGCGGTTACGCCCCTGCTTCGCAGAGCCGCCCGCGGAGTCCCCTTCC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM20_0.5 CCACAGCCAAGCGCGGTGATAAGCGTCGCCACTTCCTGAGAAGAGAGCATCTTATCGAAGCGCGCTTTCTCGACGTTGAGGATTTTACCC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM21_0.5 ACGTCCGCATCGGTCATGATGATGATGCTGTGATAACGCAGTTTGTCCGGGTTGTACTCGTCACGACCGATACCACAGCCAAGCGCGGTG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM22_0.5 CCGCGTTCAACGATTTCCGGCATCTGACGATAGAAGAAGGTCAACAGCAGCGTACGAATGTGCGAGCCGTCGACGTCCGCATCGGTCATG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM23_0.5 TCGTCTTTAATGTACTGTTCCTGCTTGCCTTTCTTCACTTTGTACAGCGGCGGCTGAGCGATGTAGACGTGACCGCGTTCAACGATTTCC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM24_0.5 GGTGCACTGGCGTTGGTGTGCAGCGTTGCGCCGTCCAGCGCGATAGAGATCTGGTACTGATCCATCGCTTCGTCGTCTTTAATGTACTGT Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM25_0.5 ATACGATTGATCATTTTCTGCGTCGCGTTGTACTCAGATACCAGTTTCTCTAACGCTTCGCCAGCCAATGCCGGTGCACTGGCGTTGGTG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM26_0.5 GAAAGGTCAGCTTCCGTCAACGTCGGCTGATAGATAAGCTCTTTCAGCATTGCTTTCGGATAACGACGCTCCATACGATTGATCATTTTC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM27_0.5 CTGCCGTGCTGTTCTTTGTCGTTCAGTTCGCTGACCAGCGCGTTCACCCAGCGGGTAACGGTCTGCTCATCAGAAAGGTCAGCTTCCGTC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM28_0.5 TGGGTACGCACGCGAACAATCGGCTCGAACAGGTTTTGCTCAGCATTGGTGTGAACATCAAACTTCCACTGGCTGCCGTGCTGTTCTTTG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM29_0.5 AGCGTGCAGATACGACGATATTCGCCACCGGTGATAAACTCGTGATCCAGCGGATAGTCAGTATCCACACCGTGGGTACGCACGCGAACA Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM30_0.5 GCTACCGGCTGACGACGCTCGCCACGTTCGATAAACGCATCTTCTTCCAGCAAGCCACGCAGTTTCTCACCCAGCGTGCAGATACGACGA Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM31_0.5 CCTTTATAACGCTGGATGGAGAGGCCGCGACGGGACTCTTTCACCAGCCAGTCCAGCGCCTGCTCGAAGCTGGCTACCGGCTGACGACGC Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM32_0.5 ACGCGCAGCATACGACGACTTTCCGGGTCCATAGTGGTTTCCCACAGCTGTTCCGGGTTCATCTCGCCCAGACCTTTATAACGCTGGATG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM33_0.5 CGGCGCGGTTCAACGGCGTCGCCCATCAGCGTGGTGAACAACTGGTCGGCAGCAATCGCATCTTTAACGGTAACGCGCAGCATACGACGA Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MgyrB.ORM34_0.5 GCACGCTCGCATGGTTAGCGCCATTAAATATCGATATTCGCCGCTTTCAGGGCGTTCTCTTCAATAAACGCACGGCGCGGTTCAACGGCG Spiked-oligonucleotide with 0,5% spiking, targeting the gyrB locus of E. coli K-12 MG1655
MparC.ORM1_0.5 GTAGTTTAAGTAGGCGTTTTCCGTAAATTCATGTAGCGCAAGGCGCTCTGCCATATCGCTCATTAATTCTGATTCCTCAACTTATTCGCC Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM2_0.5 AATGCGGCGCTGAACAGGTTTCAGACCATCACCAATAAACGGCAACGCACGGTCCATGATCACGTACATGGAGTAGTTTAAGTAGGCGTT Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM3_0.5 GTCACCGACGGTACGGGCCGATTTTTTAAATTTGGCGCTGGCATTCAGGCCCAGTTCAGACATCGCATACACAATGCGGCGCTGAACAGG Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM4_0.5 GAACGGTTGCGCCATCAGGACCATCGCTTCATAACAGGCGCTATCGCCGTGCGGATGGTATTTACCCAGTACGTCACCGACGGTACGGGC Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM5_0.5 TGCCGCGAACGATTTCGGATCGTCCGGCGCGCCCCAGTTCCCCTGACCATCAACCAGCGGATAACGGTAAGAGAACGGTTGCGCCATCAG Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM6_0.5 AGCCGTCCCCTGCCCCAGCTCGCTCAATAGCAGCTCGGAATATTTCGACAACCGGGATTCGGTGTAACGCATTGCCGCGAACGATTTCGG Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM7_0.5 CAAAATGTTTGGCAGACGGGCAGGTAGCATTTTCGGCTCCTGCAAAGTGCCGTCGAAGTTTGGCACCCAGTCAGCCGTCCCCTGCCCCAG Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM8_0.5 AGCCACTTCACGCAGGTTATGCGGTGGAATATCGGTCGCCATGCCGACGGCAATACCGGTGGTGCCGTTAAGCAAAATGTTTGGCAGACG Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM9_0.5 CGGCCCCTGCACGATATCCAGCAGCTGATCGAGCGTGGTTTTCGGCTGGTCGATTAATGCGATTGCCGCCTGAGCCACTTCACGCAGGTT Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM10_0.5 ACCACGTCCGTTCTCGTAGATTTTACGGATCTCGGCGCGCGAAGTGATAATTTCCGCTTCAGTCGGATAATCCGGCCCCTGCACGATATC Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM11_0.5 AACCTGATGCGGCAATGCGCTGATAACCACCGCGCCATCTTCTTTCTTCCACACCGCGCGCATACGCACTGAACCACGTCCGTTCTCGTA Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM12_0.5 AGATCGTCAACCATCGGCAGCTTTTTGTTGCGCATTTGCGCAGCAATTTGCTCCAGTACGCGCGCACCTGAAACCTGATGCGGCAATGCG Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM13_0.5 TCCATATCCACGCGGTTGGAACGCGGCACAATCACCAGGCGGGTCGGGTTCTCGTGGTCAGATTCATCGCGCAGATCGTCAACCATCGGC Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM14_0.5 CCGATCATATTAAGGTTAATACGATAGCTCTTTTCCAGATCGGTGGTAGCGAAGAGGTGGTTCATCACCTGATCCATATCCACGCGGTTG Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM15_0.5 GTATCGCGGCGGAACACCAGCCATTCGGAGAGGATTTCCAGCAGGTTTTTCACCGCCGGACGACCATCCAGACCGATCATATTAAGGTTA Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM16_0.5 ACCAGCAAACCTTCGAGGATATGCAGGCGCTTGAGGACTTTCTCCAGACGATAGTTCAGTCGGCGGCGCACGGTATCGCGGCGGAACACC Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM17_0.5 GACATCAGCGCCGGTTTCGGTTCATCTTCATTACGAATGATCTCAATCACTTCGTCGATATTGAGAAACGCCACCAGCAAACCTTCGAGG Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM18_0.5 TCCAGTTTGGCAAGATGACGCAGTTTCAGTTCGAGGATCGCTTCCGCCTGGGTTTCCGTAAGGCCAAACCGCGACATCAGCGCCGGTTTC Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM19_0.5 GAAGCCAAAATGCCCTGCAACTGGTCGCGCTCTTTTTCCAGTTCACTCTGCTCACCGCGAATCTTCATCTCTTCCAGTTTGGCAAGATGA Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM20_0.5 CGACGATCGTCACCGTAGGCTTGCGCGTCTGCCTGCAGTTCTTTCTTCAGCAGGTTATTCATTTTACGCTCGGAAGCCAAAATGCCCTGC Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM21_0.5 GTGACAGGTTCAGACGGCAGCATGTCGTGCTCGCTCATCGCTTTCGCTTCTTCGCGTTCCTGCAACGGCGAACGACGATCGTCACCGTAG Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM22_0.5 TAATTCAGGCCCGGCGCGTCGATATCATGGCCTTTAGCGCTGCGTACCCAGCCCATCTGCGACAGCACAATGGTGACAGGTTCAGACGGC Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM23_0.5 GTGGAATCAACAAACACTACCGGTTGGTTGCTCTTACCTTTCACCGCCGCTTTGAAGCTATCACCCGCTTTATAATTCAGGCCCGGCGCG Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM24_0.5 TTGCCGGTGAGCGGCTCGCCCTGACCACGCGCCGACGGCAGCGTAATCGGGTCAATGGCATAGCTACGACCGGTGGAATCAACAAACACT Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM25_0.5 GCCATCAGCAGTTTCTGATCGTCGCTTTCCATCAGCATATGGTCAACGGTCGCCCCAGGCGGCAACGTTAATTTGCCGGTGAGCGGCTCG Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM26_0.5 AAAGCCTTACCTGCACGGTTACGCGCCACCAGATCGTTAAAGGTGCAGACGAAACCGTAACCCGCATCGGAAGCCATCAGCAGTTTCTGA Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM27_0.5 GCCAGCAGCATATCGGAAGCATCTTCAATCACCACCGGCGGCATAACATGGGCATTTTCCGGTAAGGTGATCAAAGCCTTACCTGCACGG Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM28_0.5 TTGCCTTTGCCCTTCGACAGCTGCGGCAGATCACTTACCGGGAACATCAACATACGGCCTGCCTGAGTGATTGCCAGCAGCATATCGGAA Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM29_0.5 GGCAGAACGTACAATTGCGCCAGACCATCTTCTCCACGCGCGGCTTCTGCCGATGGAATGTTGATAATCTTGTTGCCTTTGCCCTTCGAC Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM30_0.5 ACTTTCTGTAACTCTTCCGGGCGCAGTTTAATTTTGCGTTTCCCAACATGAATGGTCAGCGTGCTTTGCGGCGGCAGAACGTACAATTGC Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM31_0.5 GAGTCGATCTCAACACGATCGATACGCTGCAAACCGCGCATCAACGTACCGCGGCGTCCACGTTCGCCAGTGACTTTCTGTAACTCTTCC Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparC.ORM32_0.5 TGCAAGCGGGAGGAAACAGCGCCCTCCCCGGCATATTACTCTTCGCTATCACCGCTGCTGGCACGGCGAGGAGAGTCGATCTCAACACGA Spiked-oligonucleotide with 0,5% spiking, targeting the parC locus of E. coli K-12 MG1655
MparE.ORM1_0.5 CGGCGAACCGGCTCAAGCCCGGTGAGTACCTCAATGGCATCAGCGTTATAAGTTTGCGTCATGGTTTAAGTTAGTAATTCGAGTTGATCG Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM2_0.5 TCCACACTGTTATCAATGACTTCTTGCCCCAAATGGTTAGGGCGAGTGGTATCGGTATACATCCCCGGACGGCGGCGAACCGGCTCAAGC Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM3_0.5 TCAATAACTTCTAACGACTGGTCAGCATGTAAAATAACGTCCACGCGTTTTGCGTGACCCGCCAGTGCTTCATCCACACTGTTATCAATG Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM4_0.5 CGGCAAAGAATCAGTTCAACCGCCGGTACACCCTCTTCCGGGTGAATATCCACCGGCATCCCGCGCCCATCGTCAATAACTTCTAACGAC Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM5_0.5 GAAATCCCCACGCCATGCAGGCCGCCAGAGAACTGGTAATTTTTGTTAGAGAATTTACCGCCTGCATGCAGACGGCAAAGAATCAGTTCA Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM6_0.5 AAGGCGATGTTATAAACCTGACCATCGCGGCGCACGTTAACTTCTACGCGCTTCGACAGGGCGTTAACCACCGAAATCCCCACGCCATGC Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM7_0.5 ACACTGGTACCAGTATTGCGTTTACCGCAAGTGCCGACAACCTGTAAATCCTGCACCTTTTCGCCATTTTCAAAGGCGATGTTATAAACC Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM8_0.5 TTCAGCACATGCGTCAGGCGTGAAACAGAAAATCGCGGGCTGTCAAAGAAGGTTTCATCCGGCCAGAAGTGCACACTGGTACCAGTATTG Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM9_0.5 CAGCGTTGTTCGGTATTGTTGATCTCATCTTTAAAAGTGATCTCAACGCCAGGGCACAATACCGCTTTGGCTTTCAGCACATGCGTCAGG Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM10_0.5 GGTTTTTCCGGCAGCGTCGGCAGACCATTTACCGCTTCCGCCAGGTAATCATTCAGACCGTCCTGATAGCACCAGCGTTGTTCGGTATTG Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM11_0.5 TCACCGCCTTCCGGCAGCCACAGTAGCGCCCAGTCCACAGCTTCAGTATCACCAGCGAAATTACCGATAAACGGTTTTTCCGGCAGCGTC Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM12_0.5 TGACGCAGACCATTAACATGGGTACCGCCCTGCATCGTTGGGATAAGGTTGACGTAGCTTTCGGTCAGCAGTTCACCGCCTTCCGGCAGC Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM13_0.5 GCCGACAGCTTTACACCGCGCGGCAGAATATTGCGGTATTCACAGAACTCACGCATCGCGTCCAACAGGCCCTGACGCAGACCATTAACA Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM14_0.5 GTCTGCCCGGCAAACTGCGGATCCTGCATTTTTACTGACAGCACATAGGCGCAGCGATCCCAGATATCTTCCGCCGACAGCTTTACACCG Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM15_0.5 CACAGGATAAAGGCATCTTTCACCACGCCAGAAACGAATGCCGCGCATTGACGCGAAGAGAGACGCTCTTTCGTCTGCCCGGCAAACTGC Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM16_0.5 CGCATACGGCGCTGGGCGCTGGAAATCGCCATCTCCGCCAGCAGTTCAGCCGCCTGAACGTTCTGGTTCAGCCACAGGATAAAGGCATCT Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM17_0.5 GTACAATCAGCCAGTTTGCCAGGCAACGCCGGGCCGCTGGTCAGCTTTTTACGCACCACTTTTTTGGCCGCACGCATACGGCGCTGGGCG Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM18_0.5 GCCTGCTTGGCAGATCCGCCTGCGGAGTCACCTTCCACAAGGAACAGCTCGGTACGGTTAAGGTCCTGCGCGGTACAATCAGCCAGTTTG Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM19_0.5 TCGGAAGAGACTTCCCAGGTGTTAAGGATCTTACCTTTCAGTGGCATGATCGCCTGATATTCGCGATCGCGCGCCTGCTTGGCAGATCCG Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM20_0.5 AGATCGTCGCTGTCAGGATCGATACCGATCGCTACCGAAATATCGTGCACTTCCTGCGAAGCCAGCACTTCGTCGGAAGAGACTTCCCAG Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM21_0.5 AGCGTGGCAATGTGCAGACCATCAGAGTCCGCATCCGCGAGGATACAGATTTTGCCATAACGAAGCTGGCTCAGATCGTCGCTGTCAGGA Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM22_0.5 GGTGGCAGTGCGACGTAAACGTGACCGTGTTTCACCAACGCGCGGAAATGTTTTACGAACAAAGCGCAGAGCAGCGTGGCAATGTGCAGA Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM23_0.5 TCAAGTACGCCCTCTTTCTCTTCTTCCGTCAGCGCGTAATAAACCTCTTTCCCGAGATCAATACGGTAGAGCGGTGGCAGTGCGACGTAA Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM24_0.5 TGCATCGGGTTCATTTCCCCCAGACCTTTAAAACGCTGGACGTTCGGCTTGCCTTTCTTGCGTTTTAATTGCTCAAGTACGCCCTCTTTC Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM25_0.5 TGATCGTCTTCATCATCGATAGTCAACTGCACCAGACGGCGAGTGTTCGGATCAAGCGTGGTTTCGCGCAATTGCATCGGGTTCATTTCC Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM26_0.5 TCTTGCAACCAGTTGCGGCGATCTTCCGAGCGTTTCTTCGCCAGCAGCATATCCATCATCGCGTCAGTACGCTGATCGTCTTCATCATCG Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
MparE.ORM27_0.5 CTTGTTTGCCCGGCCATCCTGACCGGGCAATGTTCTTTCCTTTAAACCTCAATCTCCGCCATGTCGCCTTTCTCTTGCAACCAGTTGCGG Spiked-oligonucleotide with 0,5% spiking, targeting the parE locus of E. coli K-12 MG1655
DIvERGE Oligonucleotides
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Appendix 3. List of PCR primers used in this study 
Oligonucleotides 
Oligo name Sequence Description 
mutL2 5P-TCATCGCCATTTCACTCATCTTTCAGGGCTTTTATC Primers for cloning mutL into pSIM8 
mutL32F 5P-GTGAAAAACAGCCTCGATGC Primers for introducing dominant E32K mutation into mutL 
mutL32R 5P-TAGTTCTTTGACTACCGACGCAGG Primers for introducing dominant E32K mutation into mutL 
LExoF 5’-AAATGCCTGGTACTTTGCCAA Primers for sequencing mutL on pORTMAGE 
tL3R 5’-ATAACAGAAAGGCCGGGAA Primers for sequencing mutL on pORTMAGE 
pZAF 5’- GCTTAATTAGCTGAGTCTAGAGGC 
Primers for amplification of pZA31 plasmid backbone for 
mutLE32K cloning 
pZAR 5’- CCTTTCTCCTCTTTAATGAATTCGGT 
Primers for amplification of pZA31 plasmid backbone for 
mutLE32K cloning 
mutLRBS 5P-GAGAGGAGGTATATACATGCCAATTCAGGTCTTACCGCC 
Primer for the introduction of a strong RBS upstream mutL on 
pORTMAGE1 
pL32K frame_1 5'-CGGTACCACTCTTCCTTTTTCAATAT 
Primer for amplification of pORTMAGE1 from flanking region 
of Ap resistance cassette 
pL32K frame_2 5’-CGGATCCTAACTGTCAGACCAAGTTTA 
Primer for amplification of pORTMAGE1 from flanking region 
of Ap resistance cassette 
Gibson Kan_Fw 5’-AAAGGAAGAGTGGTACCGAATATGTATCCGCTCATGAG 
Primer for amplification of Km resistance cassette with 
homologous sequence to pORTMAGE for Gibson assembly 
Gibson Kan_rev 5’-GGTCTGACAGTTAGGATCCG ATGAAGTTTTGACGGTATCG 
Primer for amplification of Km resistance cassette with 
homologous sequence to pORTMAGE for Gibson assembly 
Gibson Chlo_Fw 5’-AAAGGAAGAGTGGTACCG CGCAGAATAAATAAATCCTG 
Primer for amplification of Cm resistance cassette with 
homologous sequence to pORTMAGE for Gibson assembly 
Gibson Chlo_rev 5’-GGTCTGACAGTTAGGATCCG AGGCACCAATAACTGCCTTA 
Primer for amplification of Cm resistance cassette with 
homologous sequence to pORTMAGE for Gibson assembly 
ARCK1 5’-CTGAATTGCTATGTTTAGTGAGT 
Checking primer for antibiotic resistance marker switch on 
pORTMAGE 
ARCK2 5’-CACAGTACCCAATGATCCCA 
Checking primer for antibiotic resistance marker switch on 
pORTMAGE 
tetDS1 5’-AAGGCTAATTGATTTTCGAGA Deep-sequencing primers for the landing-pad 
tetDS2 5’-CATAAATTTGAGAGAAGAGTT Deep-sequencing primers for the landing-pad 
Cint_F 
5’-
ATGAAAACCGCTTACATTGCCAAACAACGTCAAATTAGCTTCGTAAAATCTCATTTTTCTTGTAGCAC
CTGAAGTCAGC 
Primer used for landing pad incorporation into Citrobacter 
freundii 
Cint_R 
5’- 
TTACAGCAGAGAAGCGACGCTTTCACGTACCTGGGCCGGCCATACGCCACACTGAACCTGGTAAGT
TAGCGCGAATTGTC 
Primer used for landing pad incorporation into Citrobacter 
freundii 
Sint_F 
5’-
ATGAAAACCGCTTACATTGCCAAACAACGTCAAATTAGCTTCGTGAAATCACATTTCTCTTGTAGCAC
CTGAAGTCAGC 
Primer used for landing pad incorporation into Salmonella 
enterica LT2 
Sint_R 
5’- 
TTATAAAATAGCAGGAATGCTTTCGCGAACCTGCGCGGGCCATACGCCGCACTGTACCTGGTAAGTT
AGCGCGAATTGTC 
Primer used for landing pad incorporation into Salmonella 
enterica LT2 
Eint_F 
5’-
ATGAAAACCGCTTACATTGCCAAACAACGTCAAATTAGCTTCGTGAAATCTCACTTTTCTCTGTAGCA
CCTGAAGTCAGC 
Primer used for landing pad incorporation into Escherichia coli 
K-12 MG1655 
Eint_R 
5’- 
TTACAGCAGAGAAGGGACGCTCTCGCGAACAGCAGCTGGCCATACTCCACACTGAACCTGGTAAGT
TAGCGCGAATTGTC 
Primer used for landing pad incorporation into Escherichia coli 
K-12 MG1655 
CHK_F 5’- CAGATTGTCGATCAGATAATTTTCCAT Primer to test for landing pad integration 
CHK_R 5’- CATGCGCATTTTCGATCATATCTG Primer to test for landing pad integration 
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Sequencing Data ID (.fastq in 
Single Molecule Real_Time 
Sequencing Data)
Sample
Amplification 
Primers
Barcode (5'-3') Amplification Primer 1. (5'-3') Amplification Primer 2. (5'-3')
SMRT_3 E. coli DIvERGE TRM3-1 (Sample 1) EfolAF3-EfolAR3 >0017_Forward CATAGCGACTATCGTG CATAGCGACTATCGTGTCATTGTAATGCGGCGAGTCCA CACGATAGTCGCTATGAAGCGGCGGCGTCTTAAACA
SMRT_4 E. coli DIvERGE TRM3-2 (Sample 2) EfolAF4-EfolAR4 >0019_Forward CGCATCTGTGCATGCA CGCATCTGTGCATGCATCATTGTAATGCGGCGAGTCCA TGCATGCACAGATGCGAAGCGGCGGCGTCTTAAACA
SMRT_5 E. coli DIvERGE TRM50-1 (Sample 1) EfolAF5-EfolAR5 >0021_Forward GTACACGCTGTGACTA GTACACGCTGTGACTATCATTGTAATGCGGCGAGTCCA TAGTCACAGCGTGTACAAGCGGCGGCGTCTTAAACA
SMRT_6 E. coli DIvERGE TRM50-2 (Sample 2) EfolAF6-EfolAR6 >0029_Forward GCTCGACTGTGAGAGA GCTCGACTGTGAGAGATCATTGTAATGCGGCGAGTCCA TCTCTCACAGTCGAGCAAGCGGCGGCGTCTTAAACA
SMRT_7 E. coli DIvERGE TRM200-1 (Sample 1) EfolAF7-EfolAR7 >0032_Forward TATCTCTGTAGAGTCT TATCTCTGTAGAGTCTTCATTGTAATGCGGCGAGTCCA AGACTCTACAGAGATAAAGCGGCGGCGTCTTAAACA
SMRT_8 E. coli DIvERGE TRM200-2 (Sample 2) EfolAF8-EfolAR8 >0034_Forward ACTCTCGCTCTGTAGA ACTCTCGCTCTGTAGATCATTGTAATGCGGCGAGTCCA TCTACAGAGCGAGAGTAAGCGGCGGCGTCTTAAACA
SMRT_9 S. enterica DIvERGE TRM3-1 (Sample 1) SfolAF11-SfolAR11 >0040_Forward CAGTGAGAGCGCGATA CAGTGAGAGCGCGATAACCCGAGGTCAAACCGTCAATC TATCGCGCTCTCACTGCGCTACGCTTATCAGGCCTACA
SMRT_10 S. enterica DIvERGE TRM3-2 (Sample 2) SfolAF12-SfolAR12 >0041_Forward GTACATATGCGTCTGT GTACATATGCGTCTGTACCCGAGGTCAAACCGTCAATC ACAGACGCATATGTACCGCTACGCTTATCAGGCCTACA
SMRT_11 S. enterica DIvERGE TRM50-1 (Sample 1) SfolAF17-SfolAR17 >0054_Forward GTGTGAGATATATATC GCTCGTCGCGCGCACAACCCGAGGTCAAACCGTCAATC TGTGCGCGCGACGAGCCGCTACGCTTATCAGGCCTACA
SMRT_12 S. enterica DIvERGE TRM50-2 (Sample 2) SfolAF14-SfolAR14 >0048_Forward TCACACTCTAGAGCGA TCACACTCTAGAGCGAACCCGAGGTCAAACCGTCAATC TCGCTCTAGAGTGTGACGCTACGCTTATCAGGCCTACA
SMRT_13 S. enterica DIvERGE TRM200-1 (Sample 1) SfolAF15-SfolAR15 >0051_Forward ACACACAGACTGTGAG ACACACAGACTGTGAGACCCGAGGTCAAACCGTCAATC CTCACAGTCTGTGTGTCGCTACGCTTATCAGGCCTACA
SMRT_14 S. enterica DIvERGE TRM200-2 (Sample 2) SfolAF16-SfolAR16 >0052_Forward GCAGACTCTCACACGC GCAGACTCTCACACGCACCCGAGGTCAAACCGTCAATC GCGTGTGAGAGTCTGCCGCTACGCTTATCAGGCCTACA
SMRT_15
E. coli CFT073 library after 5 DIvERGE cycles, selected on 3 
ug/ml TRM, sample 1
folCDS11F - folCDS11R >0070_Forward CTGCGCAGTACGTGCA CTGCGCAGTACGTGCAGTGGACTCGCCAGCAGAATAT TGCACGTACTGCGCAGTGCAGTCATGATCTCGTGCTCCT
SMRT_16
E. coli CFT073 library after 5 DIvERGE cycles, selected on 3 
ug/ml TRM, sample 2
folCDS12F - folCDS12R >0075_Forward GAGATACGCTGCAGTC GAGATACGCTGCAGTCGTGGACTCGCCAGCAGAATAT GACTGCAGCGTATCTCTGCAGTCATGATCTCGTGCTCCT
SMRT_17
E. coli CFT073 library after 5 DIvERGE cycles, selected on 
50 ug/ml TRM, sample 1
folCDS13F - folCDS13R >0082_Forward ATGCTCACTACTACAT ATGCTCACTACTACATGTGGACTCGCCAGCAGAATAT ATGTAGTAGTGAGCATTGCAGTCATGATCTCGTGCTCCT
SMRT_18
E. coli CFT073 library after 5 DIvERGE cycles, selected on 
50 ug/ml TRM, sample 2
folCDS14F - folCDS14R >0009_Forward CTGCGTGCTCTACGAC CTGCGTGCTCTACGACGTGGACTCGCCAGCAGAATAT GTCGTAGAGCACGCAGTGCAGTCATGATCTCGTGCTCCT
SMRT_19
E. coli CFT073 library after 5 DIvERGE cycles, selected on 
200 ug/ml TRM
folCDS15F - folCDS15R >0002_Forward CTATACATGACTCTGC CTATACATGACTCTGCGTGGACTCGCCAGCAGAATAT GCAGAGTCATGTATAGTGCAGTCATGATCTCGTGCTCCT
SMRT_20 E. coli MG1655 folA naive library after 5+5 DIvERGE cycles EfolAF4-EfolAR4 >0019_Forward CGCATCTGTGCATGCA CGCATCTGTGCATGCATCATTGTAATGCGGCGAGTCCA TGCATGCACAGATGCGAAGCGGCGGCGTCTTAAACA
SMRT_21
E. coli MG1655 folA library after 5+5 DIvERGE cycles, 
selected on 1000 ug/ml TRM
EfolAF7-EfolAR7 >0032_Forward TATCTCTGTAGAGTCT TATCTCTGTAGAGTCTTCATTGTAATGCGGCGAGTCCA AGACTCTACAGAGATAAAGCGGCGGCGTCTTAAACA
SMRT_22 E coli. MG1655 folA naive library after 5 DIvERGE cycles EfolAF2-EfolAR2 >0010_Forward GCGCGATACGATGACT GCGCGATACGATGACTTCATTGTAATGCGGCGAGTCCA AGTCATCGTATCGCGCAAGCGGCGGCGTCTTAAACA
SMRT_23 E. coli MG1655 wild type folA control EfolAF1-EfolAR1 >0001_Forward TCAGACGATGCGTCAT TCAGACGATGCGTCATTCATTGTAATGCGGCGAGTCCA ATGACGCATCGTCTGAAAGCGGCGGCGTCTTAAACA
SMRT_24 E. coli CFT073 wild type folA control folCDS16F-folCDS16R >0003_Forward TACTAGAGTAGCACTC TACTAGAGTAGCACTCGTGGACTCGCCAGCAGAATAT GAGTGCTACTCTAGTATGCAGTCATGATCTCGTGCTCCT
SMRT_31
E. coli MG1655 gyrA-gyrB-parE-parC library, selected on 2 
fold of the wild-type MIC of Ciprofloxacin
F170GA2F - R182GA2R >0070_Forward CTGCGCAGTACGTGCA // >0082_Reverse ATGTAGTAGTGAGCAT GTCGAGTTGATCCATGGTCTCTGCGCAGTACGTGCAGGCACTTCTACTCCGTAATTGG TGACACAGACGCATAGGATCATGTAGTAGTGAGCATAGCGGAAAGCAGTGCTATTG
SMRT_32
E. coli MG1655 gyrA-gyrB-parE-parC library, selected on 2 
fold of the wild-type MIC of Ciprofloxacin
F170GB2F - R182GB2R >0070_Forward CTGCGCAGTACGTGCA // >0082_Reverse ATGTAGTAGTGAGCAT GTCGAGTTGATCCATGGTCTCTGCGCAGTACGTGCAGAATATGCTGAGGTGCTGGAAC TGACACAGACGCATAGGATCATGTAGTAGTGAGCATCGGGATGATAATTGCGGATTGC
SMRT_33
E. coli MG1655 gyrA-gyrB-parE-parC library, selected on 2 
fold of the wild-type MIC of Ciprofloxacin
F170PCF - R182PCR >0070_Forward CTGCGCAGTACGTGCA // >0082_Reverse ATGTAGTAGTGAGCAT GTCGAGTTGATCCATGGTCTCTGCGCAGTACGTGCAGCACCGCTGATTCCTATCTAC TGACACAGACGCATAGGATCATGTAGTAGTGAGCATGTTCGATGCTGTCACCATGTC
SMRT_34
E. coli MG1655 gyrA-gyrB-parE-parC library, selected on 2 
fold of the wild-type MIC of Ciprofloxacin
F170PEF - R182PER >0070_Forward CTGCGCAGTACGTGCA // >0082_Reverse ATGTAGTAGTGAGCAT GTCGAGTTGATCCATGGTCTCTGCGCAGTACGTGCACATCACCCTGACGTTGAGATG TGACACAGACGCATAGGATCATGTAGTAGTGAGCATCTGGAACGCACCAATGGAAG
Oligo ID Sequence (5'-3') Description
TET_DS3 AAACATATCCATGAAATCCCG Landing pad Illumina deep-sequencing primer
TET_DS4 AATGTACTTTTGCTCCATCG Landing pad Illumina deep-sequencing primer
folAF TCATTGTAATGCGGCGAGTCCA E. coli K12 MG1655 folA Illumina deep-sequencing primer
folAR AAGCGGCGGCGTCTTAAACA E. coli K12 MG1655 folA Illumina deep-sequencing primer
SFOL1 ACCCGAGGTCAAACCGTCAATC Salmonella enterica LT2 folA Illumina deep-sequencing primer
SFD2 CGCTACGCTTATCAGGCCTACA Salmonella enterica LT2 folA Illumina deep-sequencing primer
FOLCDS1 GTGGACTCGCCAGCAGAATAT E. coli CFT073 UPEC folA Illumina deep-sequencing primer
folACR TGCAGTCATGATCTCGTGCTCCT E. coli CFT073 UPEC folA Illumina deep-sequencing primer
MgyaA_G288D ACTCGTCACGCAGCGCGCTGATGtCTTCCACGCGTTTTTCTTTTACCAGTTCCGCAATCTTCTCGATCAG pORTMAGE allele-reconstruction oligo for Escherichia coli K12 MG1655 GyrA G288D
MGYRAS1 CTGCCGTCGATGGTATCCAGAT E. coli K-12 gyrA sequencing primer 1.
MGYRAS2 TCGTGGCGGGAAAGGTAAATCT E. coli K-12 gyrA sequencing primer 1.
MGYRAS3 CGCATGACGGATCAGTTCGATG E. coli K-12 gyrA sequencing primer 2.
MGYRAS4 CGGTCAGGGTAACTTCGGTTCT E. coli K-12 gyrA sequencing primer 2.
UnivGA1 GCGAGAGAAATTACACCGGTCAACATT gyrA sequencing primer 1.
UnivGA3 CATCGCGTTTCACTTCAATCACGAT gyrA sequencing primer 2.
CFT073Pc1 GCTACATGAATTTACGGAAAACGCCTACTT Escherichia coli O6:K2:H1 CFT073 (UPEC) parC sequencing primer 1.
CFT073Pc3 TCACCTGATCCATATCCACGCGGTT Escherichia coli O6:K2:H1 CFT073 (UPEC) parC sequencing primer 2.
8090Pc1 TTGAGGAACCACGATTAATGAGCGATA Citrobacter freundii ATCC 8090  parC sequencing primer 1.
8090Pc3 AGGTGGTTCATCACCTGCTCCATA Citrobacter freundii ATCC 8090  parC sequencing primer 2.
gyrAF_ILM TTCGTGGTCTACGTTATGGTTTAC E. coli K-12 gyrA sequencing primer with MgyrAS3, for QRDR
folA2F GATGAACCGGAAACGAAACCC E. coli K-12 folA sequencing primer, with folAR
MfolA_A7T GATCTACCGCTAACGtCGCAATCAGACTGATCATTGAGATTTCCCGATAAAAAAAATTGTCGCCACTATA pORTMAGE allele-reconstruction oligo for Escherichia coli K12 MG1655 folA
MfolA_A7S CGATAACGCGATCTACCGCTAACGaCGCAATCAGACTGATCATTGAGATTTCCCGATAAAAAAAATTGTC pORTMAGE allele-reconstruction oligo for Escherichia coli K12 MG1655 folA
MfolA_M20I GTTTATTTAAGGTGTTGCGTTTAAACCAGGCGAGATCGGCAGGCAGGTTCCACGGaATGGCGTTTTCCAT pORTMAGE allele-reconstruction oligo for Escherichia coli K12 MG1655 folA
MfolA_M20V TATTTAAGGTGTTGCGTTTAAACCAGGCGAGATCGGCAGGCAGGTTCCACGGCAcGGCGTTTTCCATGCC pORTMAGE allele-reconstruction oligo for Escherichia coli K12 MG1655 folA
MfolA_P21T GTTTATTTAAGGTGTTGCGTTTAAACCAGGCGAGATCGGCAGGCAGGTTCCACGtCATGGCGTTTTCCAT pORTMAGE allele-reconstruction oligo for Escherichia coli K12 MG1655 folA
MfolA_W30S TAATCACGGGTTTATTTAAGGTGTTGCGTTTAAACgAGGCGAGATCGGCAGGCAGGTTCCACGGCATGGC pORTMAGE allele-reconstruction oligo for Escherichia coli K12 MG1655 folA
MfolA_G97S GTTTTTGCGCTTTTGGCAAGAACTGTTCATAAACGCGACtGCCGCCAATCACCATGATTTCTGGTACGTC pORTMAGE allele-reconstruction oligo for Escherichia coli K12 MG1655 folA
MfolA_G-32C GAGATTTCCCGATAAAAAAAATTGTCGCCAGTATACGTAAAGCGTAAACCGTCGTCGACTGGTGCGAGGA pORTMAGE allele-reconstruction oligo for Escherichia coli K12 MG1655 folA
CfolA_W30S TAATCACGGGTTTATTTAAAGTGTTGCGTTTAAACgAGGCGAGATCGGCAGGCAGGTTCCACGGCATGGC pORTMAGE allele-reconstruction oligo for Escherichia coli O6:K2:H1 CFT073 (UPEC) folA
CfolA_G-32A ATAAAAAAAATTGTCGCCATTATACGTAAAGCGTAAACCGTCGTCGACTGGTGCGAGGATGATGTTGAGG pORTMAGE allele-reconstruction oligo for Escherichia coli O6:K2:H1 CFT073 (UPEC) folA
CfolA_C-58T ATAAAAAAAATTGTCGCCACTATACGTAAAGCGTAAACCGTCGTCAACTGGTGCGAGGATGATGTTGAGG pORTMAGE allele-reconstruction oligo for Escherichia coli O6:K2:H1 CFT073 (UPEC) folA
CfolA_G-54A ATAAAAAAAATTGTCGCCACTATACGTAAAGCGTAAACCGTTGTCGACTGGTGCGAGGATGATGTTGAGG pORTMAGE allele-reconstruction oligo for Escherichia coli O6:K2:H1 CFT073 (UPEC) folA
CfolA_G-32C ATAAAAAAAATTGTCGCCAGTATACGTAAAGCGTAAACCGTCGTCGACTGGTGCGAGGATGATGTTGAGG pORTMAGE allele-reconstruction oligo for Escherichia coli O6:K2:H1 CFT073 (UPEC) folA
CFT_folA_I5F ATCTACCGCTAACGCCGCAAaCAGACTGATCATTGAGATTTCCCGATAAAAAAAATTGTCGCCACTATAC pORTMAGE allele-reconstruction oligo for Escherichia coli O6:K2:H1 CFT073 (UPEC) folA
CFT_folA_D27E CACGGGTTTATTTAAAGTGTTGCGTTTAAACCAGGCGAGtTCGGCAGGCAGGTTCCACGGCATGGCGTTT pORTMAGE allele-reconstruction oligo for Escherichia coli O6:K2:H1 CFT073 (UPEC) folA
CFT_folA_L28R GGGTTTATTTAAAGTGTTGCGTTTAAACCAGGCGcGATCGGCAGGCAGGTTCCACGGCATGGCGTTTTCC pORTMAGE allele-reconstruction oligo for Escherichia coli O6:K2:H1 CFT073 (UPEC) folA
CFT_folA_I94L GCTTTCGGCAGGAACTGCTCATAAACGCGACCGCCGCCAAgCACCATGATTTCTGGTACGTCACCACACG pORTMAGE allele-reconstruction oligo for Escherichia coli O6:K2:H1 CFT073 (UPEC) folA
CFT_folA_R98P TTTTTGCGCTTTCGGCAGGAACTGCTCATAAACGgGACCGCCGCCAATCACCATGATTTCTGGTACGTCA pORTMAGE allele-reconstruction oligo for Escherichia coli O6:K2:H1 CFT073 (UPEC) folA
CFT_folA_A7S TTTTCCATGCCGATAACGCGATCTACCGCTAACGaCGCAATCAGACTGATCATTGAGATTTCCCGATAAA pORTMAGE allele-reconstruction oligo for Escherichia coli O6:K2:H1 CFT073 (UPEC) folA
CFT_folA_A7T TTTTCCATGCCGATAACGCGATCTACCGCTAACGtCGCAATCAGACTGATCATTGAGATTTCCCGATAAA pORTMAGE allele-reconstruction oligo for Escherichia coli O6:K2:H1 CFT073 (UPEC) folA
CFT_folA_M20I TAAACCAGGCGAGATCGGCAGGCAGGTTCCACGGaATGGCGTTTTCCATGCCGATAACGCGATCTACCGC pORTMAGE allele-reconstruction oligo for Escherichia coli O6:K2:H1 CFT073 (UPEC) folA
CFT_folA_P21L TTTAAACCAGGCGAGATCGGCAGGCAGGTTCCACaGCATGGCGTTTTCCATGCCGATAACGCGATCTACC pORTMAGE allele-reconstruction oligo for Escherichia coli O6:K2:H1 CFT073 (UPEC) folA
CFT_folA_W30R ATCACGGGTTTATTTAAAGTGTTGCGTTTAAACCgGGCGAGATCGGCAGGCAGGTTCCACGGCATGGCGT pORTMAGE allele-reconstruction oligo for Escherichia coli O6:K2:H1 CFT073 (UPEC) folA
CFT_folA_W30G ATCACGGGTTTATTTAAAGTGTTGCGTTTAAACCcGGCGAGATCGGCAGGCAGGTTCCACGGCATGGCGT pORTMAGE allele-reconstruction oligo for Escherichia coli O6:K2:H1 CFT073 (UPEC) folA
CFT_folA_F153S TAATATACAAAATTACCGCCGCTCCAGAATCTCAgAGCAATAGCTGTGAGAGTTCTGCGCATCGGCATCG pORTMAGE allele-reconstruction oligo for Escherichia coli O6:K2:H1 CFT073 (UPEC) folA
MG_GyrA_S83L CGAGAATGGCTGCGCCATGCGGACGATCGTGTCATAGACCGCCAAGTCACCATGGGGATGGTATTTACCGATTACGTCACCAACGACACG pORTMAGE allele-reconstruction oligo for Escherichia coli K-12 MG1655 GyrA
MG_GyrA_S83L_D87N CGCCATGCGGACGATCGTGTtATAGACCGCCaAGTCACCATGGGGATGGTATTTACCGATTACGTCACCAACGACACGGGCAGATTTTTT pORTMAGE allele-reconstruction oligo for Escherichia coli K-12 MG1655 GyrA
KPGAD82N GCACGATGGTGTCGTATACCGCGGAGTTGCCGTGCGGGTGGTATTTACCGATTACGTCACCAACGACACGGGCTGATTTTTTATAGGCTT pORTMAGE allele-reconstruction oligo for Klebsiella pneumoniae subsp. pneumoniae
KPPCD79N GCACCATCGCTTCATAGCAGGCGCTGTTGCCGTGCGGGTGATATTTACCCAACACGTCGCCGACGGTGCGGGCGGACTTTTTGAATTTCG pORTMAGE allele-reconstruction oligo for Klebsiella pneumoniae subsp. pneumoniae
CFGA82N GACGTAATCGGTAAATACCACCCTCATGGTaatACCGCCGTTTACGACACCATTGTTCGTATGGCGCAGCCATTCTCCTTGCGTTACATG pORTMAGE allele-reconstruction oligo for Citrobacter freundii ATCC 8090
CFPC79N AAATTTAAAAAATCCGCCCGTACCGTCGGTGACGTGCTGGGTAAATACCATCCGCACGGCaacAGCGCCTGCTATGAAGCGATGGTGCTG pORTMAGE allele-reconstruction oligo for Citrobacter freundii ATCC 8090
CFTGA82N ACGATCGTGTCATAAACCGCCGAgttACCATGGGGATGGTATTTACCGATTACGTCACCAACGACACGGGCAGATTTTTTATAGGCTTTG pORTMAGE allele-reconstruction oligo for Escherichia coli O6:K2:H1 CFT073 (UPEC)
CFTPC79N ATAACGGTAAGAGAACGGCTGCGCCATCAGGACCATCGCTTCATAACAGGCACTattGCCGTGCGGATGGTATTTACCCAGTACGTCACC pORTMAGE allele-reconstruction oligo for Escherichia coli O6:K2:H1 CFT073 (UPEC)
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Appendix 5. Off-target mutations identified by whole-genome sequencing 
Parental strain: E. coli K-12 MG1655 + pORTMAGE 
 
Parental strain: E. coli K-12 MG1655 + pSIM8 
Reference 
Position Type Reference Allele Count Coverage Frequency Overlapping annotations Coding region change Amino acid change
69999 SNV A T 49 49 100 Gene: araB, CDS: araB AAC73174.1:c.50T>A AAC73174.1:p.Leu17*
365654 SNV T A 49 49 100 Gene: lacZ, CDS: lacZ AAC73447.1:c.652A>T AAC73447.1:p.Lys218*
2093633 SNV C T 66 66 100 Gene: hisB, CDS: hisB AAC75083.2:c.166C>T AAC75083.2:p.Gln56*
3474425 SNV T C 59 59 100 Gene: rpsL, CDS: rpsL AAC76367.1:c.128A>G AAC76367.1:p.Lys43Arg
4247035 SNV C G 37 37 100 Gene: malK, CDS: malK AAC77005.1:c.252C>G AAC77005.1:p.Tyr84*
4296381 Insertion - CG 17 17 100 Repeat region: RIP321 (repetitive extragenic palindromic) element; contains 11 REP sequences and 4 IHF sites
4430002 MNV AA TG 68 68 100 Gene: cycA, CDS: cycA AAC77165.1:c.139_140delAAinsTGAAC77165.1:p.Lys47*
#
6
1
0
Targeted mutations:
Mutation from parental strain:
Off-target mutations:
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Parental strain: E. coli K-12 MG1655 ∆mutS + pSIM8 
 
Reference 
Position Type Reference Allele Count Coverage Frequency Overlapping annotations Coding region change Amino acid change
69999 SNV A T 82 83 99 Gene: araB, CDS: araB AAC73174.1:c.50T>A AAC73174.1:p.Leu17*
365654 SNV T A 76 76 100 Gene: lacZ, CDS: lacZ AAC73447.1:c.652A>T AAC73447.1:p.Lys218*
703545 SNV G C 72 72 100 Gene: nagB, CDS: nagB AAC73772.1:c.67C>G AAC73772.1:p.Arg23Gly
2093633 Deletion CAGGA - 77 77 100 Gene: hisB, CDS: hisB AAC75083.2:c.166_170delCAGGA AAC75083.2:p.Gln56fs
2093639 Replacement GGTCT A 77 77 100 Gene: hisB, CDS: hisB AAC75083.2:c.172_176delGGTCTinsA AAC75083.2:p.Gly58fs
2904366 SNV G T 26 27 96
3474425 SNV T C 70 73 96 Gene: rpsL, CDS: rpsL AAC76367.1:c.128A>G AAC76367.1:p.Lys43Arg
4247035 SNV C G 84 84 100 Gene: malK, CDS: malK AAC77005.1:c.252C>G AAC77005.1:p.Tyr84*
4296381 Insertion - CG 50 50 100 Repeat region: RIP321 (repetitive extragenic palindromic) element; contains 11 REP sequences and 4 IHF sites
4430002 MNV AA TG 84 84 100 Gene: cycA, CDS: cycA AAC77165.1:c.139_140delAAinsTG AAC77165.1:p.Lys47*
#
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1
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Targeted mutations:
Mutation from parental strain:
Off-target mutations:
Reference Position Type Reference Allele Count Coverage Frequency Overlapping annotations Coding region change Amino acid change
26396 SNV A G 51 51 100 Gene: ispH, CDS: ispH AAC73140.1:c.120A>G
37584 SNV C T 52 53 98 Gene: caiC, CDS: caiC AAC73148.2:c.241G>A AAC73148.2:p.Gly81Arg
47601 SNV C T 58 61 95 Gene: kefF, CDS: kefF AAC73157.1:c.356C>T AAC73157.1:p.Pro119Leu
69999 SNV A T 69 69 100 Gene: araB, CDS: araB AAC73174.1:c.50T>A AAC73174.1:p.Leu17*
131653 SNV C T 50 53 94 Gene: acnB, CDS: acnB AAC73229.1:c.39C>T
139086 SNV C T 82 84 98 Gene: gcd, CDS: gcd AAC73235.1:c.2140G>A AAC73235.1:p.Gly714Arg
252969 SNV C T 70 70 100 Gene: yafP, CDS: yafP AAC73338.1:c.261C>T
253413 SNV T C 38 48 79
278118 SNV C T 28 29 97 Gene: afuC, CDS: afuC, Misc. feature: cryptic prophage CP4-6 AAC73365.2:c.685G>A AAC73365.2:p.Ala229Thr
345829 SNV A G 53 53 100 Gene: yahN, CDS: yahN AAC73431.1:c.509T>C AAC73431.1:p.Val170Ala
347605 SNV G A 49 49 100 Gene: prpR, CDS: prpR AAC73433.1:c.839C>T AAC73433.1:p.Ala280Val
365654 SNV T A 51 51 100 Gene: lacZ, CDS: lacZ AAC73447.1:c.652A>T AAC73447.1:p.Lys218*
407729 SNV A G 83 85 98 Gene: aroM, CDS: aroM AAC73493.1:c.302A>G AAC73493.1:p.Asn101Ser
415870 SNV G A 74 75 99 Gene: sbcD, CDS: sbcD AAC73501.1:c.1083C>T
542805 SNV G A 48 48 100 Gene: glxK, CDS: glxK AAC73616.1:c.918G>A
552660 SNV A G 37 37 100 Gene: purE, CDS: purE AAC73625.1:c.441T>C
636153 SNV T C 70 70 100 Gene: ybdN, CDS: ybdN AAC73703.1:c.417A>G
705964 Deletion T - 41 46 89
899485 SNV C T 50 54 93 Gene: rlmC, CDS: rlmC AAC73946.1:c.968C>T AAC73946.1:p.Thr323Met
987523 SNV A G 57 57 100
1015009 SNV C T 51 51 100 Gene: pqiC, CDS: pqiC AAC74038.2:c.114C>T
1037429 SNV G A 75 79 95 Gene: hyaF, CDS: hyaF AAC74062.1:c.681G>A
1053197 SNV A G 52 52 100 Gene: yccM, CDS: yccM AAC74077.1:c.166T>C AAC74077.1:p.Tyr56His
1082600 SNV A G 65 65 100 Gene: efeO, CDS: efeO AAC74103.1:c.358A>G AAC74103.1:p.Thr120Ala
1105797 SNV A G 65 65 100
1224114 SNV T C 57 59 97
1225089 SNV T C 68 68 100 Gene: minD, CDS: minD AAC74259.1:c.273A>G
1485344 SNV C T 48 48 100 Gene: hrpA, CDS: hrpA AAC74495.2:c.2284C>T AAC74495.2:p.Arg762Cys
1575474 SNV C T 91 95 96 Gene: yddB, CDS: yddB AAC74568.1:c.2146G>A AAC74568.1:p.Glu716Lys
1595306 SNV C T 58 58 100 Gene: yneO, CDS: yneO yneO:c.2682G>A
1603448 SNV T C 56 56 100 Gene: lsrC, CDS: lsrC AAC74587.1:c.430T>C
1660661 SNV A G 79 79 100 Gene: ynfF, CDS: ynfF AAC74660.4:c.106A>G AAC74660.4:p.Thr36Ala
1781659 SNV G A 59 62 95 Gene: ydiS, CDS: ydiS AAC74769.1:c.265G>A AAC74769.1:p.Asp89Asn
1872236 SNV C T 81 82 99 Gene: yeaJ, CDS: yeaJ AAC74856.2:c.196C>T AAC74856.2:p.Arg66Cys
1902259 SNV G A 74 75 99 Gene: manX, CDS: manX AAC74887.1:c.212G>A AAC74887.1:p.Gly71Asp
1904680 SNV G A 45 45 100 Gene: manZ, CDS: manZ AAC74889.2:c.786G>A
1938164 SNV A G 61 62 98 Gene: pykA, CDS: pykA AAC74924.1:c.516A>G
1980655 SNV G A 71 71 100 Gene: otsA, CDS: otsA AAC74966.1:c.958C>T AAC74966.1:p.Arg320*
2071002 SNV G A 57 57 100 Gene: yeeP, CDS: yeeP, Misc. feature: cryptic prophage CP4-44 yeeP:c.343G>A yeeP:p.Ala115Thr
2093633 SNV C T 47 47 100 Gene: hisB, CDS: hisB AAC75083.2:c.166C>T AAC75083.2:p.Gln56*
2208450 SNV G A 45 45 100 Gene: yehP, CDS: yehP AAC75182.1:c.484G>A AAC75182.1:p.Val162Ile
2283699 SNV C T 66 67 99 Gene: yejK, CDS: yejK AAC75247.1:c.249G>A
2319619 SNV A G 76 77 99 Gene: rcsC, CDS: rcsC AAC75278.2:c.258T>C
2326914 SNV G A 47 47 100 Gene: atoB, CDS: atoB AAC75284.1:c.806G>A AAC75284.1:p.Gly269Asp
2386124 SNV A G 57 57 100 Gene: yfbL, CDS: yfbL AAC75331.2:c.265A>G AAC75331.2:p.Thr89Ala
2688541 SNV G A 45 48 94 Gene: glrR, CDS: glrR AAC75607.1:c.263C>T AAC75607.1:p.Ser88Phe
2753329 SNV C T 62 62 100 Gene: recN, CDS: recN AAT48145.1:c.1535C>T AAT48145.1:p.Ala512Val
2818145 SNV T C 12 13 92
2818149 SNV T C 11 13 85
2818158 SNV T A 10 10 100
2818162 SNV A T 10 10 100
2819391 SNV T C 66 67 99 Gene: alaS, CDS: alaS AAC75739.1:c.2621A>G AAC75739.1:p.Lys874Arg
2836760 SNV G A 39 40 98 Gene: hypF, CDS: hypF AAC75754.1:c.666C>T
2838000 SNV T C 74 74 100 Gene: hydN, CDS: hydN AAC75755.1:c.106A>G AAC75755.1:p.Thr36Ala
2867032 SNV C T 55 56 98 Gene: rpoS, CDS: rpoS AAC75783.1:c.520G>A AAC75783.1:p.Glu174Lys
2883989 SNV C T 71 71 100 Gene: casA, CDS: casA AAC75802.1:c.150G>A
2940575 SNV G A 51 51 100 Gene: rlmM, CDS: rlmM AAC75848.1:c.669C>T
2956746 SNV T C 49 50 98 Gene: ptrA, CDS: ptrA AAC75860.1:c.2139A>G
2975948 SNV G A 61 61 100 Gene: aas, CDS: aas AAC75875.1:c.67C>T AAC75875.1:p.Gln23*
3053403 SNV G A 46 46 100 Gene: ubiH, CDS: ubiH AAC75945.1:c.116C>T AAC75945.1:p.Ser39Leu
3100610 SNV T C 77 77 100 Gene: ansB, CDS: ansB AAC75994.1:c.119A>G AAC75994.1:p.Asp40Gly
3132771 SNV T C 38 45 84 Gene: yghR, CDS: yghR AAC76020.1:c.442A>G AAC76020.1:p.Ile148Val
3155620 SNV T C 37 37 100 Gene: yqhD, CDS: yqhD AAC76047.1:c.266T>C AAC76047.1:p.Leu89Pro
3222157 SNV G A 71 71 100 Gene: ebgR, CDS: ebgR AAC76110.1:c.692G>A AAC76110.1:p.Arg231Gln
3252467 SNV T C 59 62 95 Gene: yhaH, CDS: yhaH AAC76138.1:c.164T>C AAC76138.1:p.Leu55Pro
3263556 SNV G A 82 83 99 Gene: tdcD, CDS: tdcD AAC76150.2:c.105C>T
3299463 SNV C T 35 35 100 Gene: yhbO, CDS: yhbO AAC76187.2:c.490C>T AAC76187.2:p.Arg164Cys
3304164 SNV T C 40 42 95 Gene: yhbW, CDS: yhbW AAC76194.1:c.717T>C
3342102 Insertion - G 74 84 88 Gene: kdsD, CDS: kdsD AAC76229.1:c.836_837insG AAC76229.1:p.Pro279fs
3350200 SNV T C 63 63 100 Gene: elbB, CDS: elbB AAC76241.2:c.260A>G AAC76241.2:p.Asp87Gly
3474425 SNV T C 54 54 100 Gene: rpsL, CDS: rpsL AAC76367.1:c.128A>G AAC76367.1:p.Lys43Arg
3542923 SNV G A 50 57 88 Gene: feoC, CDS: feoC AAC76435.1:c.196G>A AAC76435.1:p.Glu66Lys
3546156 SNV G A 47 48 98 Gene: nfuA, CDS: nfuA AAC76439.1:c.533G>A AAC76439.1:p.Arg178His
3586147 SNV T C 59 60 98 Gene: ggt, CDS: ggt AAC76472.1:c.677A>G AAC76472.1:p.Asn226Ser
3742817 SNV T C 50 51 98 Gene: yiaK, CDS: yiaK AAC76599.1:c.85T>C AAC76599.1:p.Cys29Arg
3760852 SNV G A 57 57 100 Gene: selA, CDS: selA AAC76615.1:c.398C>T AAC76615.1:p.Ala133Val
3778841 SNV T C 53 53 100 Gene: lldP, CDS: lldP AAC76627.1:c.1443T>C
3900055 SNV G A 101 101 100 Gene: yieL, CDS: yieL AAC76742.3:c.523C>T AAC76742.3:p.Pro175Ser
4175885 SNV A G 61 61 100
4182512 SNV A G 60 60 100 Gene: rpoB, CDS: rpoB AAC76961.1:c.1268A>G AAC76961.1:p.Asp423Gly
4232708 SNV C T 74 77 96 Gene: lysC, CDS: lysC AAC76994.1:c.526G>A AAC76994.1:p.Glu176Lys
4247035 SNV C G 39 39 100 Gene: malK, CDS: malK AAC77005.1:c.252C>G AAC77005.1:p.Tyr84*
4296381 Insertion - CG 30 30 100 Repeat region: RIP321 (repetitive extragenic palindromic) element; contains 11 REP sequences and 4 IHF sites
4326999 SNV A G 41 41 100
4411889 SNV C T 67 67 100 Gene: yjfK, CDS: yjfK AAC77140.1:c.588C>T
4430002 MNV AA TG 82 82 100 Gene: cycA, CDS: cycA AAC77165.1:c.139_140delAAinsTGAAC77165.1:p.Lys47*
4479257 SNV T C 61 61 100 Gene: yjgM, CDS: yjgM AAT48245.1:c.281A>G AAT48245.1:p.Tyr94Cys
4529218 SNV C T 52 52 100 Gene: sgcC, CDS: sgcC AAC77260.1:c.1026G>A
4563609 SNV T C 78 84 93
4567871 SNV A G 68 68 100 Gene: mdtM, CDS: mdtM AAC77293.1:c.649T>C AAC77293.1:p.Phe217Leu
4610455 SNV T C 50 50 100 Gene: prfC, CDS: prfC AAC77328.1:c.1042T>C AAC77328.1:p.Phe348Leu
#
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Appendix 6. Data deposition 
Sequencing data reported in this thesis have been deposited in the National Center for 
Biotechnology Information (NCBI) Sequence Read Archive at 
https://www.ncbi.nlm.nih.gov/sra/SRP144255 (Accession number: SRP144255) 
